JM
Uploaded byJohn C. Ruckdeschel, M.D.
DOCX, PDF982 views

CURRICULUM VITAE 2015

This curriculum vitae summarizes the professional experience and qualifications of Dr. John C. Ruckdeschel. He has over 40 years of experience in oncology, including serving as CEO of several major cancer centers. His educational background includes an MD from Albany Medical College and further training at NIH. He has held professorships at multiple universities and has received many honors for his contributions to oncology.

Embed presentation

Download to read offline
CURRICULUM VITAE John C. Ruckdeschel, M.D. PERSONAL DATA: Date and Place of Birth: January 5, 1946, Newport, Rhode Island Residence: 10838 Willow Heights Drive Las Vegas, NV 89135 313-485-7808 Email: jruckdeschel@me.com, jruckdeschel@synergyccn.com EDUCATIONAL EXPERIENCE: Oceanside High School, Oceanside, NY - Regents Diploma (honors)1963 Rensselaer Polytechnic Institute, Troy, NY - B.Sc. Biology 1967 Albany Medical College, Albany, NY - M.D. 1971 Foundation for Advanced Education in the Sciences, NIH 1973, 1983 – 1984 Intermountain Advanced Training Program in Clinical Practice Improvement Institute for Health Care Delivery Research, Salt Lake City, UT 2012 PROFESSIONAL EXPERIENCE: Current Positions: Attending Physician, Synergy Cancer Center of Nevada CEO, Ruckdeschel Consultants,LLC Chief Medical Officer, EMX Advanced Technologies Professor of Medicine (Adjunct), University of Utah, Huntsman Cancer Institute, Salt Lake City, UT Editor (United States)Cochrane Lung Cancer Group Vice-president, Red Rock Audubon Society Previous Positions: Medical Director, Oncology Clinical Program, Intermountain Healthcare, Salt Lake City, UT 2012-2014 Chair, Utah Cancer Action Network 2013-2014 Professor of Medicine University of Utah, Huntsman Cancer Institute,Salt Lake City, UT Professor of Medicine, University of Nevada School of Medicine 2009-2011 Chair, Patient Services Committee, Health Advisory Board of the University Medical Center of Southern Nevada 2010-2011 Chief Executive Officer and Director, Nevada Cancer Institute 2009-2011 VP Health Affairs/Dean; University of NV School of Medicine Search Committee 2010-2011 President and Chief Executive Officer, Barbara Ann Karmanos Cancer Institute 2002-2009 Associate Dean, Cancer Affairs, Wayne State University School of Medicine 2002-2009 Professor of Medicine and Oncology, Wayne State University School of Medicine 2002-2009 Board of Directors, Michigan Cancer Consortium 2002-2009 Senior VP - Cancer, The Detroit Medical Center: President, The Cancer Hospital 2002-2005 Interim Chair, Radiation Oncology Wayne State University School of Medicine 2002-2003 Professor of Oncology and Medicine, University of South Florida College of Medicine 1991-2002 Director and Chief Executive Officer, H. Lee Moffitt Cancer Center, Tampa, FL 1991-2002 Case Research Professor, University of Tampa College of Business 1996-2002 President, Florida Division, American Cancer Society 2001-2002 Director, Joint Ctr for Cancer and Blood Disorders Albany Medical College, Albany, NY1989 1991 Professor of Medicine (1985 - 1991); Associate Professorof Medicine (1979 - 1985); 1976-1991 Assistant ProfessorofMedicine, (1976 - 1979); Albany Medical College, Albany, NY Visiting Professor, Foundation for Promotion of Cancer Research, National Cancer Center, Tokyo, Japan 1990 Visiting Scientist, NCI - Navy Medical Oncology Branch, NCI, Bethesda, Maryland 1983-1984 Senior Assistant Resident - Medicine, Beth Israel Hospital, Boston,MA 1975-1976 Staff Associate,NCI - Baltimore Cancer Research Center, Baltimore, MD 1972-1975 Straight Medical Intern, Johns Hopkins Hospital, Baltimore, MD 1971-1972 04 December 2014
John C. Ruckdeschel,M.D. HONORS: Distinguished John Hopkins School of Medicine Alumni Award 2009 Michigan Cancer Consortium Spirit of Collaboration Award 2007 Hour Magazine Top Doctors in Detroit 2006 Best Doctors in America 1993 - America's Top Doctors 2000 - Honorary Member, USF Golden Key International Honor Society 2001 Distinguished Southern Oncologist Award 2001 Tampa Bay Magazine’s “Doctors Chosen by Doctors” 2001 Exemplary Alumni Award, Albany Medical College, Albany, NY 2000 11th Annual Florida Medical Business Healthcare Physician Business Leadership Award 2000 Town and Gown Community Service Award 1999 The Medical Business Top 25: The Most Influential Physicians in Tampa Bay 1998 Bellwether Award for Lifetime Achievement 1997 Who’s Who in Medicine and Healthcare 1996 Rensselaer Alumni Association Fellows Award - Biology 1996 Brooks Brothers Man of the Year 1994 Excel Award for Excellence in Communication Leadership 1994 Who’s Who in Science and Engineering 1991 Sigma Xi 1986 -2002 American Medical Association,Physicians Recognition Award 1974 - Alpha Omega Alpha (Medicine) 1971 Henry B. Barnet, Jr., Commencement Award for Significant Contribution in Cancer 1971 S. Oakley Vander Poel Commencement Award for Best Clinical Exam in Medicine 1971 Who’s Who Among Students in American Colleges and Universities 1967 Pi Delta Epsilon (Journalism) 1966 PROFESSIONAL ORGANIZATIONS: Center and Institute Advisory Committee (CIAC), Wayne State University Division of Research 2004-2009 U.S. National Committee for the International Union Against Cancer (USNC/UICC) American Joint Committee on Cancer 2000-2008 National Comprehensive Cancer Network Board of Directors 1998-2002 Executive Committee (2000 - 2002) National Coalition for Cancer Research (NCCR) Board of Directors 1999-2006 Council of Teaching Hospitals (COTH) - American Association of Medical Colleges 1997-2002 American College of Chest Physicians Fellow 1993 - American Association of Cancer Institutes 1992 - 2009 Board of Directors (1997 - 1999); Legislative Committee (2001 - 2009) American Medical Association 1992 - American College of Physician Executives 1988 - Lung Cancer Study Group 1982-1990 (Executive Officer 1986 - 1990) American Cancer Society 1977 - 2002 Junior Faculty Clinical Fellow (1977 - 1980); National Advisory Committee on Psychosocialand Behavioral Research (1986 - 1989; Chair 1989); Board of Directors, Greater Tampa (1992 - 1997); Chair, Research Committee of Florida Division (1999 - 2000); Florida Division Board of Directors (1997 - 2002); Executive Committee (1998 - 2002); Medical Vice President of Florida Division (1999 - 2000); President, Florida Division (2001 - 2002)
John C. Ruckdeschel,M.D. American Association for Cancer Education 1977 - International Association for the Study of Lung Cancer 1977 - American Society of Clinical Oncology 1977 - Publications Committee (2004 - ) Cancer Education Committee (2005 – Chair Health Services Research Track, 2006-2008) American Federation for Clinical Research 1977 - 1986 Councilor, Eastern Section (1981 - 1986) American Association for Cancer Research 1976 -2009 Finance Committee (2001 - 2005 American College of Physicians 1975 - Fellow (1979 - ) LICENSURE: New York (inactive), Maryland (inactive),Massachusetts (inactive),Florida (ME0068653), Michigan (inactive) Nevada (13104), Utah (8192686-1205) MILITARY: United States Public Health Service 1972 – 1975 BOARDS: American Board of Internal Medicine, Certified 6/76, no. 53664 Medical Oncology, Certified 10/77 GRANT SUPPORT: Prior Funding: NIH: NCI Outcomes of Triaged Family Care in Advanced Cancer 5R01CA107383-04 $9,758 (annual direct) 09/28/04 - 05/31/09 (PI:Northouse) NIH: NCI Cancer Center Support Grant 5P30CA022453-26 $1,607,780 (annual direct) 09/08/97 – 11/30/90 (PI:Ruckdeschel NIH: NCI Cancer Center Support Grant – Supplement: Cryo-immunotherapy for Lung Tumors 2P30CA022453-24 $2,500,000 (annual direct) 12/01/04 – 11/30/09 (PI:Ruckdeschel) NIH: NCI Cancer Center Support Grant – Supplement : caBIG Technology Assessment and Implementation EPA National Center for Vermiculite and Asbestos Related Cancers 83299701-0 $967,000 (total award) 09/01/06 –08/31/08 (PI: Ruckdeschel) DOD National Oncogenomic and Molecular Imaging Center (NOMIC) ERMS 07078003 $1,571,186 04/01/08 – 03/31/13 (PI Ruckdeschel) Threshold Pharmaceuticals, Inc An Open-Label, Phase II Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients with Recurrent Sensitive Small Cell Lung Carcinoma THCR- 304 $108,693 (total)11/01/06 – 11/08/07 (PI:Ruckdeschel) NCI: Parental role in Pediatric Cancer Pain and Survivorship. 5R01CA10027-01 - $866,105 09/19/03 – 08/31/07(PI Albrecht) NCI: Effects of Physician Communication on Patient Accrual. 7R01CA75003-01A3 $268,204 (annual direct),04/01/01 - 03/31/06. Dr. Teri Albrecht, PI NCI: Biopsychosocial Processes and Treatment Decision Making. 1R21CA113220-01 $75,000 (annual direct),09/30/04 – 09/29/06. Dr. Teri Albrecht, PI. CDC Cancer Prevention and Control Earmarks (National Center for Vermiculite and Asbestos Related Cancers) ACS: Institutional Research Grant. ACS 93-032-07-02 - $120,000 (annual direct). 07/01/00 - 06/30/03. PI. NCI: Moffitt Cancer Center PRCC Partnership. $125,000 (annual direct). P20CA91353-01, 5/18/01- 4/30/04. PI. NCI: Cancer Center Support Grant. P30 CA 76292-05 - $1,647,244 (annual direct). 03/06/01-01/31/05. PI. NCI: Project Link: Leaders in New Knowledge. Supplement to P30 CA76292 - $72,424 (annual direct). 05/18/01-01/31/06. PI. NIH: Mouse Barrier Facility. C06 RR017510-01 - $2,000,000 (annual direct). 9/01/02-8/31/04. PI.
John C. Ruckdeschel,M.D. EDITORIAL/REVIEW ACTIVITIES: Editorial: Editor in Chief: Evidence-Based Oncology (1999 - 2002) Co-Editor: Textbook of Thoracic Oncology, I and II Editions Editorial Board: Chest Current Treatment Options in Oncology Medical Oncology Social Marketing Quarterly Journal of Cancer Education Cancer Control: Journal of the Moffitt Cancer Center Section Editor for Lung and Mediastinum – Current Opinion in Oncology Reviewer: Annals of Internal Medicine Cancer Chemotherapy and Pharmacology Cancer Research Chest Journal of Clinical Oncology Journal of the National Cancer Institute Journal of Neuro-Oncology Journal of Thoracic Oncology Investigational New Drugs Preventive Medicine Proceedings, National Academy of Sciences (U.S.A.) Social Science and Medicine NATIONAL CANCER INSTITUTE - SITE VISITOR - AD HOC REVIEWER: NIH-Support Centers for Population Health and Health Disparities (P50) Co-chair 2009 NIH Loan Repayment Program Awards 2008, 2009 MD Anderson Cancer Center Support Grant 2003 Biological Mechanisms of PsychosocialEffects on Disease (BiMPED) 2002 Lung Progress Review Group (PRG) Co-Chair 2000 NCI/ACS Conference on Lung Screening, Co-Chair 2000 University of Rochester Core Grant (R. Abraham) 1999 Rapid Access to Intervention Development (RAID) Reviewer 1998 Program Project Review Committee (Subcommittee C) 1994 Cornell University Program Project (F. Barany) - Chairman 1994 Yale Cancer Center Support Grant (V. DeVita) 1994 Behavioral Medicine Study Section (Ad Hoc Reviewer) 1991, 1993 Non-Small Cell Lung Cancer Strategy Meeting (Ad Hoc Reviewer) 1990, 1992 University of Tennessee Program Project (H. Schuller) - Chairman 1992 Specialized Program of Research Emphasis - Prostate Cancer 1992 Specialized Program of Research Emphasis - Lung Cancer 1992 Special Review Committee - Community Clinical Oncology Program 1990 Dana Farber Cancer Center Program Project (E. Frei) 1990 Memorial Sloan-Kettering Cancer Center Program Project (J. Bertino) 1989 Middle Atlantic Oncology Program 1985 Piedmont Oncology Group (R. Capizzi) 1985 Catholic Medical Center Program Project (D. Martin) 1979 Lung Cancer Study Group (E. Holmes) 1978 External Advisor/Reviewer: Samuel Ochsin Cancer Center, Cedars Sinai 2010-
John C. Ruckdeschel,M.D. University of Hawaii 2007-2008 UT San Antonio/CTRC, Chair 2007-2010 University of Oklahoma Cancer Center 2005 -2006 Penn State Cancer Center (Chair) 2003 -2010 Behavioral Review Panel for the Nebraska Cancer & Smoking Disease Research Program 2001 - USC/Norris Comprehensive Cancer Center External Advisory Committee 1999 -2002 Rensselaer Polytechnic Institute College of Science External Advisory Board 1999 -2010 American Institute of Biological Sciences (Army, DOD reviews) 1997 - 2009 Wake Forest Cancer Center External Advisory Board, (Chair 1999 -) 1997 - 2009 U.S. Army Medical R&D Command Breast Cancer Research Program (Reviewer) 1994 - Illinois Cancer Council External Advisory Board 1989 - 1992 Tobacco Related Disease Research Program Study Section (California) 1990 - VA Merit Review Program 1989 - 1993 ACS Psychosocialand Behavioral Review Committee, (Chair 1989 -) 1986 – 1989 COMMUNITY: Health Advisory Board, University Medical Center of Southern Nevada 2010- Clark County Committee on Priorities 2009-2010 Greater Detroit Area Health Council 2007-2009 Board of Directors, University Liggett School 2006-2009 Wayne County Health Authority; Provider Advisory Committee (co-chair) 2005 -2007 Community Advisory Board, Junior League of Tampa 2002 Committee of 100 Steering Committee of Tampa Chamber of Commerce 2001 - 2002 Sun Trust Bank Board of Directors and Trust Committee of the Board 2000 - 2002 Jesuit High School Board of Trustees 2000 - 2002 Chair, Health/Bio-Medical Committee of the Tampa Chamber of Commerce 1999 Sacred Heart Church, General Chair of Capital Campaign 1998 Jesuit High School Foundation Board of Directors 1998 - 2000 Leukemia Society of America, Suncoast Chapter Board of Trustees 1995 - 1998 West Sand Lake Volunteer Fire Department, West Sand Lake, NY President 1981 - 1983, Line Officer 1982 - 1983, 1985 - 1986 1979 - 1991 Sand Lake Ambulance, West Sand Lake, NY 1984 - 1991 Board of Directors 1984 - 1985, Line Officer 1985 - 1987, Board President 1989 - 1991 President, Board of Directors, United Urban Ministry of Troy, NY 1976 - 1980 Staff Physician, People’s Free Medical Clinic, Baltimore, MD 1972 - 1975 PUBLICATIONS - PEER REVIEWED 1. Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med. 1972;287:1013-7. 2. Ruckdeschel JC, Peters T, Lee KT. Fibrinogen catabolism in rats fed thrombogenic diets. Atherosclerosis.1972;16:277-85. 3. Graziano KD, Ruckdeschel JC, Mardiney Jr MR. Cell associated immunity to measles (rubeola): the demonstration of in vitro lymphocyte tritiated thymidine incorporation in response to measles complement fixation antigen. Cellular Immunol. 1975;15:247-359. 4. Ruckdeschel JC, Graziano, KD, Mardiney Jr MR. Additional evidence that the cell associated immune systemis the primary host defense against measles (rubeola). Cell Immunol. 1975;17:11-18. 5. Ruckdeschel JC, Chang P, Martin RG, Byhardt RW, O’Connell MJ, Sutherland JC, Wiernik PH. Radiation-related pericardial effusions in patients with Hodgkin’s disease.Medicine (Baltimore). 1975;54:245-59. 6. Byhardt RW, Brace K, Ruckdeschel JC, Chang P, Martin RW, Wiernik PH. Dose and treatment factors in radiation related pericardial effusion associated with the mantle technique for hodgkin’s disease.Cancer. 1975;35:795-802. 7. Martin RW, Ruckdeschel JC, Chang P, Byhardt RW, Bouchard P, Wiernik PH. Radiation-related
John C. Ruckdeschel,M.D. pericarditis. Am J Cardiol. 1975;35:216-20. 8. Dummire C, Ruckdeschel JC, Mardiney Jr MR. Suppression of in vitro lymphocyte responsiveness to PPD by measles virus: a re-exploration of the phenomenon. Cell Immunol. 1975;20:205-17. 9. Drake WP, Porkorney DR, Ruckdeschel JC, Levy CC, Mardiney Jr MR. A white blood cell ribonuclease assay forthe monitoring of malignancy. J Natl Cancer Inst. 1975;54:1475-78. 10. Ruckdeschel JC, Kramarsky B, Mardiney Jr MR. Mycoplasma contamination of membrane associated measles antigens.Inability to demonstrate in vitro lymphocyte responsiveness to measles. Cell Immunol. 1975;20:110-16. 11. Ruckdeschel JC, Schimpff SC, Smyth AC, Mardiney Jr MR. Correlation of susceptibility to herpes zoster with impaired cell associated immunity to the varicella-zoster virus in patients with hodgkin’s disease.Am J Med. 1977;62:77-85. 12. Ruckdeschel JC, Mardiney Jr MR. The demonstration of cell associated immunity to viruses.In vitro lymphocyte responsiveness to varicella-zoster antigen. J Immunol Methods.1976;13:131-43. 13. Ruckdeschel JC, Doukas J, Drake WP, Mardiney Jr MR. Application of laser cytometry to the analysis of immunologically induced in vitro lymphocyte blastogenesis.Transplantation.1977;23:396-403. 14. Doukas J, Ruckdeschel JC, Mardiney Jr MR. Quantitative and qualitative analysis of human peripheral lymphocyte proliferation to specific antigen in vitro by use of the helium neon laser. J Immunol Methods. 1977;15:229-38. 15. Mardiney Jr MR, Ruckdeschel JC. Inhibition of in vitro lymphocyte response by measles virus antigen: a reply [letter]. Cell Immunol. 1977;28:229. 16. Hahn DM, Schimpff SC, Ruckdeschel JC, Wiernik PH. Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thiotepa, or bleomycin. Cancer Treat Rep. 1977;61(8):1585-7. 17. Lempert N, MacDowell RT, Karmody A, Knight E, Cunningham TJ, Sponzo R, Horton J, Ruckdeschel JC. Vascular access for cancer chemotherapy. Cancer. 1979;43:1934-6. 18. Caradonna R, Paladine W, Ruckdeschel JC, Goldstein JC, Olsen JE, Jaski JW, Silvers SA, Hillinger S, Horton J. Methotrexate, bleomycin and high dose cis-platinum for advanced epidermoid carcinoma of the head and neck. Cancer Treat Rep. 1979;63:489-91. 19. Ruckdeschel JC, Baxter DH, McKneally MR, Killan DA, Lunia SL, Horton J. Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity. Int J Radiat Oncol Biol Phys. 1979;5:1323-8. 20. Ruckdeschel JC, Lininger L, Brzyski H, Miani M, Becker J. Serial quantitation of in vitro lymphocyte responsivenessto Concanavalin-A. Transplantation. 1979;28(3):203-6. 201 Ruckdeschel JC, Caradonna R, Paladine WJ, Hillinger SM, Horton J. Small cell anaplastic carcinoma of the lung: changing concepts and emerging problems. CA Cancer J Clin. 1979;29:84-95. 22. Blanchard C, Ruckdeschel JC, Cohen RE, Horton J, McSharry J, Shaw E. Attitudes towards cancer. I: the impact of a comprehensive oncology course on second year medical students. Cancer. 1981;47:2756-62. 23. Lunia SL, Ruckdeschel JC, McKneally MF, Killam E, Baxter D, Kellar S, Ray P, McIlduff J, Lininger L, Chodos R, Horton J. Non-Invasive evaluation of mediastinal metastases in bronchogenic carcinoma: a prospective comparison of chest radiography and gallium-67 scanning.Cancer. 1981;47:672-9. 24. Rodichok LD, Harper GR, Ruckdeschel JC, Price A, Roberson G, Barron KD, Horton J. Early diagnosis of spinal epidural metastases.Am J Med. 1981;70:1181-7. 25. Ruckdeschel JC, Mehta CR, Salazar OM, Cohen M, Vogl S, Koons LS, Lerner H. Chemotherapy of inoperable non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1981;65:965-72. 26. Ruckdeschel JC, Mehta CR, Salazar OM, Cunningham TJ, Creech RH, Sponzo RW. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575 generation III, HAM vs CAMP. Cancer Treat Rep. 1981;65:959-63. 27. Brandman J, Ruckdeschel JC, O’Donnell M, Horton J. Rapid tumor necrosis leading to serious pulmonary infections in patients treated intensively for small cell cancer of the lung. N Y State J Med. 1981;81:1332-4. 28. Ruckdeschel JC, McKneally MF, Baxter DH, Devore C, Kellar S, Killam D, Caradonna R, Sedransk N, McIlduff J, Horton J. Regional immunotherapy has a detrimental effect on the response to combined irradiation and chemotherapy in locally advanced non-small cell bronchogenic carcinoma. Cancer Immunol Immunother. 1981;11:277-82. 29. Ferraro JA, Horton J, Weissman C, Ruckdeschel JC, O’Donnell M, Ludlum D. Treatment of advanced colorectal carcinoma with AMSA. Cancer Treat Rep. 1981;65:345-7. 30. Cohen RE, Ruckdeschel JC, Blanchard CG, Rohrbaugh M, Horton J. Attitudes towards cancer. II: a
John C. Ruckdeschel,M.D. comparative analysis of cancer patients,medical students,medical residents,physicians and cancer educators.Cancer. 1982;50:1218-23. 31. Ruckdeschel JC, Lea JW, Brown S, Horton J. Content-bias in the neoplastic-related items of the national board of medical examiners part II examination. Med Pediatr Oncol. 1982;10:269-74. 32. Ettinger SD, Day R, Ferraro JA, Ruckdeschel JC, Woll JE, Vogl SE. A phase II study ofAMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma: an Eastern Cooperative Oncology Group study.Am J Clin Oncol. 1983;6:167-70. 33. Ahles TA, Blanchard EB, Ruckdeschel JC. The multidimensional nature of cancer-related pain. Pain. 1983;17:277-88. 34. Blanchard CB, Ruckdeschel JC, Blanchard EB, Arena JG, Saunders NL, Malloy ED. Interactions between oncologists and patients during rounds.Ann Intern Med. 1983;99:694-9. 35. Ahles T, Ruckdeschel JC, Blanchard EB. Cancer-related pain. I: prevalence in an outpatient setting as a function of stage of disease and type of cancer. J PsychosomRes. 1984;28:115-9. 36. Zimmerman MS, Ruckdeschel JC, Hussain M. Chemotherapy-induced interstitial pneumonitis during treatment of small cell anaplastic lung cancer. J Clin Oncol. 1984;2:396-405. 37. Ahles T, Ruckdeschel JC, Blanchard EB. Cancer-related pain. II: assessment with visual analogue scales. J PsychosomRes. 1984;28:121-4. 38. Arsenau JC, Wolter JM, Juperminc M, Ruckdeschel JC. A phase II study of bruceantin (NSC-165, 563) in advanced malignant melanoma. Invest New Drugs. 1983;1:239-42. 39. Creech RH, Tritchler D, Ettinger DS, Ferraro JA, Ruckdeschel JC, Vogl SE, Woll J. Phase II study of PALA amsacrine, teniposide and zinostatin in small cell lung carcinoma (EST-2579). Cancer Treat Rep. 1984;68:1183-4. 40. Spiers ASD, Ruckdeschel JC, Horton J. Effectiveness of pentostatin (2’-deoxyoformycin) in refractory lymphoid neoplasms. Scand J Haematol. 1984;32:130-4. 41. Ruckdeschel JC, Day R, Weissman CH, Stolbach LL, Creech RH. Chemotherapy for metastatic non- small cell bronchogenic carcinoma: cyclophosphamide, doxorubicin and etoposide versus mitomycin- vinblastine (EST 2575, generation IV). Cancer Treat Rep. 1984;68:1325-9. 42. Ruckdeschel JC, Finkelstein D, Creech RH, Mason BA. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, general V: a randomized comparison of four cisplatin-containing regimens. J Clin Oncol. 1985;3:72-9. 43. Vogl SE, Camacho F, Berenzweig M, Ruckdeschel JC. Chemotherapy for esophagealcancerwith mitoguanazone, methotrexate, bleomycin and cisplatin. Cancer Treat Rep. 1985;69:21-3. 44. O’Donnell MR, Ruckdeschel JC, Baxter D, McKneally MF, Caradonna R, Horton J. Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung. Cancer Treat Rep. 1985;69:571-5. 45. Bonomi P, O’Reilly W, Vogl SE, Ruckdeschel JC, Stolbach L, Bunting N, Creech RH. Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide,methotrexate and etoposide.Cancer Treat Rep.1985;69:1007-9. 46. Ettinger DS, Finkelstein DM, Harper GR, Ruckdeschel JC, Chang AY, Camacho FJ, Marsh JC, Silber R, Wolter JM. Phase II study of mitoxantrone, aclarubicin and diaziquinone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.Cancer Treat Rep. 1985;69:1033-4. 47. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RA, Mason RC, Joss BA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol. 1986;4:14-22. 48. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: anEastern Cooperative Oncology Group study.J Clin Oncol. 1986;4:702-9. 49. Blanchard CG, Ruckdeschel JC, Fletcher BA, Blanchard EB. The impact of oncologists behavioron patient satisfaction with morning rounds.Cancer. 1986;58:387-93. 50. Cohen RE, Blanchard EB, Ruckdeschel JC, Smolen RC. Prevalence and correlates of post-treatment and anticipatory nausea and vomiting in cancer chemotherapy. J PsychosomRes. 1986;30:643-54. 51. Funa K, Dawson N, Jewett PB, Agren H, Ruckdeschel JC, Bunn Jr PA, Gazdar AF. Automated fluorescent analysis for drug-induced cytotoxicity assays.Cancer Treat Rep. 1986;70:1147-51. 52. Rodichok LD, Ruckdeschel JC, Harper GR, Cooper G, Prevosti L, Fernando L, Baxter DH. Early detection and treatment of spinal epidural metastases:the role of myelography. Ann Neurol. 1986;20:696- 702. 53. Mulshine J, Glatstein E, Ruckdeschel JC. Treatment of non-small cell lung cancer [invited review]. J
John C. Ruckdeschel,M.D. Clin Oncol.1986;11:1704-15. 54. Blanchard CG, Ruckdeschel JC. Psychosocialaspects ofcancer in adults: implications for teaching medicalstudents. J Cancer Educ. 1986;1:237-48. 55. Ruckdeschel JC, Carney DN, Oie H, Russell EF, Gazdar AF. In vitro chemosensitivity of human lung cancer cell lines. Cancer Treat Rep. 1987;71:697-704. 56. Trump DL, Elson P, Borden EC, Harris J, Tuttle R, Whisnant JK, Oken M, Carignan JR, Ruckdeschel JC, Davis TE.High dose lymphoblastoid interferon in advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study.Cancer Treat Rep. 1987;71:165-69. 57. Baker RR, Ettinger DS, Ruckdeschel JC, Eggleston JC, McKneally MF, Abeloff MD, Woll JE, Adelstein DJ. The role of surgery in the management of selected patients with small cell carcinoma of the lung. J Clin Oncol.1987;5:697-702. 58. Blanchard CG, Ruckdeschel JC, Labrecque MS, Frisch S, Blanchard EB. The impact of a designated cancer unit on house staffbehaviors toward patients.Cancer. 1987;60:2348-54. 59. Finkelstein DM, Cassileth BR, Bonomi PD, Ruckdeschel JC, Ezdinli EZ, Wolter JM. A pilot study of the functional living index-cancer (FLIC) scale for the assessment ofquality of life for metastatic lung cancer patients: an Eastern Cooperative Oncology Group study.Am J Clin Oncol. 1988;11:630-33. 60. Ruckdeschel JC. Whither screening for lung cancer [editorial]. J Natl Cancer Inst.1988;80:78-9. 61. Blanchard CG, Labrecque MS, Ruckdeschel JC, Blanchard EB. Information and decision-making preferences of hospitalized adult cancer patients.Soc Sci Med. 1988;27:1139-45. 62. Ruckdeschel JC. Attempts to enhance locoregional control of cancer by radiotherapy, phototherapy and combined modality therapy [invited review]. Curr Opin Oncol. 1989;1:231-5. 63. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J. Combination chemotherapy versus single agents followed by combination chemotherapy in stageIVnon-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group study.J Clin Oncol. 1989;7:1602-13. 64. Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol.1990;8:230-40. 65. Aisner SC, Finkelstein DM, Ettinger DS, Abeloff MD, Ruckdeschel JC, Eggleston JC. The clinical significance of variant-morphology small cell carcinoma of the lung. J Clin Oncol. 1990;8:402-8. 66. Blanchard CG, Labrecque MS, Ruckdeschel JC, Blanchard EB. Physician behaviors, patient perceptions and patient characteristics as predictors of satisfaction of hospitalized adult cancer patients.Cancer. 1990;65:186-92. 67. Ettinger DS, Finkelstein DM, Donehower RC, Chang AYC, Greene M, Blum R, Hahn RG, Ruckdeschel JC. A phase II study of n-methylformamide, spirogermanium and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583). An ECOG Study.Med Ped Oncol. 1989;17:197- 201. 68. Braun MA, Killam DA, Remick SC, Ruckdeschel JC. Lung cancer in patients seropositive for human immunodeficiency virus. Radiology. 1990;175:341-3. 69. Remick SC, Diamond C, Migliozzi JA, Solis O, Wagner H, Haase RF, Ruckdeschel JC. Primary central nervous systemlymphoma (PCL) in patients with and without AIDS. A retrospective analysis and review of the literature. Medicine. 1990;69(6):345-60. 70. Ruckdeschel JC. Is chemotherapy for metastatic non-small cell lung cancer “worth it?” [editorial]. J Clin Oncol. 1990;8:1293-6. 71. Nelles WB, Blanchard CG, McCaffrey RJ, Ruckdeschel JC. Social supports and breast cancer: a review. J Psychosoc Oncol. 1991;9(2):21-34. 72. Kobassa SCO, Spinetta JJ, Cohen J, Crano WD, Hatchett S, Kaplan BH, Lansky SB, Prout MN, Ruckdeschel JC, Siegel K, Wellisch DK. Social environment and social support.Cancer. 1991;67 (suppl 1):788-93. 73. Johnson DH, Ruckdeschel JC, Keller JH, Lyman GH, Kallas GJ, MacDonald J, DeConti RC, Lee J. A randomized trial to compare intravenous and orally administered etoposide in combination with cisplatin for the treatment of small cell lung cancer. Cancer. 1991;67(suppl):245. 74. Ettinger DS, Finkelstein DM, Abeloff MD, Chang YC, Smith TJ, Oken MM, Ruckdeschel JC. Phase II study of nmethylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of
John C. Ruckdeschel,M.D. advanced small cell lung cancer. Invest New Drugs. 1990;9(2):183-85. 75. Remick SC, Harper GR, Abdullah MA, McSharry JJ, Ross JS, Ruckdeschel JC. Metastatic breast cancer in a young patient seropositive for human immunodeficiency virus. J Natl Cancer Inst. 1991;83:447. 76. Labrecque MS, Blanchard CG, Ruckdeschel JC, Blanchard EB. The impact of family presence on the physician cancer patient interaction. Soc Sci Med. 1991;33:1253-61. 77. Remick SC, Ruckdeschel JC. Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy and outcome. Med Pediatr Oncol. 1992;20:89-99. 78. Ruckdeschel JC, Piantadosi S, and the LCSG. Quality-of-life assessment in lung surgery for bronchogenic carcinoma. Theor Surg. 1991;6:201-5. 79. Ruckdeschel JC, Moores D, Lee JY, Einhorn LH, Mandelbaum I, Koeller J, Weiss GR, Losada M, Keller J. Intrapleural therapy for malignant pleural effusions: a randomized comparison of bleomycin and tetracycline. Chest. 1991;100:1528-35. 80. Henry DH, Beall GN, Benson CA, Carey J, Cone L, Eron LJ, Fiala M, Fischl M, Gabin S, Galpin J, Gottlieb M, Groopman JE, Hooton T, Jemsek J, Levine R, Miles S, Rinehart JJ, Rios A, Robbins W, Ruckdeschel JC, Smith J, Spruance S, Starrett B, Toney J, Zalusky R, Abels R, Bryant E, Larholt R, Sampson A, Rudnick S. Recombinant human erythropoietin in the treatment of the anemia associated with human immunodeficiency virus infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med. 1991;117:739-48. 81. Ruckdeschel JC. Chemotherapy of metastatic non-small cell carcinoma of the lung. Hematol Oncol. 1992;10:25-30. 82. Ruckdeschel JC. Special problems in the older cancer patient: spinal cord compression and pleural effusions. Oncology. 1992;6(2):119-23. 83. Sklarin NT, Wiernik PH, Grove WR, Benson L, Mittelman A, Maroun JA, Steward JA, Robert F, Doroshow JH, Rosen PJ, Jolivet J, Ruckdeschel JC, Robert NJ, Velez-Garcia E, Bergsagel DE, Panasci LC, van der Merwe AM, Longueville JJ, Leiby J. A phase II trial of CI-921 in advanced malignancies. Invest New Drugs. 1992;10:309-12. 84. Ruckdeschel JC, Modi SP, el-Hamouly W, Portuese E, Archer S. N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines. J Med Chem. 1992;35(26):4854-7. 85. Grossman SA, Ruckdeschel JC, Moynihan T, Finkelstein D, Ettinger DS, Mahoney E, Trump DL. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11:561-9. 86. Ruckdeschel JC. Therapeutic options for the treatment of small cell and non-small cell cancer of the lung. Curr Opin Oncol. 1993;5(2):323-34. 87. Ruckdeschel JC. Cellular characterization of lung cancer - a caveat [editorial]. Chest. 1993;104(2):331. 88. Scott F, Cuttitta F, Treston A, Avis I, Gupta P, Ruckdeschel JC, Kelly K, Piantadosi S, Tockman M, Mulshine J. Prospective trial evaluating immune-cytochemical-based sputumtechniques for early lung cancer detection: assays for promotion factors in the bronchial lavage. J Cell Biochem Suppl. 1993;17F:175-83. 89. Maroun J, Ruckdeschel JC, Natale R, Morgan R, Dallaire B, Sisk R, Gyves J. Multicenter phase II study of brequinar sodium in patients with advanced lung cancer. Cancer Chemother Pharmacol. 1993;21(1):64-6. 90. Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagner H, Portuese E, Wighton T, Powell D, Pearce T, Horton J, Ruckdeschel JC. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-hodgkin’s lymphoma. J Clin Oncol. 1993;11(9):1691- 702. 91. el-Hamouly WS, Ruckdeschel JC, Archer S. Preparation and antitumor activity of an n- methylcarbamate derivative of amsacrine. Eur J Med Chem. 1993;28:913-6. 92. Tockman MS, Erozan YS, Gupta P, PiantadosiS, Mulshine JL, Ruckdeschel JC, and the LCEDWG Investigators. The early detection of second primary lung cancers by sputum immune-staining. Chest. 1994;106(6):385s-90s. 93. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel JC, Giaccone G, the LCSG, the Eastern Cooperative Oncology Group and the European Organization for Research and Treatment of Cancer. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response ofsmall cell lung cancer to combination chemotherapy. Chest. 1994;106(6):320s-3s. 94. Ruckdeschel JC, Piantadosi S, for the Lung Cancer Study Group. Quality of life in lung cancer
John C. Ruckdeschel,M.D. surgical adjuvant trials. Chest. 1994;106(6):324s-8s. 95. Wagner H, Lad T, Piantadosi S, Ruckdeschel JC, for the Lung Cancer Study Group. Randomized phase II evaluation of pre-operative radiation therapy and pre-operative chemotherapy with mitomycin-c, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung: LCSG 881. Chest. 1994;106(6):348s-54s. 96. Linnoila RI, PiantadosiS, Ruckdeschel JC, for the Lung Cancer Study Group. Impact of neuroendocrine differentiation in non-small cell lung cancer: the LCSG experience. Chest. 1994;106(6):367s-71s 97. Shaw GL, Falk RT, DesLauriers J, Nesbitt JC, McKneally MF, Frame JN, Feld R, Issaq HJ, Ruckdeschel JC, Hoover RN. Lung tumor resection does not affect debrisoquine metabolism. Cancer Epidemiol Biomarkers Prev. 1994;3:141-4. 98. Ruckdeschel JC. Chemical pleurodesis for malignant pleural effusions: a reply [letter]. Ann Intern Med. 1994;121(2):150. 99. Remick SC, Reddy M, Herman D, Grace C, Harper G, Willis K, Candon B, Horton J, Ruckdeschel JC. Continuous infusion bleomycin in AIDS-related kaposi sarcoma. J Clin Oncol. 1994;12(6):1130-6. 100. Ruckdeschel JC. Special report: Lung Cancer Study Group - final analysis. Cancer Control. 1994;1:283-5. 101. Ruckdeschel JC. Lung cancer: time for an end to nihilism. Cancer Control. 1994;2(5):430-1. 102. Ruckdeschel JC, Blanchard C, Albrecht T. Psychosocialoncology research: where we have been, where we are going and why we won’t get there. Cancer. 1994;74(4):1458-63. 103. Holmes EC, Ruckdeschel JC. Preoperative chemotherapy for locally advanced non-small cell lung cancer. Semin Oncol. 1994;21:3(6):97-100. 104. McCaffrey RJ, Orsillo SM, Ortega A, Pendry, D., Haase RF, Ruckdeschel JC, WagnerH. Neuropsychological sequelae of prophylactic cranial irradiation therapy: a prospective study.Assessment in Rehabilitation and Exceptionality. 1995;2(1):25-33. 105. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.J Clin Oncol. 1995;13(7):1615-22. 106. Blanchard CG, Albrecht TL, Ruckdeschel JC, Grant III CH, Hemmick RM. The role of social support in adaptation to cancer and to survival. J Psychosoc Oncol. 1995;13(1/2):75-95. 107. Remick SC, Chmura M, Bromberg C, Sporn J, Healey B, Hilstro J, DeConti RC, Horton J, Ruckdeschel JC, Harper GR. Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Cancer Clin Trials. 1996;19(2):125-31. 108. Stock HS, Rosellini RA, Abrahamsen GC, McCaffrey RJ, Ruckdeschel JC. Methotrexate does not interfere with an appetitive pavlovian conditioning task in sprague-dawley rats. Physiol Behav. 1995;58(5):969-73. 109. Ruckdeschel JC. Rapid, cost-effective diagnosis of spinal cord compression due to cancer. Cancer Control. 1995;2(4):320-3. 110. Antonia S, Wagner H, Williams C, Alberts WM, Hubbell, D., Robinson L, Hilstro J, Ruckdeschel JC. Concurrent paclitaxel/cisplatin with thoracic radiation in patients with non-small cell carcinoma of the lung. Semin Oncol. 1995;22(4):34-7. 111. Ruckdeschel JC. Management of malignant pleural effusions. Semin Oncol. 1995;22(2):58-63. 112. Ruckdeschel JC, Albrecht T, Blanchard C, Hemmick R. Communication, accrual to clinical trials and the physician patient relationship: implications for training program. J Cancer Educ. 1996;11(2):73-9. 113. Ruckdeschel JC. Preoperative paclitaxel plus carboplatin for patients with intermediate-risk non- small cell lung cancer. Semin Oncol. 1996;23(6):62-7. 114. Pisters KMW, Kris MG, Bunn Jr PA, Johnson DH, Ruckdeschel JC, Crowley JJ, Ginsberg RJ. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Semin Oncol. 1997;24(4)(suppl 4):41-4. 115. Antonia S, Ruckdeschel JC. Improving our management of NSCLC and mesothelioma [editorial]. Cancer Control. 1997;4(4):293. 116. Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK, Ruckdeschel JC, Taylor PR, Zhurkov T, Zhou W, Qiao Y, Yas SX. Prospective detection of preclinical lung cancer: preliminary results from two studies ofhnRNP A2/B1 overexpression. Clin Cancer Res. 1997;3:2237-46. 117. Spiers ASD, Esseltine DLW, Ruckdeschel JC, Davies NP, Horton J. Metastatic adenoid cystic carcinoma of salivary glands.Case reports and review of the literature. Cancer Control. 1996;3(4):336-42.
John C. Ruckdeschel,M.D. 118. Blanchard CG, Albrecht TL, Ruckdeschel JC. The crisis of cancer: psychologicalimpact on family caregivers. Oncology. 1997;11(2):189-94. 119. Larson GP, Zhang G, Ding S, Foldenauer K, Vdar N, Gatti RA, Neuberg D, Lunetta KL, Ruckdeschel JC, Longmate J, Flanagan S, Krontiris TG. An allelic variant in the ATM locus implicated in breast cancer susceptibility. Genet Test. 1998;1(3):165-70. 120. Ruckdeschel JC. Slow but real progress in the treatment of thoracic malignancy [editorial review]. Curr Opin Oncol. 1998;10(2):119-21. 121. Ruckdeschel JC, Gridelli C, Perrone F, Monfardini S, Giaccone G. Current controversies in cancer: are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer? Pro. Eur J Cancer. 1998;34(13):1993-9. 122. Remick SC, Sedransk N, Haase R, Craffey M, Subramanian N, Dowlati A, Nazeer T, Ramnes C, Blanchard C, Mastrianni D, Balducci L, Horton J, Ruckdeschel JC. Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies. Drugs. 1999;58(3):99-107. 123. Albrecht TL, Blanchard C, Ruckdeschel JC, Coovert M, Strongbow RM. Strategic physician communication and oncology clinical trials. J Clin Oncol. 1999;17(10):3324-32. 124. Ruckdeschel JC. Update in oncology. Ann Intern Med. 1999;16:131(10):760-7. 125. Yuen AR, Fuks JZ, Ettinger DS, Chang AY, Ruckdeschel JC, Phan SC, Blum RH. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group study (PA586). Cancer J Sci Am. 2000;6(1):34-9. 126. Simendinger E, Ruckdeschel JC, Vizzi D. Does e-commerce belong in a cancer & research institution? J Healthcare Manag. 2000;45:3. 127. Chirikos TN, Ruckdeschel JC, Krischer JP. Impact of clinical trials on the cost of cancer care. Med Care. 2001;39(4):373-83. 128. Bennett CL, Stinson TJ, Votel V, Robertson L, Leedy D, O’Brien P, Hobbs J, Sutton T, Ruckdeschel JC, Chirikos TN, Weiner RS, Ramsey MM, Wicha MS. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000;18(15):2805-10. 129. Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease Jr RF, Weeks JC: Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2B for high- risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002;20(5):1311-8. 130. Chirikos TN, Ruckdeschel JC, Krischer JP. Economic analysis of cancer treatment costs:anothertool for oncology managers. J Oncol Mgmt. 2001;10(3):11-17. 131. Jacobsen PB, Meade CD, Stein KD, Chirikos TN, Small BJ, Ruckdeschel JC. Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol. 2002;20:2851-62. 132. Riddle DL, Albrecht TL, Coovert MD, Penner LA, Ruckdeschel JC, Blanchard CG, Quinn G, Urbizu D. Differences in audiotaped versus videotaped physician – patient interactions. J Nonverbal Behavior. 2002;26:219-39. 133. Albrecht TL, Ruckdeschel JC, Ray III FL, Pethe BJ, Riddle DL, Strohm J, Penner LA, Coovert MD, Quinn G, Blanchard CG. A portable, unobtrusive device for videorecording clinical interactions. Behav Res Methods.2005;37(1):165-9. 134. Albrecht TL, Ruckdeschel JC, Riddle DL, Blanchard CG, Penner LA, Coovert MD, Quinn G. Communication and consumer decision making about cancer clinical trials. Patient Educ Couns. 2003;50:39-42. 135. Albrecht TL, Penner LA, Ruckdeschel JC. Understanding patient decisions about clinical trials: a proposed theoretical model and associated methodologies to examine the process.J Cancer Educ. 2003;18:210-4. 136. Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, WagnerH, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (Iressa, ZD1839) in previously treated advanced non-small cell lung cancer. Experience from a single institution. Cancer Control. 2003;10:388-95. 137. Larson GP, Ding Y, Cheng LSC, Lundberg C, Gagalang V, Rivas G, Geller L, Weitzel J, MacDonald D, Archambeau J, Slater J, Neuberg D, Daly MB, Angel I, Benson III AB, Smith K, Kirkwood JM,
John C. Ruckdeschel,M.D. O'Dwyer PJ, Raskay B, Sutphen R, Drew R, Stewart JA, Werndli J, Johnson D, Ruckdeschel JC, Elston RC, Krontiris TG. Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. Cancer Research. 2004;65: 805-814. 138. Quinn GP, Jacobsen PB, Albrecht TL, Ellison BAB, Newman NW, Bell M, Ruckdeschel JC. Real- time patient satisfaction survey and improvement process.Hosp Top. 2004;82(3):26-32 139. Ruckdeschel JC. Fatigue is becoming an exhausting problem [editorial]. Cancer. 2005;103(2):213-5. 140. Albrecht TL, Ruckdeschel JC, Ray FL 3rd,Pethe BJ, Riddle DL, Strohm J, Penner LA, CoovertMD, Quinn G, Blanchard CG. A portable, unobtrusive device for video recording clinical interactions. Behav Res Methods 2005, 37(1):165-9. 141. Ruckdeschel JC. The problem of lung cancer as a paradigm-keynote address.Ethnicity Dis. 2005; 15(suppl 1):S1-2. 142. Ruckdeschel JC. Early detection and treatment of spinal cord compression. Oncology. 2005; 19(1):81-92. 143. Albrecht TL, Franks MM, Ruckdeschel JC. Communication and informed consent.Curr Opin Oncol. 2005;17:336-9. 144. Cote ML, Kardia SL, Wenzlaff AS, Ruckdeschel JC, Schwartz AG. Risk of lung cancer among white and black relatives of individuals with early lung cancer. JAMA; 2005;293(24): 3036-42. 145. Eggly S, Penner L, Albrecht TL, Cline RJW, FosterT, Naughton M, Peterson A, Ruckdeschel, JC. Discussing 'bad news' in the outpatient oncology clinic: rethinking current communication guidelines. J Clin Oncol. 2006, 24(4):716-719. 146. Schwartz AG and Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2006; 173(1): 16-22. 147. Ruckdeschel JC. Second line chemotherapy for non-small cell lung cancer. Chest 2006; 129(4):840-2 148. Albrecht TL, Kuerer H, Ruckdeschel JC, Mendez J, Harper F, American College of Surgeons Oncology Group. Transdisciplinary studies of surgical oncology trial accrual: A National Institute of Health/ National Cancer Institute Roadmap-affiliated project update. Cancer. 2006; 107(1): 171-4. 149. Eggly S, Penner LA, Greene M, Harper FW, Ruckdeschel JC, Albrecht TL. Information seeking during “bad news” oncology interactions: Question asking by patients and their companions. Soc Sci Med. 2006; 63(11): 2974-85. 150. Robinson LA, Ruckdeschel JC, WagnerH Jr, Stevens CW. Treatment of non-small cell lung cancer- stage IIIA; ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007, 132(3Suppl): 243S-265S. 151. Paterson A., Cline R., FosterT, Jones E, Penner L, Parrott R,. Keller C, Naughton M, Taub J, Ruckdeschel JC, Albrecht T. Parent’s interpersonal distance and touch behavior and child pain and distress:Journal of Nonverbal Behavior 2007;31: 79-97. 152. Penner L, Orom H, Franks M, Albrecht T, FosterT, Ruckdeschel JC. Camera-related behaviors during video recorded medical interactions: Journal of Nonverbal Behavior 2007;31: 99-117. 153. Cline RJW, Penner LA, Harper FWK, FosterTS, Ruckdeschel JC, Albrecht T. Patients’ Internet use for cancer information and socioeconomic status as co-advantages in oncologist-patient communication. Journal of Oncology Practice. 2007; 3: 167-171. 154. Gadgeel SM, Ruckdeschel JC, Heath EL, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and celecoxib a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007;2(4): 299-305. 155. Eggly, S., Albrecht, T.L., Harper, F.W.K., Foster, T.,., Franks, M.M., Ruckdeschel, JC. Oncologists’ recommendation of clinical trial participation to patients.Patient Education and Counseling. 2008; 70(1):143-8. 156. Albrecht, T.L., Eggly S.S., Gleason M.E., Harper F.W., Foster T.S., Petereson A.M., Orom H, Penner L.A., Ruckdeschel JC. Influence of clinical communication on patients’decision making on participation in clinical trials. J Clin Oncol. 2008; 26(16): 2666-73. 157. Gadgeel SM, Wozniak A, Ruckdeschel JC, Heilbrun LK, Venkatramanamoorthy R, Chaplen RA, Kraut MJ and Kalemkerian GP. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer. J Thor Oncol. 2008; 3:1293-300. 158. Whitehouse AC, Black CB, Heppe MS, Ruckdeschel JC, Levin SM. Environmental exposure to
John C. Ruckdeschel,M.D. Libby Asbestos and mesotheliomas. Am J Ind Med. 2008; 51:877-80. 159. Schwartz AG, Cote ML, Wenzlaff AS, Van Dyke A, Chen W, Ruckdeschel JC, Gadgeel S, Soubani A. Chronic obstructive lung diseases and risk of non-small cell lung cancer. J Thorac Oncol 2009; 4: 291-9. 160. Albrecht TL, Eggly SS, Penner LA, Cline RJW, Ruckdeschel JC. Studying the Process of Clinical Communication: Issues ofContext, Concepts and Research Directions. J Health Commun. 2009; 14 Suppl1: 47-56. 161. Pena T, LoRusso PM, Ruckdeschel JC, Goncalves P, Soubani AO. Pulmonary metastasis of basal cell carcinoma: a rare manifestation of a common disease with variable clinical course. J Thorac Oncol. 2009; 4:1026-7. 162. Gleason ME, Harper FW, Eggly S, Ruckdeschel JC, Albrecht TL. The influence of patient expectations regarding cure on treatment decisions.Patient Educ Couns.2009;75:263-9. Epub 2009 Jan 14. 163. Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, Tarca A, Dou QP, Lonardo F, Ruckdeschel JC, Pass HI, Wali A. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol. 2010:66:455-66. 164. Schneider BJ, Kalemkerian GP, Ramnath N, Kraut MJ, Wozniak AJ, Worden FP, Ruckdeschel JC, Zhang X, Chen W, Gadgeel SM. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kitpositive, extensive-stage small-cell lung cancer. Clin Lung Cancer. 2010; 11:223-7. 165. Cline RJ, Orom H, Berry-Bobovski L, Hernandez T, Black CB, Schwartz AG, Ruckdeschel JC. Community-level social support responses in a slow-motion technological disaster: the case of Libby, Montana.AM J Community Psychol. 2010; 46: 1-18. 166. Turner JT, Khoury JD, Ruckdeschel JC. Granulomatous Solitary Pulmonary Nodule. J Bronchol Intervent Pulmonol. 2011; 18:111. 167. Soubani AO, Ruckdeschel JC, The outcome of medical intensive care for lung cancer patients: the case for optimism. J Thorac Oncol, 2011; 6:633-8. 168. Gadgeel SW, Ruckdeschel JC, Patel, BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Marquette L, Turrisi A. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients.J Thorac Oncol 2011: 6; 927-33. 169. Northouse LL, Mood DW, Schafenacker A, Kalemkerian G, Zalupski M, LoRusso P, Hayes DF, Hussain M, Ruckdeschel JC, Fendrick MA, Trask PC, Ronis DL, Kershaw T. Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancerpatients and their family caregivers. Psycho- Oncology 2013;22: 555-63. 170. Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston M,Goodman G, Clamon G,Okawara G, Marks R, Frechette E, McCaskill-Stevens W, Lippman SM, Ruckdeschel JC, and Khuri FR. A Randomized, Double Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non Small Cell Lung Cancer (ECOG 5597) J. Clin Oncol2013, 31:4179-85. 171. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez C, Ros HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC , Fein L, He X, Hall HR, Kawabe T, Sharma S. Randomized Phase II Trial of Pemetrexed/Cisplatin with or without CBP501 in Patients with Advanced Malignant Pleural Mesothelioma Lung Cancer. 2014 Sep; 85(3):429-34. 172. Hahn EE, Tang T, Lee JS, Munoz-Plaza C, Adesina O, Shen E, Rowley B, Maeda JL, Mosen DM, Ruckdeschel JC, Gould M.Use of advanced imaging for staging of early breast cancer in two integrated health care systems:Adherence with a Choosing Wisely Recommendation. Submitted J Oncol Practice 2014 BOOK CHAPTERS, LETTERS, MONOGRAPHS, SYMPOSIA REPORTS 1. Ruckdeschel JC. Tumor registries [letter]. JAMA. 1973;266-72. 2. Ruckdeschel JC. Case records of the Massachusetts General Hospital [invited discussion].N Engl J Med.1974;291:1297-1303. 3. Ruckdeschel JC, Wiernik PH. Reactions to radiation therapy [letter]. N Engl J Med. 1975;293:668-9. 4. Ruckdeschel JC. Amantadine and pulmonary peripheral airways [letter]. Ann Int Med. 1977;86:369-70. 5. Ruckdeschel JC, Lininger L, Brzyski H, Miani M, Becker J. Re-analysis of in vitro lymphocyte blastogenesis using the laser cytometry assay.In: Baum S, editor. Experimental hematology today.
John C. Ruckdeschel,M.D. Farmington, CT: Karger; 1979.p.123-8. 6. Ruckdeschel JC. Diagnosis and management of small cell anaplastic (oat cell) cancer of the lung. Current concepts in oncology.1979;1:18-24. 7. Ruckdeschel JC. Lung cancer - mediguide to oncology. 1981;1(6). 8. Ruckdeschel JC. Early diagnosis of lung cancer [editorial]. Clinical Cancer Briefs. 1981;2:2. 9. Ruckdeschel JC. Immunotherapy of Human Cancer: An Overview. In: Schimpff S, Moossa AR, Robson MC, eds.Comprehensive Textbook of Oncology. Baltimore: Willliams and Wilkins Publishers; 1984. 10. Ruckdeschel JC, Balint J, Gross P, Laufer F. Instructionalcosts for full-time faculty in an academic department of internal medicine. In: Hurst W, editor. Teaching internal medicine. 1984. 11. Ruckdeschel JC, Blanchard CG, Blanchard EB. Direct measurement of physician behavior as a potential method of evaluating medical education. In: Hurst W, editor. Teaching internal medicine. 1984. 12. Muggia FM, Goldin A, Ruckdeschel JC. New drugs in lung cancer. Proceedings of the 4th Mediterranean Congress of Chemotherapy; 1984 Oct 19-25; Rhodes, Greece. Chemioterapia. 1984;4(2 Suppl):1138-9. 13. Ruckdeschel JC, Oie HK, Gazdar AF. In vitro characterization of non-small cell lung cancer. In: Hansen HH,Nijhoff M, editors. Lung cancer: basic and clinical aspects.Boston:Kluwer; 1986. p. 49-59. 14. Ruckdeschel JC. Chemotherapy in metastatic lung cancer: Reply [letter]. J Clin Oncol. 1986;4:1151-2. 15. Ruckdeschel JC. Chemotherapy of non-small cell lung cancer. In: Kimura K, Ota K, Heberman RB, Takita H, editors. Cancer chemotherapy: challenges for the future, vo. 2. pp 202-209, Eds. K. Kimura, K. Ota, R.B. Heberman, H. Takita. Tokyo: Excerpta Medica; 1987. p 202-209. 16. Ruckdeschel JC. Management of malignant pleural effusions.Semin Oncol. 1988;15(3 suppl3):24-8. 17. Ruckdeschel JC, Moores D. Malignant pleural effusions: diagnosis and management [monograph, video]. NewYork, NY: LP Communications; 1988. 18. Ruckdeschel JC. Chemotherapy of disseminated non-small cell lung cancer. In Bitram J, Golomb H, editors. Lung cancer: a comprehensive treatise. New York, NY: Grune & Stratton; 1988. p 233-41. 19. Ruckdeschel JC. Clinical advances in management of malignant pleural effusions.J Crit Illn. 1988. 20. Ruckdeschel JC, Moores D. Non-small cell lung cancer: a multimodality approach to treatment [monograph, video]. New York, NY: LP Communications, 1989. 21. Ruckdeschel JC. Lung cancer: an introduction. In: Roth J, Ruckdeschel J, WeisenburgerT, editors. Textbook of Thoracic Oncology. Philadelphia, PA: WB Saunders; 1989. p 2-5. 22. Mulshine J, Ruckdeschel JC. The role of chemotherapy in the management of disseminated non-small cell lung cancer. In: Roth J, Ruckdeschel J, WeisenburgerT, editors. Textbook of thoracic oncology. Philadelphia, PA: WB Saunders; 1989. p 220-8. 23. Blanchard CG, Ruckdeschel JC. Quality of life. In: Roth J, Ruckdeschel J, Weisenburger T, editors. Textbook of Thoracic Oncology. Philadelphia, PA: WB Saunders; 1989. p. 681-6. 24. Ruckdeschel JC. Book review: Arriagada R, LeChevalier T, editors. Treatment modalities in lung cancer. J Natl Cancer Inst. 1989; 8:633-4. 25. Ruckdeschel JC, Moores D. MPE II: recent findings in the clinical management of malignant pleural effusions [monograph, video]. New York: LP Communications; 1990. 26. Ruckdeschel JC. Etoposide in the management of non-small cell lung cancer. Cancer. 1991;67(suppl):250. 27. Ruckdeschel JC, editor. Malignant pleural effusions:recent advances in diagnosis and management. Bristol-Myers Squibb; 1992. 28. Ruckdeschel JC, Holmes EC. Preoperative chemotherapy for locally advanced non-small cell lung cancer. In: Pass H, editor. Chest Clinics of North America. 1991;1:1-12. 29. Holmes EC, Ruckdeschel JC. Postoperative chemotherapy for non-small cell lung cancer. In: Pass H, editor. Chest Clinics of North America. 1991;1(1):89-97. 30. Ruckdeschel JC. “Current surgical approach to non-small cell lung cancer” by McCormack P [invited commentary]. Oncology. 1991;5(11):44-6. 31. Ruckdeschel JC. Comprehensive textbook of oncology [review]. J Natl Cancer Inst. 1992;84:1596-7. 32. Moffett MJ, Ruckdeschel JC. Bleomycin and tetracycline in malignant pleural effusions.Semin Oncol. 1992;19(suppl):59-62. 33. Ruckdeschel JC. A comparative overview of non-small cell lung cancer: 1980 v 1991. Lung cancer. 1993;9(suppl):15-24.
John C. Ruckdeschel,M.D. 34. Remick SC, WagnerH, Ruckdeschel JC. Management of the patient with HIV-associated lymphomas and hodgkins disease.AIDS reader. 1991;1:204-13. 35. Ruckdeschel JC. Lung cancer - 1993. Mediguide to oncology.1994;14(1):1-8. 36. Ruckdeschel JC. The role of standard dose etoposide in the management of non-small cell lung cancer. Semin Oncol. 1992;19(6):39-44. 37. Wagner H, Ruckdeschel JC. Treatment of locally advanced and metastatic non-small cell lung cancer. Advances in Oncology. 1993;9(5):22-9. 38. Ruckdeschel JC. Preoperative and postoperative adjunctive therapy for resectable non-small cell lung cancer. In: Roth J, Cox J, Hong WK, editors. Lung cancer. Boston: Blackwell Scientific Publications; 1993. p. 239-51. 39. Ruckdeschel JC. The future role of carboplatin. Semin Oncol. 1994;21(5):114-8. 40. Ruckdeschel JC. Spinal cord compression due to cancer: early diagnosis and treatment. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, editors. Clinical oncology.New York: Churchill Livingstone; 1995. p. 619-28. 41. Ruckdeschel JC. Carcinoma of the lung current therapy. In: Rakel R, editor. Conn’s current therapy. Philadelphia: WB Saunders; 1994. p.156-63. 42. Ruckdeschel JC, Robinson LA. Non-small cell lung cancer: surgery and postoperative adjuvant chemotherapy. In: Pass H, Mitchell D, Johnson A,Turrisi J, editors. Lung cancer: principles & practice. Philadelphia: JB Lippincott; 1996. P.839-49. 43. Ruckdeschel JC. Current status and future role of carboplatin [monograph]. Bristol-Myers Squibb, 1994. 44. Ruckdeschel JC. Future directions in non-small cell lung cancer-a personalview. Lung cancer. 1995;12(2):s147- 52. 45. Ruckdeschel JC. Lung cancer: an overview. In: Roth J, Ruckdeschel J, Weisenburger T, editors. Thoracic Oncology II. Philadelphia: WB Saunders; 1995. p.3-4. 46. Williams C, Ruckdeschel JC. Management of disseminated non-small cell lung cancer. In: Roth J, Ruckdeschel J, Weisenburger T, editors. Thoracic Oncology II. Philadelphia: WB Saunders; 1995. p.181-7. 47. Moores D, Ruckdeschel JC. Pleural effusions in patients with malignancy. In: Roth J, Ruckdeschel J, WeisenburgerT, editors. Thoracic Oncology II. Philadelphia: WB Saunders; 1995. p.556-66. 48. Wagner H, Ruckdeschel JC. Screening, early detection and early intervention strategies for cancer of the respiratory system(lung and bronchus).In: Reintgen D, Clark RA, editors. Cancer screening. St. Louis: Mosby Year Book; 1995. p.118-49. 49. Ruckdeschel JC. The cost of success in the treatment of thoracic malignancies [commentary]. Curr Opin Oncol. 1995;7:131-3. 50. Blanchard C, Ruckdeschel JC, Albrecht T. Patient-family communication with physicians.In: Bader, Cooper, DeNour, editors. Cancer and the family. West Sussex : John Wiley & Sons; 1996. p.369-87. 51. Ruckdeschel JC. Introduction: LCSG - the final analysis.Chest. 1994;106(6):279s. 52. Ruckdeschel JC, Aisner J, Ettinger DS, Johnson DH, Wagner H. Small cell lung cancer [monograph]. Bristol Myers Squibb, 1995. 53. Ruckdeschel JC. Malignant effusions in the chest.In: Kirkwood JM, Lotze MT, Yasko JM, editors. Current cancer therapeutics.2nd ed. Philadelphia: Churchill-Livingstone; 1996. p.304-8. 54. Ruckdeschel JC. We have met the enemy . . . and they is us![commentary]. Curr Opin Oncol. 1996;8:103-5. 55. Ruckdeschel JC. Malignant pleural effusion: a cost-effectiveness analysis ofpleurodesis [monograph]. Bristol Myers Squibb, 1996. 56. Ruckdeschel JC, Wagner H, Robinson L. Locally advanced lung cancer - controversies in management. ASCO Educational Book, 1996. 57. Ruckdeschel JC, Wagner H, Robinson L. Locally advanced lung cancer: controversies in management. Advances in Oncology. 1996;12(3):22-8. 58. Ruckdeschel JC, Wagner H, Robinson L. Cáncer de Pulmón Localmente Avanzado [Locally Advanced Lung Cancer] (Spanish). Revista argentina cancerología.1996;24(2):90-2. 59. Ruckdeschel JC. Breaking clinical and administrative barriers. In: Semendinger, editor. The challenge of health care leadership. Chicago: AHA Publishing; 1997. p.51-68. 60. Ruckdeschel JC, Robinson L. Malignant pleural effusions: questions and controversies [monograph]. Bristol Myers Squibb, 1997. 61. Ruckdeschel JC. Combined modality therapy of non-small cell lung cancer. Semin Oncol.
John C. Ruckdeschel,M.D. 1997;24(4):429-39. 62. Robinson L, Ruckdeschel JC. Management of pleural and pericardial effusions. In: Berger, Portenoy, Weissman, editors. Lung cancer: principles and practice of supportive oncology.Philadelphia: JB Lippincott; 1998. p.327-52. 63. Ruckdeschel JC. Treating lung cancer. Coping. 1997;38-9. 64. Antonia S, Robinson LA, Ruckdeschel JC, WagnerH. Lung cancer. In: Balducci, Lyman, Ersher, editors. Comprehensive geriatric oncology.2nd ed. London: Harwood Academic Publishers; 1997. p.613- 30. 65. Ruckdeschel JC. Editorial overview: lung and mediastinum. Curr Opin Oncol. 1997;9(2):147-8. 66. Bonomi P, Ruckdeschel JC. New approaches in the treatment of stage IV non-small cell lung cancer [monograph]. Bristol Myers Squibb, 1997. 67. Ruckdeschel JC. IASLC proceedings - future directions in non-small cell lung cancer: a continuing perspective [review]. Oncology. 1998;12(2):90-6. 68. Ruckdeschel JC. Preoperative and postoperative adjunctive therapy for resectable non-small cell lung cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung Cancer. 2nd ed. Boston: Blackwell Scientific; 1997. p.207-16. 69. Garland LL, Ruckdeschel JC, Wagner Jr H, Williams Jr C, Shaw G, Antonia S, Heise M, Hilstro J, Cantor A. Single agent paclitaxel as second-line chemotherapy for resistant,metastatic non-small cell lung cancer. In: Johnson, Klastersky, editors. Taxanes in lung cancer therapy. New York: Marcel Dekker, Inc.; 1998. p.117-26. 70. Ruckdeschel JC, Aisner J, Ettinger D, Jett J, Wagner H. Current approaches to managing patients with small cell lung cancer [monograph]. Smith Kline Beecham, 1997. 71. Ruckdeschel JC. A prospective randomized trial of bleomycin vs doxycycline vs talc for the intrapleural treatment of malignant pleural effusions. In: Jett J, editor. Current clinical trials in thoracic oncology - what the chest physician needs to know. 1997;1(3). 72. Ruckdeschel JC. Malignant effusions in the chest.In: Kirkwood JM, Lotze MT, Yasko JM, editors. Current Cancer Therapeutics,3rd ed. New York: Churchill Livingstone; 1998. p.324-8. 73. Ruckdeschel JC, Aisner J, Evans W, Gandara D, Green M, Holmes EC, Ihde DC, Johnson DH, Sause WT, Wagner Jr H. Commentary and review of presentations on lung cancer [monograph]. Bristol Myers Squibb, 1998. 74. Mackey CS, Ruckdeschel JC. Lung cancer. In: Sullivan P, Guilford AM, editors. Swallowing Intervention in Oncology. San Diego: Singular Publishing; 1999. p.117-33. 75. Ruckdeschel JC. Chemotherapy for lung cancer: new agents with significant benefit. Primary Care & Cancer. 1998;18(5):26-32. 76. Ruckdeschel JC. Spinal cord compression. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, editors. Clinical Oncology. 2nd ed. New York: Churchill Livingstone; 1999. p.811-9. 77. Tockman M, Ruckdeschel JC, Mulshine J. The early detection of second primary lung cancers by sputum immunostaining. In: Jett J, editor. Current clinical trials in thoracic oncology - what the chest physician needs to know. 1998;2(1):3,8-9. 78. Yanes B, Bonomi PD, Curran Jr WJ, Ginsberg RJ, Khuri FR, Ruckdeschel JC, Weiland JE. Advances in lung cancer management: 1997 Miami Valley hospitallung conference [monograph]. Bristol Myers Squibb, 1998. 79. Ruckdeschel JC. Myths and facts about lung cancer: What You Need to Know. Melville (NY): PRR Publishers; 1999. 80. Blanchard C, Albrecht T, Ruckdeschel JC. Patient family communication with physicians.In: Bader, Cooper, DeNour, editors. Cancer and the family. 2nd ed. West Sussex(England): John Wiley & Sons,Ltd; 2000. p.477-95. 81. Ruckdeschel JC. Intrapleural therapy.In: Ratain MJ, Tempero M, Skosey C, editors. Oncology therapeutics:a quick reference guide. Philadelphia: WB Saunders; 2000. 82. Simon G, Ginsberg R, Ruckdeschel JC. Small cell lung cancer. Chest Surg Clin N Am. 2001;11(1):165-8. 83. Ruckdeschel JC, Robinson L. Management of pleural and pericardial effusions. In: Berger, Portenoy, Weissman, editors. Lung cancer ; principles and practice of palliative care and supportive oncology. Philadelphia: Lippincott,Williams & Wilkins. In press 2001. 84. Ruckdeschel JC, Jablons D. Malignant effusions of the chest.In: Kirkwood JM, Lotze MT, Yasko JM,
John C. Ruckdeschel,M.D. editors.Current Cancer Therapeutics.4th ed. Philadelphia: Current Medicine; 2001. 85. Ruckdeschel JC. Myths and facts about lung cancer: What You Need to Know. Melville (NY): PRR Publishers; 2002. 86. Robinson LA, WagnerH, Ruckdeschel JC. Lung cancer guidelines, treatment of stage IIIA non-small cell lung cancer. Chest. 2003;123(suppl 1): 3325-75. 87. Albrecht TA, Blanchard CG, Ruckdeschel JC, Coovert MA. The mediating role of communication in cancer treatment decision making. In: Brashers D, Goldsmith D, and Lammers L, editors. Communication in the management of health and illness. Manwah (NJ): Lawrence Erlbaum & Associates.In press. 88. Ruckdeschel JC, Greene J, Sommers KE, Fields KK. Respiratory complications of cancer and its treatment. In: Kufe DW, Holland JF, Frei E, editors. Cancer Medicine 6. Hamilton (ON); Lewiston (NY) [distributor]: BC Decker. 2003. 89. Alberts WM, Bepler G, Hazelton T, Ruckdeschel JC, Williams Jr JH. Lung cancer. Practice organization. Chest. 2003;123(suppl 1):2202-5. 90. Ninane V, LePechoux C, Curran W, Furuse K, Liptay M, Meert AP, Paesmans M, Rami-Porta R, Roelandts R, Ruckdeschel JC, Sculier JP, Senan S, Smit EF. Critical factors for patient management. Lung Cancer. 2003;42(suppl):57-8. 91. Ruckdeschel JC, guest editor. Update in the management of lung cancer. New York (NY): RogersMIS. 2004;3(2). 92. Ruckdeschel JC. Spinal cord compression [book chapter]. In: Abeloff M, Armitage J, and Niederhuber J, editors. Clinical Oncology. Philadelphia: Churchill-Livingstone; 2004. p.1063-71. 93. Ruckdeschel JC. Lung cancer [book chapter]. In: Abeloff M, Armitage J, and Niederhuber J, editors. Clinical Oncology. Philadelphia: Churchill-Livingstone; 2004. p.1649-743. 94. Ruckdeschel JC. Myths and facts about lung cancer. What You Need to Know. Melville (NY): PRR Publishers; 2004. 95. Helft PR, Albrecht TL, Back A, Ruckdeschel JC. Challenges to physician communication about treatment options to patients.ASCO Educational Book Alexandria: American Society of Clinical Oncology; 2006 96. Ruckdeschel JC. At the Core of Oncology (book chapter) In: The Art and Science of Oncology. Boston (MA): Aspatore Books; 2007. pp33-44. ABSTRACTS 1. Ruckdeschel JC, Wiernik PH. Carcinoembryonic antigen in patients with hematologic malignancies [abstract].USAEC Report Conf. 1974;73:1141. 2. Ruckdeschel JC, Graziano KD, Mardiney Jr MR. Parameters of in vitro lymphocyte responsiveness to measles antigen [abstract]. Fed Proc. 1974;33:619. 3. Ruckdeschel JC, Doukas J, Mardiney Jr MR. Direct, quantitative analysis of in vitro lymphocyte responsivenessto antigen,mitogen and allogeneic cells using a new laser based cell sizing apparatus [abstract]. Fed Proc. 1975;34:995. 4. Ruckdeschel JC, Schimpff SC, Dunmire C, Smyth AC, Wiernik PH, Mardiney Jr MR. Correlation of susceptibility to herpes zoster with impaired cell associated immunity to the varicella zoster virus in patients with hodgkin’s disease [abstract]. Clin Res. 1975;23:311A. 5. Ruckdeschel JC, Martin RG, Byhardt RW. Nonradiotherapeutic factors in the development of radiation related pericardial effusions in patients treated for hodgkin’s disease [abstract]. Proc ASCO. 1975;16:238. 6. Ruckdeschel JC, Dunmire C, Mardiney Jr MR. Cell associated immunity to measles in SSPE. Evidence for impaired lymphocyte transformation in response to measles antigen [abstract]. Arch Neurol. 1975;32:497. 7. Ruckdeschel JC, Doukas J, Mardiney Jr MR. Application of laser cytometry to the analysis of immunologically induced in vitro lymphocyte responsiveness [abstract].Clin Res. 1975;23:585A. 8. Jones III PP, Ruckdeschel JC, Eckert C, Horton J. Management of rectal villous adenomas with particular reference to the high incidence of associated colonic malignancies [abstract]. Clin Res. 1977;25:408A. 9. Ruckdeschel JC, Lininger L, Brzyski H, Miani M, Becker J. Re-analysis of in vitro lymphocyte blastogenesis using the laser cytometry assay [abstract]. Exp Hematol. 1978;6:70.
John C. Ruckdeschel,M.D. 10. Caradonna R, Paladine W, Goldstein J, Ruckdeschel JC, Hillinger S, Horton J. Combination chemotherapy with high dose cis-diamine dichloroplatinum, methotrexate and bleomycin for epidermoid carcinoma of the head and neck [abstract]. Proc Am Assoc Cancer Res. 1978;19:401. 11. Ruckdeschel JC, Horton J, McKneally MF. Cytoxan, adriamycin, methotrexate and procarbazine (CAMP) in the management of bronchogenic carcinoma [abstract]. Proc ASCO. 1978;19:378. 12. Ruckdeschel JC, Becker JR, Miani MA, Lininger L, Brzyski H. Sequential analysis of cell-associated immunity (CAI) by laser cytometry [abstract]. Fed Proc. 1978;37(6):1843. 13. Ruckdeschel JC, McSharry J, Caliguiri L, Horton J. Cellular basis of cancer medicine: an integrated approach to the clinical and biological aspects of oncology [abstract]. Fed Proc. 1978;37(6):1548. 14. Ferraro J, Lansing L, Ruckdeschel JC. Giant cell cancer of the lung: a rapidly fatal histologic variant [abstract]. Proc ASCO. 1979;20:405. 15. Lunia SL, Ruckdeschel JC, McKneally MF, Killam D, Baxter D, McIlduff JB, Ray P, Chodos R, Horton J. Mediastinal involvement by bronchogenic carcinoma: correlation of chest radiography, gallium scanning and surgical biopsy [abstract]. Proc ASCO. 1979;20:405. 16. Brzyski H, Konchanin L, Baustin A, Ruckdeschel JC. Abnormal mitogen induced lymphocyte proliferation in patients with lung cancer: possible role of the surface modulating assembly [abstract]. Proc AACR. 1979;20:148. 17. Ruckdeschel JC, Brzyski H. Dissociation of blast transformation and radionucleotide incorporation by agentsinterfering with surface modulating assembly activity [abstract]. Clin Res. 1979;27:335A. 18. Ruckdeschel JC, McKneally MF, Devore C, Baxter D, Sedransk N, Caradonna R, Horton J. Regional immunotherapy fails to improve response to combined radiation and chemotherapy in patients with stage III non-oat cell bronchogenic carcinoma confined to the thorax: a controlled comparison [abstract]. Proc ASCO/AACR. 1980;21:374. 19. Harper GR, Rodichok LD, Ruckdeschel JC, Price A, Sedransk N, Horton J. Early Detection of Spinal Epidural Metastases [abstract].Proc ASCO/AACR. 1980;21:189. 20. Cohen RE, Blanchard C, Rohrbaugh M, Horton J, Ruckdeschel JC. Physician attitudes towards cancer: variations based on experience and specialty [abstract]. Proc ASCO/AACR. 1980;21:383. 21. Brandman J, Ruckdeschel JC, O’Donnell M, Horton J, Harrington G. Unexpected pulmonary complications of intensive therapy for small cell cancer of the lung (SCCL) [abstract]. Proc ASCO/AACR. 1980;21:459. 22. Ferraro J, Hillinger S, O’Donnell M, McNamee R, Ruckdeschel JC, Horton J. Treatment of advanced large bowel cancer with m-AMSA. A GITSG pilot study [abstract].Proc ASCO/AACR. 1980;21:420. 23. Weissman CH, Ruckdeschel JC, Ferraro J, Reilly C, Horton J. Cyclophosphamide, adriamycin and VP-16-213 (CAVP-16) chemotherapy in the management of advanced non-oat cell bronchogenic carcinoma (NOBC) [abstract]. Proc ASCO/AACR. 1980;21:459. 24. Ruckdeschel JC, Creech R, Mehta C. Chemotherapy of advanced non-oat cell bronchogenic carcinoma: the Eastern Cooperative Oncology Group experience [abstract]. In: Hansen H, Dombernowsky, editors. Abstracts II world conference on lung cancer. Princeton (NJ): Excerpta Medica; 1980. p.237. 25. McKneally MF, Maver C, Bennett J, Ruckdeschel JC. Evaluation of regional BCG in lung cancer [abstract]. In: Hansen H, Dombernowsky, editors. Abstracts II world conference on lung cancer. Princeton (NJ): Excerpta Medica; 1980. p.108. 26. Ruckdeschel JC, Harper GR, Rodichok LD. Early diagnosis of spinal epidural metastases [abstract]. Clin Res. 1980;28:652A. 27. Cohen R, Ruckdeschel JC, Blanchard C, Last C, Horton J. Adaptation to mastectomy: variation based on time from surgery and use of adjuvant chemotherapy [abstract]. Abstract Medical and Pediatric Oncology 8:424, 1980. 28. O'Donnell M, Ruckdeschel JC, Sedransk N, Baxter D, Spiers A, Horton J. Does intensive induction chemotherapy improve survival in small cell cancer of the lung (SCCL)?: a randomized comparison [abstract]. Proc ASCO/AACR. 1981;22:168. 29. Ruckdeschel JC, Filardi HG, Konchanin L, Wiener G, Sedransk N. S/G2 arrest: an alternate mechanism for diminished lymphocyte proliferation in patients with cancer [abstract]. Proc ASCO/AACR. 1981;22:319. 30. Cohen RE, Sheehan AP, Ruckdeschel JC, Blanchard EB, Hall VI, Poleto MA, Cassidy MH, Horton J. Patient and treatment factors in the development of chemotherapy-related nausea and vomiting [abstract]. Proc ASCO/AACR. 1981;22:418.
John C. Ruckdeschel,M.D. 31. Horton J, Eyerson W, Baxter D, Ruckdeschel JC. Post operative radiation (RT) for rectal cancer is not always innocuous [abstract]. Proc ASCO/AACR. 1981;22:414. 32. Blanchard CG, Ruckdeschel JC, Saunders NL, Malloy D, Horton J. The measurement of physician behavior on inpatient rounds [abstract].Med Ped Oncol. 1981;9:567. 33. Ruckdeschel JC, Blanchard CG, Cohen RE. Assessment ofattitudes toward cancer [abstract]. Med Ped Oncol. 1981;9:452-3. 34. Ruckdeschel JC, Blanchard CG, Saunders N, Malloy ED, Blanchard E, Horton J. Patient-physician interactions: the measurement of physician behavior on inpatient oncology rounds [abstract]. Proc ASCO. 1982;1:49. 35. Ahles T, Blanchard EB, Ruckdeschel JC, Sheehan AP. Assessing the multidimensional aspects of cancer-related pain: toward a practical assessment package [abstract]. Proc ASCO. 1982;1:49. 36. Harper GR, Rodichok LD, Prevosti L, Lininger L, Ruckdeschel JC. Early diagnosis of spinal epidural metastases leads to improved treatment outcome [abstract]. Proc ASCO. 1982;1:6. 37. Ruckdeschel JC, Mason B, Ettinger D, Creech R, Mehta C, Stanley K. Failure to define a "standard" chemotherapy for metastatic non-small cell bronchogenic carcinoma [abstract]. Proc AACR. 1982;23:39. 38. Ruckdeschel JC, Mason B, Ettinger D, Creech R, Mehta C, Stanley K. Chemotherapy of metastatic non-oat cell bronchogenic carcinoma: the Eastern Cooperative Oncology Group experience [abstract]. In Secretariat, editor. Abstracts III World Conference on Lung Cancer. Proceedings of the 3rd World Conference on Lung Cancer; 1982 May 17-20; Tokyo, Japan. p.185. 39. Blanchard CG, Ruckdeschel JC, Blanchard EB, Arena J, Saunders N, Malloy D. Do attitudes predict behavior? Correlation of oncologists'attitudes with their observed behavior toward cancer patients [abstract]. Med Pediatr Oncol. 1982;10:49A. 40. Spiers ASD, Ruckdeschel JC, Horton J, Rauch AE, O'Donnell MR, Burkart PT. Effectiveness of pentostatin (2' deoxycoformycin, DCF) in refractory lymphoid neoplasms [abstract]. Blood. 1982;60(1):163a. 41. Ruckdeschel JC, Zimmerman MS, Hussain M. Chemotherapy-induced interstitial pneumonitis during treatment of small cell anaplastic lung cancer [abstract]. Proc ASCO. 1983;2:199. 42. Bonomi P, O'Reilly W, Vogl S, Ruckdeschel JC, Creech R, Stolbach L. A phase II trial of cyclophosphomide,VP16 and methotrexate in small cell bronchogenic carcinoma (SCBC): an Eastern Cooperative Oncology Group pilot study [abstract].Proc ASCO. 1983;2:199. 43. Berenzweig M, Vogl S, Camacho F, Ruckdeschel JC. Esophageal squamous cancerchemotherapy (CT) with methylglyoxal bis-guanylhydrazone (MGBG), methotrexate (M), bleomycin (B) and diamminedichloroplatinum (D) - "MGBG-MBD" [abstract]. Proc ASCO. 1983;2:125. 44. Blanchard CG, Ruckdeschel JC, Blanchard EB, Murray S, Pallmeyer TP, Fried K. The relationship between physician behavior on inpatient oncology rounds and patient satisfaction [abstract]. Med Pediatr Oncol. 1983;11:43A-44A. 45. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Mason BA, Vogl SE, Joss RA. Chemotherapy of metastatic nonsmall cell bronchogenic carcinoma (NSCBC): a randomized comparison of the four most active regimens [abstract]. Proc AACR. 1984;25:171. 46. Armstrong M, Harper G, Line B, Ruckdeschel JC. Dual isotope technique for in vitro quantitative assessment ofintra-arterial (IA) drug delivery to hepatic metastases [abstract].Proc AACR. 1984;25:169. 47. Harper G, Cooper L, Baxter D, Fernando L, Ruckdeschel JC. Value of myelography (MG) for planning treatment (RT) of spinal epidural metastases (SEM) [abstract]. Proc ASCO. 1984;3:72. 48. Blanchard CG, Ruckdeschel JC, Blanchard EB, Fletcher BA. Patient satisfaction with specific behaviors of medical oncologists during inpatient rounds [abstract]. Proc ASCO. 1984;3:72. 49. Bunting N, Bonomi P, O'Reilly W, Vogl S, Creech R, Ruckdeschel JC, Stolbach L, Ettinger D. Prognostic factors in patients with small cell bronchogenic carcinoma treated on an eastern cooperative oncology group phase II trial [abstract]. Proc ASCO. 1984;3:228. 50. Ruckdeschel JC, Finkelstein DM, Creech RH, Ettinger DS. Chemotherapy of metastatic non-small cell bronchogenic carcinoma [abstract]. Clin Res. Apr 1984. 51. Blanchard CG, Ruckdeschel JC, Fletcher BA, Blanchard EB. Predictors of high and low patient satisfaction on inpatient oncology rounds [abstract].Med Pediatr Oncol. 1984;12:24A. 52. Line BR, Harper GR, Armstrong M, Ruckdeschel JC. Dual isotope technique for in vivo quantitative assessment ofintra-arterial (IA) drug delivery to hepatic metastases [abstract].J Nucl Med. 1984;25:41. 53. Ettinger DS, Baker RR, Eggleston JC, Abeloff MD, Ruckdeschel JC, McKneally MF, Woll J, Adelstein D. Prospective evaluation of the role of surgery in limited disease (LD) small cell lung cancer.
John C. Ruckdeschel,M.D. An Eastern Cooperative Oncology Group pilot study [abstract].Proc ASCO. 1985;4:180. 54. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Mason BA, Vogl SE, Joss RA. Predictors of improved response and survival in metastatic non-small cell bronchogenic carcinoma (NSCBC) [abstract]. Proc ASCO. 1985;4:187. 55. Ruckdeschel JC, Gazdar AF, Carney DN, Russell EF, Oie H. The use of human lung cancer cell lines for in vitro chemosensitivity testing [abstract]. Proc AACR. 1985;26:367. 56. Gazdar AF, Oie H, Russell E, Carney DN, Linnoila J, Ruckdeschel JC, et al. Establishment and characterization of a large comprehensive panel of cell lines demonstrates the diversity of human lung cancer [abstract]. Proc AACR. 1985;26;27. 57. Ruckdeschel JC, Finkelstein DM, Ettinger DS. Chemosensitivity of metastatic non-small cell lung cancer (NSCLC) [abstract]. Proc. IV World Conference on Lung Cancer; 1985 Aug 25-30; Toronto, Canada. 58. Ruckdeschel JC, Gazdar AF, Carney DN, Russell EF, Oie H. In Vitro chemosensitivity testing for human non-small cell lung cancer: the role of cell lines [abstract]. Proc. IV World Conference on Lung Cancer; 1985 Aug 25-30; Toronto, Canada. 59. Blanchard CG, Fletcher BA, Ruckdeschel JC, Frisch S, Blanchard EB, Brady AC. The measurement of house staff interactions with cancer and non-cancer patients [abstract]. Med Pediatr Oncol. 1985;13:14A. 60. Wagner H, Ruckdeschel JC, Bonomi P, Danjux C, Richter M, Ettinger D. Treatment of locally advanced non-small cell lung cancer (NSCLC) with mitomycin C, vinblastine and cis-DDP (MVP) followed by radiation therapy (RT): an Eastern Cooperative Oncology Group pilot study [abstract]. Proc ASCO. 1985;4:183. 61. Ettinger DS, Mehta CR, Abeloff MD, Ruckdeschel JC, Aisner S. A randomized comparison of conventionalchemotherapy with immediate alternation of non-cross resistant chemotherapy in extensive disease (ED) small cell lung cancer (SLCLC) [abstract]. Proc ASCO. 1986;5:170. 62. Bennett JA, Ruckdeschel JC, Riley K, Kaye-Wenzel M. Differential chemosensitivity of lewis lung carcinoma (LLC) to cyclophosphamide (CYT) and doxorubicin (DOX): accurate prediction by the subrenal capsule (SRC) and novel dye exclusion (NDE) assays [abstract].Proc AACR. 1986;27:413. 63. Ruckdeschel JC, Riley K. In vitro chemosensitivity of human cancer cell lines to 4-hydroperoxy- cyclophosphamide (4HC), melphalan (M), phosphoramide mustard (PM) and nitrogen mustard (NM) [abstract]. Proc AACR. 1986;27:411. 64. Labrecque MS, Blanchard CG, Ruckdeschel JC, Blanchard EB. The impact of cancer patient decision- making preferences on patient satisfaction [abstract]. J Cancer Educ. 1986;1(3):213. 65. Ruckdeschel JC, Riley K. Dose-dependent cytotoxicity of etoposide in human lung cancer cell lines: role of thesolvent carrier [abstract]. Proc AACR. 1987;28:425. 66. Ettinger DS, Mehta CR, Abeloff MD, Ruckdeschel JC, Aisner S. Maintenance chemotherapy versus no maintenance chemotherapy in complete responders following induction chemotherapy in extensive disease (ED) small cell lung cancer (SCLC) [abstract]. Proc ASCO. 1987;6:175. 67. Bonomi P, Mehta C, Ruckdeschel JC, Blum R, Mason B, Greene M. Phase II-III trial of mitomycin- vinblastinecisplatin (MVP); vinblastin-cisplatin (VP); MVP alternating with cyclophosphamide- adriamycin-methotrexateprocarbazine (MVP/CAMP); CBDCA followed by MVP; and CHIP followed by MVP in patients with metastatic non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group study [abstract]. Proc ASCO. 1987;7:177. 68. Aisner SC, Ettinger D, Finkelstein D, Ruckdeschel JC, Mehta C, Abeloff M, Eggleston J. The clinical significance of variant morphology (small cell/large cell) small cell carcinoma of the lung (SCCL) [abstract]. Proc ASCO. 1988;7:A752. 69. Fudin J, DeConti R, Ruckdeschel JC. Chemical phlebitis due to CI-921: The role of formulation/ dissolution characteristics [abstract]. Proc AACR. 1989;30:A968. 70. Ruckdeschel JC, Piantadosi S. Assessment ofquality of life (QL) by the functional living index-cancer (FLIC) is superior to performance status for prediction of survival in patients with lung cancer [abstract]. Proc ASCO. 1989;8:A1209. 71. Ruckdeschel JC, Archer S. Rational design of a novel ellipticine derivative with significant activity against human lung cancer cell lines [abstract]. Proc AACR. 1989;30:A2420. 72. Ruckdeschel JC, Moores D, Lee J, Einhorn L, Mandelbaum J, Koeller J, Weiss G, Losada M, Keller J. Management of malignant pleural effusions (MPE): a randomized comparison of tetracycline and bleomycin [abstract]. Proc ASCO. 1990;9:323. 73. Moores D, Ruckdeschel JC, Lee J, Einhorn L, Mandelbaum I, Koeller J, Weiss G, Losada M, Keller J.
John C. Ruckdeschel,M.D. Malignant pleural effusion: a randomized comparison of tetracycline and bleomycin [abstract]. Chest. 1990;98(2):44. 74. Wagner Jr H, Lad T, Ruckdeschel JC. Randomized phase I comparison of preoperative radiation therapy (XRT) and chemotherapy with mitomycin-C, vinblastine and cisplatin for patients with pathologic stage IIIA and IIIB non-small cell lung cancer (NSCLC) [abstract]. Proc ASTRO. 1990 Oct. 75. Diamond C, Remick S, Migliozzi J, Solis O, WagnerH, Haase R, Ruckdeschel JC. Primary central nervous systemlymphoma (PCL) in patients with and without acquired immunodeficiency syndrome (AIDS) [abstract]. Proc ASCO. 1990;9:A367. 76. Ross JS, Samaan S, Ruckdeschel JC, Wagner H. DNA ploidy in atypical carcinoid tumors of the lung [abstract]. Lab Invest.1991;64(1):118A. 77. Ruckdeschel JC, Archer S, Cioli D, Portuese E. Antitumor properties of some n-methylcarbamates derived from ellipticine and olivacine [abstract]. Proc AACR. 1991;32:2412. 78. Remick S, McSharry J, Wolf B, Blanchard C, Gorman P, Slaga J, Wagner H, Harper G, Horton J, Ruckdeschel JC. Novel oral combination chemotherapy (CT) in the management of AIDS-related non- hodgkin's lymphoma (NHL) [abstract]. Proc ASCO. 1991;10:32. 79. Bromberg C, Remick S, Harper G, Sporn J, Healey B, Hilstro J, von Roemeling R, Horton J, Ruckdeschel JC. Concurrent 72-hour continuous infusion (CI) of etoposide (VP-16) and cisplatin (DDP) in metastatic breast cancer [abstract]. Proc ASCO. 1991;10:49. 80. Grossman SA, Ruckdeschel JC, Moynihan T, Finkelstein D, Ettinger D, Mahoney E, Trump D. Randomized prospective comparison of intraventricular (IT) methotrexate (MTX) and thiotepa (TT) for neoplastic meningitis (NM) [abstract]. Proc ASCO. 1991;10:127. 81. Moore M, Robert F, Cripps F, Ruckdeschel JC, Neidhart J, Natale R, Dallaire B, Gyves J. A phase II study of brequinar sodium (DuP 785, NSC 368390) in gastrointestinal(GI) cancers (ca) [abstract]. Proc ASCO. 1991;10:152. 82. von Roemeling R, Fisher H, DeConti R, Horton J, Wilbur H, Hrushesky W, Ruckdeschel JC. Continuous FUDR infusion for hormone refractory prostate cancer: A phase I/II study [abstract].Proc ASCO. 1991;10:171. 83. Ruckdeschel JC, Linnoila RI, Mulshine JL, Kim K, Aisner S, Gazdar AF, Jensen SM, Bonomi P. The impact of neuroendocrine (NE) and epithelial (EPI) differentiation on response and survival in lung cancer: the ECOG experience [abstract]. Proc ASCO. 1991;10:248(A849). 84. Linnoila RI, Ruckdeschel JC, Piantadosi S, Jensen SM, Mulshine JL. The impact of neuroendocrine (NE) and epithelial (EPI) differentiation on recurrence and survival in patients (pts) with resected non- small cell lung cancer (NSCLC): the LCSG experience [abstract]. Proc ASCO. 1991;10:248(A850). 85. Maroun J, Ruckdeschel JC, Natale R, Morgan R, Robert F, Berkowitz I, Dallaire B, Wilgosz G. A phase II study of brequinar sodium (DuP 785, NSC 368390) in lung cancers [abstract]. Proc ASCO. 1991;10:A850. 86. Bonomi P, Finkelstein D, Chang A, Ruckdeschel JC. Decreasing response rates in eastern cooperative oncology group (ECOG) stage IV non-small cell lung cancer (NSCLC) trials: comparison of sequential studies [abstract].Proc ASCO. 1991;10:261. 87. Hisington S, Remick S, MacDowell R, Hilstro J, Ramnes C, Izqierdo R, Harper G, Ruckdeschel JC. Venous access via a peripherally implanted device: a preliminary trial [abstract]. Proc ASCO. 1991;10:327. 88. Ruckdeschel JC, Linnoila RI, Mulshine JL, Kim K, Piantadosi S, Aisner S, Jensen SM, Gazdar AF for the Eastern Cooperative Oncology Group and Lung Cancer Study Groups. The impact of neuroendocrine and epithelial differentiation on recurrence and survival in patients with lung cancer [abstract]. Sixth World Conference on Lung Cancer; 1991 Nov 10-14; Melbourne, Australia. Lung Cancer. 1991;7 (suppl):56. 89. Doroshow J, Ruckdeschel JC, Freytes C, Robert F, Havlin K, Adams D, Sisk R, Dallaire B, Gyves J. A phase II study of DUP 937 in head and neck cancer [abstract]. Proc ASCO. 1992;11:247. 90. von Roemeling R, DeConti R, Horton J, Remick S, Harper G, Hrushesky W, Ruckdeschel JC. Toxicity of circadian FUDR infusion: a randomized phase I pilot study [abstract].Chronobiology: Mechanisms and Therapeutic Applications; 1991; Paris, France. 91. Wagner Jr H, Ruckdeschel JC, Williams C, Heise M, Hilstro J. Single agent taxol (Tax) as second-line chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer. 1994;11(suppl 1):120. 92. Ruckdeschel JC, Wagner Jr H, Williams C, Heise M, Hilstro J. Second-line chemotherapy for resistant,
John C. Ruckdeschel,M.D. metastatic, non-small cell lung cancer (NSCLC): the role of taxol (Tax) [abstract]. Proc ASCO. 1994;13:A1200. 93. Farrell P, Horton J, Ruckdeschel J, Simon J, Cohen G. A national education program in oncology for physicians - role of a new medical journal [abstract]. J Cancer Educ. 1994;9(3):A17. 94. Ruckdeschel JC, Albrecht TL, Blanchard C, Hemmick RM. Communication strategies for accruing patients to clinical trial: implications for training programs [abstract]. Proceedings of the AACE 30th Annual Meeting; 1995. p.A70. 95. Wolff AC, Ettinger DS, Neuberg D, Comis R, Ruckdeschel JC, Bonomi PD, Johnson DH. A phase II study ofifosfamide, carboplatin and oral etoposide (ICE) chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Group study [abstract].Proc ASCO. 1994;3:A1198. 96. Ruckdeschel JC, Pattern SG, Cutherbertson DD, Murtagh FR, Arrington JA. Spinal cord compression in lung cancer. MRI as the first diagnostic test is more cost effective [abstract]. Lung Cancer. 1997;18(1):A826. 97. Wagner H, Antonia SJ, Williams C, Alberts M, Hubble D, Robinson L, Hilstro J, Ruckdeschel JC, Shaw G. Concurrent paclitaxel/cisplatin (PC) with thoracic radiation (TR) in patients with stage IIIA/B non-small cell lung cancer (NSCLC) [abstract]. Proc ASCO. 1997;16:A1610. 98. Robinson LA, Ruckdeschel JC. Induction chemotherapy in pleural mesothelioma precludes the technical performance of an extrapleural pneumonectomy [abstract]. 4th International Mesothelioma Conference; 1997 May 13- 15; p.47. 99. Krontiris TG, Larson GP, Weitzel JN, Benson AB, Daly MB, DeVore RF, Kirkwood JM, Lunetta KL, Neuberg DS, O’Dwyer PJ, Ruckdeschel JC, Wagner H, Stewart JA. Mapping interactive cancer susceptibility loci (eastern cooperative oncology group) [abstract]. Proc ASCO. 1998;17:A2147. 100. Jiroutek M, Johnson D, Blum R, Bonomi P, Chang A, Ettinger D, Ruckdeschel J, Schiller J, Sandler A. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of eastern cooperative oncology group (ECOG) trials from 1981-1982 [abstract]. Proc ASCO. 1998;17:A1774. 101. Garland LL, WagnerH, Shaw GS, Williams CC, Anatonia SA, Khoor A, Meulemans LM, Nimmons KA, Ruckdeschel JC. Phase I dose-escalation study of constant rate infusion gemcitabine in combination with taxotere in advanced non-small cell lung cancer [abstract]. Proc ASCO. 1998;17:A1864. 102. Chirikos T, Ruckdeschel JC. Some predictors of the cumulative costs of lung cancer care [abstract]. Proc ASCO. 1999;A1946. 103. Garland LL, WagnerJr HJ, Shaw GS, Williams CC, Antonia SA, Muelemans LM, Nimmons KA, Ruckdeschel JC. Phase I study of constant dose rate infusion gemcitabine with taxotere in advanced non- small cell lung cancer [abstract]. Proc ASCO. 1999;A1632. 104. Garland L, Khoor A, Grendys E, Fiorica J, Walsh F, Alberts W, Role M, Anderson W, Ruckdeschel J. Utility of thyroid transcription factor-1 (TTF-1) in differentiating pulmonary adenocarcinoma from ovarian or primaryperitoneal adenocarcinoma in women with malignant pleural effusion (MPE) [abstract]. Proc ASCO. 2000;19:548a. 105. Wright D, Garland L, Wagner H, Clark R, Hazelton T, Shaw G, Antonia S, Williams C, Alberts WM, Ruckdeschel JC. MRI imaging of the spine is superior to bone scintigraphy in diagnosis of spine metastases in patients with nonsmall cell lung cancer (NSCLC) [abstract]. Proc ASCO. 2000;19:503a. 106. Stinson TJ, Bennett CL, Vogel V, Lewedy D, Jobbs J, Ruckdeschel JC, Chirikos TN, Weiner RS, Wicha MS. A multi-center study ofthe costs ofenrolling cancer patients on phase II clinical trials [abstract]. Proc ASCO. 2000;19:A1695. 107. Sullivan DM, Rago R, Ruckdeschel JC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Bulanhagui C, Gupta E, Tarby C, Sonnichsen D, Gustafson N, Gallant G. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, given every three weeks in patients with advanced malignancies [abstract]. ERSOTC. 2000. 108. Ruckdeschel JC. Malignant pleural effusions [abstract]. Lung Cancer. 2000;29(2):123. 109. Sullivan DM, Mahany JJ, Tetteh LF, Ruckdeschel JC, Williams CC, Antonia SJ, Lush RM, Sun S-L. A phase I study of combination therapy with oral 9-nitrocamptothecin and oral etoposide [abstract]. Submitted 2001. 110. Ruckdeschel JC, Spitz M, Saxman S. Summary report of the national cancer institute progress review group for lung cancer [abstract]. Lung Cancer 2001;34(suppl 1):S7-S8. 111. Ruckdeschel JC, Simon G, Antonia S, Haura E, Williams C, Wagner H, Rocha Lima C, Ettienne K, Vaughn J, Bepler G. ZD1839 (‘Iressa’) as a single agent for the treatment of metastatic non-small-cell lung
John C. Ruckdeschel,M.D. cancer [abstract]. Proc ASCO. 2002. 112. Nordquist L, Simon GR, Alberts WM, Ruckdeschel JC. Improved survival in never smokers versus current smokers with primary adenocarcinoma of the lung [abstract]. Proc ASCO. 2002.9 113. Riddle DL, Albrecht TL, Coovert MD, Penner LA, Quinn G, Ruckdeschel JC, Blanchard CE. Observer video probased coding: emperical evidence of value added [abstract]. Measuring Behavior. 2002. 114. Eggly S, Albrecht T, Penner L, Cline R, Ruckdeschel JC, Berkely S, FosterT, Naughton M, Peterson A. “I know it’s bad, but how bad is it?” Challenges to current guidelines for communication bad news in the outpatient oncology clinic [abstract]. Medical Encounter. 2004;18. 115. Quinn GP, Jacobsen PB, Wells NL, Peredo C, Albrecht TL, Ruckdeschel JC, Bell M. Real-time patient satisfaction survey and improvement process [abstract].Psychooncology.2004;13(suppl 1):S29. 116. Franks M, Eggly S, Figueroa M, Hendriks M, Foster T, Ruckdeschel JC, Albrecht T. Physician communication and patient intention to accrue to cancer clinical trials [abstract]. Cancer Epidemiology, Biomarkers & Prevention. 2005;14;S2738. 117. Penner L, Franks M, Albrecht T, Foster T, Ruckdeschel JC. Using Noldus Observer® to Assess the Reactivity of Video Recordings of Medical Interactions [abstract]. Measuring Behavior. 2005. 118. Cline R, Harper F, Penner L, Albrecht T, Ruckdesche JC, Peterson A, Jones E, Taub J, Simon L. Who’s in the room? Relationships between parents’ communication and children’s stress during painful cancer treatment procedures [abstract]. Annals of Behavioral Medicine. 2005;29;S38. 119. Greene M, Eggly S, Penner L, FosterT, Albrecht T, Rehan S, Ruckdeschel JC. Patient and companion questions during discussions ofbad news in oncology interactions [poster]. APOS. 2005. 120. Penner L, Cline R, Jones E, Taub J, Ruckdeschel JC, Albrecht T. Dispositional and affective correlates of treatment related pain among pedicatric cancer patients [abstract]. Annals of Behavioral Medicine. 2006;30 121. Penner L, Cline R, FosterT, Jones E, Penner Taub J, Ruckdeschel JC, Albrecht T. Indirect support: Effects of multiple caregivers on nonverbal immediacy experienced by children during painful pediatric oncology procedures[abstract].Annals of Behavioral Medicine. 2006;30. 122. Cline R, Jones E, Peterson A, Penner L, Taub J, Ruckdeschel JC, Albrecht T,. Verbal combat: Risks of invalidating children’s experiences during painful oncology procedures [abstract]. Annals of Behavioral Medicine. 2006;30. 123. Eggly S, Franks M, Hendriks M, Figueroa M, Foster T, Ruckdeschel JC, Albrecht T. Frequency and context of oncologist’recommendations regarding clinical trials [abstract]. Annals of Behavioral Medicine. 2006;30. 124. Eggly S, Harper F, Penner L, FosterT, Rana J, Osborn D, Ruckdeschel JC, Albrecht T. Patient/companion information seeking during offers of clinical trials [abstract]. Annals of Behavioral Medicine. 2007; 33;S098. 125. Harper F, Gleason M, Eggly S, Ruckdeschel JC, Albrecht T. Expectations about cure, physician- patient communication, and treatment decision-making in cancer patients [abstract]. Annals of Behavioral Medicine. 2007;33;S097. 126. Rizvi N, Kris, M, Miller V, Azzoli C,Krug L, Bekele S,Chaplen R, Ruckdeschel J, Gadgeel S. A pahse II study of XL647 in non small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations. J Thor Oncol. 2007; 2(8) S737. 127. Karp DD, Lee S, Shae G, Johnson D, Kucuk O, Clamon G, Marks R, Johnston M,Okawara G, Ruckdeschel J. Progress Report: Eastern Cooperative Oncology Group (ECOG) E5597, an intergroup phase III randomized trial of selenium supplementation in resected stage I non small cell lung cancer. J Thor Oncol. 2007; 2(8) S811. 128. Gadgeel SM, Ruckdeschel JC, Wozniak A, Patel B, Heilbrun LK, Chen W, Venkat R, Chaplen R, Turrisi A. Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by Docetaxel in stage III nonsmall cell lung cancer (NSCLC) patients.J Clin Oncol; 2008:26(15S): 414s. 129. Gleason ME, Harper FW, Eggly S, Ruckdeschel JC, Albrecht TL. The influence of patient and companion cure expectations on treatment decisions. J Clin Oncol 2008; 26(15S): 518s. 130. Eggly S, Harper F, Penner L, FosterT, Austin T, Ruckdeschel J, Albrecht T. Information seeking by patients and companions during cancer clinical interactions. Psycho-Oncology.2008; 17: S1163. 131. Gadgeel SM, Ruckdeschel JC, Wozniak AJ, Chen W, Hackstock D, Galasso C, Burger A, Ivy SP, LoRusso P, Edelman MJ. Cebiranib, a VEGF receptor 1,2 and 3 inhibitor, and pemetrexed in patiens (pts) with recurrent nonsmall cell lung cancer (NSCLC). ASCO Annual Meeting. 2011; Abstract #77915. 132. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ,
John C. Ruckdeschel,M.D. Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, Fernandez C, Hall R, Kawabe T, and Sharma S. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM). ASCO AnnualMeeting 2012 Abstract 96454 133. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, Fernandez C, Hall R, Kawabe T, and Sharma S. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM). International Mesothelioma Research Group 2012 Abstract 223. 134. Ruckdeschel JC, Sause WT, Belnap T, Jones C, Rowley, B. Oncology quality improvement as a cornerstone of the transition to accountable care J Clin Oncol 30, 2012 (suppl 34 abst 141). 135. Sause WT, Ruckdeschel JC, Belnap TW, Jones C, Rowley BD. Building success in quality improvement: An analysis of what barriers hinder and what catalysts promote the widespread adoption of quality improvement initiatives. J Clin Oncol 30, 2012 (suppl 34, abst 122). 136. Belnap TW, Sause WT, Rowley,BD, Jones C, Ruckdeschel JC. The role, use, and nuances of clinical data systems in oncology quality improvement. J Clin Oncol 30, 2012 (suppl34, abst 135). 137. Sause WT, Rees WV, Ruckdeschel JC, Jones CW, Rowley BD, Pena K. Evolution of quality to value added care in a large healthcare organization. J Clin Oncol 31, 2013 In Press. 138. Ruckdeschel JC, Rees WV, Parkinson BT, Belnap T, Rowley BD, Pena K. The impact of screening mammography in women 40-49 years of age as a function of tumor biology. J Clin Oncol 31, 2013 In Press. 139. Pillai NR, Lee SJ, Karp DD, AisnerS, Ruckdeschel JC, Ramalingam S, and Khuri FR. Second Primary Lung Cancers:Analysis of E5597 Selenium Chemoprevention Study. J Clin Oncol: 2014 140. Hahn EE, Tang T, Lee JS, Munoz-Plaza C, Adesina O, Shen E, Rowley B, Maeda JL, Mosen DM, Ruckdeschel JC, Gould M. Use of advanced imaging for staging of early breast cancer in two integrated health care systems:Adherence with a Choosing Wisely Recommendation. J Clin Oncol 2015.

More Related Content

PDF
CV of Dr. Stephen J. Cina, Cook County Medical Examiner
bycookcountyblog
 
PDF
John Shoffner MD C.V. May 2018
byJohn Shoffner, MD
 
PDF
Torloni CV 2016 (1) (1)
byAntonio Sergio Torloni
 
DOC
ghio cv lawyers 7 1 2016
byAndrew Ghio
 
DOCX
Zafar CV 0216
byNadeem Zafar
 
DOC
Ortiz CV 12.15.16
byB. Hannah Ortiz
 
PDF
Balasubramaniam_Swarna_MD_colrect_CV rev1
bySwarna Balasubramaniam
 
DOC
CV Weber 2017 Aurora
byJoseph Weber
 
CV of Dr. Stephen J. Cina, Cook County Medical Examiner
bycookcountyblog
 
John Shoffner MD C.V. May 2018
byJohn Shoffner, MD
 
Torloni CV 2016 (1) (1)
byAntonio Sergio Torloni
 
ghio cv lawyers 7 1 2016
byAndrew Ghio
 
Zafar CV 0216
byNadeem Zafar
 
Ortiz CV 12.15.16
byB. Hannah Ortiz
 
Balasubramaniam_Swarna_MD_colrect_CV rev1
bySwarna Balasubramaniam
 
CV Weber 2017 Aurora
byJoseph Weber
 

What's hot

PDF
MPS_CV_MO_10-26-2015_Photograph_Signed_Highlighted
byMichael Sherman
 
PDF
Jefferson University Hospitals' April 2013 Cancer Survivorship Conference Pre...
byjeffersonhospital
 
PDF
JLM-CV 11.20.14
byJohn Merritt
 
PDF
Cancer survivorship
bySreedhar Tirunagari
 
PDF
Glen Justice, MD CV (Abridged)
byjohnkjustice
 
PDF
Olumi_CV_4_2016
byAria Olumi
 
PDF
Spring Handout Binder
byflasco_org
 
DOCX
CV updated March 26, 2016
byJames Burns
 
DOC
CV 9.12.14
byJudy L Schmidt MD FACP
 
DOC
Erez Dayan, MD
byErez Dayan, M.D.
 
DOC
Jialal-CV-6-2016
bykenny jialal
 
PDF
Aua annouces 2011 award winners
byМаксим Зеленский
 
PPT
OMICS Publishing Group | Journal of Cancer Science & Therapy
byOMICS International
 
PDF
May 3, 2011 - Senology.org Newsletter
bySenology.org
 
PDF
Senology.org Newsletter - April 3, 2012
bySenology.org
 
PDF
Senology.org Newsletter - October 4, 2011 - Latest Advances in Clinical Seno...
bySenology.org
 
PDF
Senology Newsletter - October 2, 2012
bySenology.org
 
PDF
Senology newsletter 5_apr_2011
bySenology.org
 
PDF
Senology Newsletter - March 12, 2013
bySenology.org
 
MPS_CV_MO_10-26-2015_Photograph_Signed_Highlighted
byMichael Sherman
 
Jefferson University Hospitals' April 2013 Cancer Survivorship Conference Pre...
byjeffersonhospital
 
JLM-CV 11.20.14
byJohn Merritt
 
Cancer survivorship
bySreedhar Tirunagari
 
Glen Justice, MD CV (Abridged)
byjohnkjustice
 
Olumi_CV_4_2016
byAria Olumi
 
Spring Handout Binder
byflasco_org
 
CV updated March 26, 2016
byJames Burns
 
CV 9.12.14
byJudy L Schmidt MD FACP
 
Erez Dayan, MD
byErez Dayan, M.D.
 
Jialal-CV-6-2016
bykenny jialal
 
Aua annouces 2011 award winners
byМаксим Зеленский
 
OMICS Publishing Group | Journal of Cancer Science & Therapy
byOMICS International
 
May 3, 2011 - Senology.org Newsletter
bySenology.org
 
Senology.org Newsletter - April 3, 2012
bySenology.org
 
Senology.org Newsletter - October 4, 2011 - Latest Advances in Clinical Seno...
bySenology.org
 
Senology Newsletter - October 2, 2012
bySenology.org
 
Senology newsletter 5_apr_2011
bySenology.org
 
Senology Newsletter - March 12, 2013
bySenology.org
 

Viewers also liked

PPSX
_Diversidad_ Todos somos diferentes by Elisa Victoria Iruzubieta
byElisa Victoria Iruzubieta Pickman
 
PDF
Implementación, evaluación y desarrollos funcionales sobre Artemisa Open Sour...
byExequiel Barrirero
 
PPTX
Tenemos química con Verne
byMiquel Duran
 
PDF
Apresentacao ECOPOWER ECOFOTON SOLAR MICROGERACAO MINIPRODUCAO RENOVAVEIS NA ...
byDomingos Morgado
 
PDF
Estandares ISO 27001
bydcordova923
 
PDF
Årsrapport 2014
byAndreas Faye-Schj
 
PDF
Curriculum vitae narrative
byAndrea Miklasová
 
PDF
Bondia.cat 18/03/2014
byBondia Lleida Sl
 
DOC
Non-Sanlam Clients Broker Email approved
byTyron Foreman
 
PDF
Pharma Market 43
byPharma Market
 
PPT
Vendaval En San Juan Del Flumen
byLapiceando
 
PPTX
Definint el meu futur...
byLuis Inclán
 
PPTX
Periodismo Digital
byMarco Paz Pellat
 
PPTX
Jornada COSE - coaching y salud empresarial
byInstituto de Coaching Ejecutivo CORAOPS
 
PPTX
GPA MA Chapter March 27: Logic Models a Different Perspective
byLisa Glickstein
 
DOCX
investigacion GOPI.
byMeli Aguirre
 
PPT
Global M&A leaders 2012
byBrunswick Group
 
PDF
Revista Catalunya 91 Novembre 2007
byRevista Catalunya
 
PPSX
Apoyo emocional y autoestima alumnado Asperger
byAsociación Asperger Granada
 
PDF
Ofiwin CRM
byaner_sistemas
 
_Diversidad_ Todos somos diferentes by Elisa Victoria Iruzubieta
byElisa Victoria Iruzubieta Pickman
 
Implementación, evaluación y desarrollos funcionales sobre Artemisa Open Sour...
byExequiel Barrirero
 
Tenemos química con Verne
byMiquel Duran
 
Apresentacao ECOPOWER ECOFOTON SOLAR MICROGERACAO MINIPRODUCAO RENOVAVEIS NA ...
byDomingos Morgado
 
Estandares ISO 27001
bydcordova923
 
Årsrapport 2014
byAndreas Faye-Schj
 
Curriculum vitae narrative
byAndrea Miklasová
 
Bondia.cat 18/03/2014
byBondia Lleida Sl
 
Non-Sanlam Clients Broker Email approved
byTyron Foreman
 
Pharma Market 43
byPharma Market
 
Vendaval En San Juan Del Flumen
byLapiceando
 
Definint el meu futur...
byLuis Inclán
 
Periodismo Digital
byMarco Paz Pellat
 
Jornada COSE - coaching y salud empresarial
byInstituto de Coaching Ejecutivo CORAOPS
 
GPA MA Chapter March 27: Logic Models a Different Perspective
byLisa Glickstein
 
investigacion GOPI.
byMeli Aguirre
 
Global M&A leaders 2012
byBrunswick Group
 
Revista Catalunya 91 Novembre 2007
byRevista Catalunya
 
Apoyo emocional y autoestima alumnado Asperger
byAsociación Asperger Granada
 
Ofiwin CRM
byaner_sistemas
 

Similar to CURRICULUM VITAE 2015

PDF
08001
bylmoench
 
PDF
Biography of Richard Pestell | CEO and Founder
byRichard Pestell
 
PDF
LM CV Updated June 2016
byLaszlo Mechtler M.D., FAAN
 
PDF
2016 Best of ASCO Brochure
byflasco_org
 
PDF
Dr. Andre Mitchell's CV
byANDRE MITCHELL, M.D.
 
PDF
Dr. Andre Mitchell's CV
byANDRE MITCHELL, M.D.
 
PDF
CancerDiscovery062014
bySarah Skirpan
 
DOCX
David S. Baskin CV Dec 2015
bypnsdsb
 
DOCX
CV Part A February 2016
byJonathan Finlay
 
DOCX
molinaro.peter.resume
byPeter Molinaro MD, MPH
 
DOCX
Sach_CV_4.22.2015
bySachin Jogal
 
DOCX
CV
byRobert Shepard
 
DOC
Biosketch 2012 R Morales Borges
byRHMBONCO
 
DOC
JPH CV update January 2015
byJoseph Hanna
 
PDF
Best Practices in Cancer Survivorship and Supportive Care
byAkinAkinsanya
 
PDF
Jco.2010.33.2742.full[1] copy
byClinica de imagenes
 
PDF
ITI.06-19-2012
byTaylor Wensley
 
DOC
CVStefanekFeb2015
byMichael Stefanek
 
PDF
Grand Rounds Monthly Seminar Brochure
byJohn Theurer Cancer Center at Hackensack University Medical Center
 
DOCX
Administrative Experience
byManoj Agarwal, MD, MBA
 
08001
bylmoench
 
Biography of Richard Pestell | CEO and Founder
byRichard Pestell
 
LM CV Updated June 2016
byLaszlo Mechtler M.D., FAAN
 
2016 Best of ASCO Brochure
byflasco_org
 
Dr. Andre Mitchell's CV
byANDRE MITCHELL, M.D.
 
Dr. Andre Mitchell's CV
byANDRE MITCHELL, M.D.
 
CancerDiscovery062014
bySarah Skirpan
 
David S. Baskin CV Dec 2015
bypnsdsb
 
CV Part A February 2016
byJonathan Finlay
 
molinaro.peter.resume
byPeter Molinaro MD, MPH
 
Sach_CV_4.22.2015
bySachin Jogal
 
CV
byRobert Shepard
 
Biosketch 2012 R Morales Borges
byRHMBONCO
 
JPH CV update January 2015
byJoseph Hanna
 
Best Practices in Cancer Survivorship and Supportive Care
byAkinAkinsanya
 
Jco.2010.33.2742.full[1] copy
byClinica de imagenes
 
ITI.06-19-2012
byTaylor Wensley
 
CVStefanekFeb2015
byMichael Stefanek
 
Grand Rounds Monthly Seminar Brochure
byJohn Theurer Cancer Center at Hackensack University Medical Center
 
Administrative Experience
byManoj Agarwal, MD, MBA
 

CURRICULUM VITAE 2015

  • 1.
    CURRICULUM VITAE John C.Ruckdeschel, M.D. PERSONAL DATA: Date and Place of Birth: January 5, 1946, Newport, Rhode Island Residence: 10838 Willow Heights Drive Las Vegas, NV 89135 313-485-7808 Email: jruckdeschel@me.com, jruckdeschel@synergyccn.com EDUCATIONAL EXPERIENCE: Oceanside High School, Oceanside, NY - Regents Diploma (honors)1963 Rensselaer Polytechnic Institute, Troy, NY - B.Sc. Biology 1967 Albany Medical College, Albany, NY - M.D. 1971 Foundation for Advanced Education in the Sciences, NIH 1973, 1983 – 1984 Intermountain Advanced Training Program in Clinical Practice Improvement Institute for Health Care Delivery Research, Salt Lake City, UT 2012 PROFESSIONAL EXPERIENCE: Current Positions: Attending Physician, Synergy Cancer Center of Nevada CEO, Ruckdeschel Consultants,LLC Chief Medical Officer, EMX Advanced Technologies Professor of Medicine (Adjunct), University of Utah, Huntsman Cancer Institute, Salt Lake City, UT Editor (United States)Cochrane Lung Cancer Group Vice-president, Red Rock Audubon Society Previous Positions: Medical Director, Oncology Clinical Program, Intermountain Healthcare, Salt Lake City, UT 2012-2014 Chair, Utah Cancer Action Network 2013-2014 Professor of Medicine University of Utah, Huntsman Cancer Institute,Salt Lake City, UT Professor of Medicine, University of Nevada School of Medicine 2009-2011 Chair, Patient Services Committee, Health Advisory Board of the University Medical Center of Southern Nevada 2010-2011 Chief Executive Officer and Director, Nevada Cancer Institute 2009-2011 VP Health Affairs/Dean; University of NV School of Medicine Search Committee 2010-2011 President and Chief Executive Officer, Barbara Ann Karmanos Cancer Institute 2002-2009 Associate Dean, Cancer Affairs, Wayne State University School of Medicine 2002-2009 Professor of Medicine and Oncology, Wayne State University School of Medicine 2002-2009 Board of Directors, Michigan Cancer Consortium 2002-2009 Senior VP - Cancer, The Detroit Medical Center: President, The Cancer Hospital 2002-2005 Interim Chair, Radiation Oncology Wayne State University School of Medicine 2002-2003 Professor of Oncology and Medicine, University of South Florida College of Medicine 1991-2002 Director and Chief Executive Officer, H. Lee Moffitt Cancer Center, Tampa, FL 1991-2002 Case Research Professor, University of Tampa College of Business 1996-2002 President, Florida Division, American Cancer Society 2001-2002 Director, Joint Ctr for Cancer and Blood Disorders Albany Medical College, Albany, NY1989 1991 Professor of Medicine (1985 - 1991); Associate Professorof Medicine (1979 - 1985); 1976-1991 Assistant ProfessorofMedicine, (1976 - 1979); Albany Medical College, Albany, NY Visiting Professor, Foundation for Promotion of Cancer Research, National Cancer Center, Tokyo, Japan 1990 Visiting Scientist, NCI - Navy Medical Oncology Branch, NCI, Bethesda, Maryland 1983-1984 Senior Assistant Resident - Medicine, Beth Israel Hospital, Boston,MA 1975-1976 Staff Associate,NCI - Baltimore Cancer Research Center, Baltimore, MD 1972-1975 Straight Medical Intern, Johns Hopkins Hospital, Baltimore, MD 1971-1972 04 December 2014
  • 2.
    John C. Ruckdeschel,M.D. HONORS: DistinguishedJohn Hopkins School of Medicine Alumni Award 2009 Michigan Cancer Consortium Spirit of Collaboration Award 2007 Hour Magazine Top Doctors in Detroit 2006 Best Doctors in America 1993 - America's Top Doctors 2000 - Honorary Member, USF Golden Key International Honor Society 2001 Distinguished Southern Oncologist Award 2001 Tampa Bay Magazine’s “Doctors Chosen by Doctors” 2001 Exemplary Alumni Award, Albany Medical College, Albany, NY 2000 11th Annual Florida Medical Business Healthcare Physician Business Leadership Award 2000 Town and Gown Community Service Award 1999 The Medical Business Top 25: The Most Influential Physicians in Tampa Bay 1998 Bellwether Award for Lifetime Achievement 1997 Who’s Who in Medicine and Healthcare 1996 Rensselaer Alumni Association Fellows Award - Biology 1996 Brooks Brothers Man of the Year 1994 Excel Award for Excellence in Communication Leadership 1994 Who’s Who in Science and Engineering 1991 Sigma Xi 1986 -2002 American Medical Association,Physicians Recognition Award 1974 - Alpha Omega Alpha (Medicine) 1971 Henry B. Barnet, Jr., Commencement Award for Significant Contribution in Cancer 1971 S. Oakley Vander Poel Commencement Award for Best Clinical Exam in Medicine 1971 Who’s Who Among Students in American Colleges and Universities 1967 Pi Delta Epsilon (Journalism) 1966 PROFESSIONAL ORGANIZATIONS: Center and Institute Advisory Committee (CIAC), Wayne State University Division of Research 2004-2009 U.S. National Committee for the International Union Against Cancer (USNC/UICC) American Joint Committee on Cancer 2000-2008 National Comprehensive Cancer Network Board of Directors 1998-2002 Executive Committee (2000 - 2002) National Coalition for Cancer Research (NCCR) Board of Directors 1999-2006 Council of Teaching Hospitals (COTH) - American Association of Medical Colleges 1997-2002 American College of Chest Physicians Fellow 1993 - American Association of Cancer Institutes 1992 - 2009 Board of Directors (1997 - 1999); Legislative Committee (2001 - 2009) American Medical Association 1992 - American College of Physician Executives 1988 - Lung Cancer Study Group 1982-1990 (Executive Officer 1986 - 1990) American Cancer Society 1977 - 2002 Junior Faculty Clinical Fellow (1977 - 1980); National Advisory Committee on Psychosocialand Behavioral Research (1986 - 1989; Chair 1989); Board of Directors, Greater Tampa (1992 - 1997); Chair, Research Committee of Florida Division (1999 - 2000); Florida Division Board of Directors (1997 - 2002); Executive Committee (1998 - 2002); Medical Vice President of Florida Division (1999 - 2000); President, Florida Division (2001 - 2002)
  • 3.
    John C. Ruckdeschel,M.D. AmericanAssociation for Cancer Education 1977 - International Association for the Study of Lung Cancer 1977 - American Society of Clinical Oncology 1977 - Publications Committee (2004 - ) Cancer Education Committee (2005 – Chair Health Services Research Track, 2006-2008) American Federation for Clinical Research 1977 - 1986 Councilor, Eastern Section (1981 - 1986) American Association for Cancer Research 1976 -2009 Finance Committee (2001 - 2005 American College of Physicians 1975 - Fellow (1979 - ) LICENSURE: New York (inactive), Maryland (inactive),Massachusetts (inactive),Florida (ME0068653), Michigan (inactive) Nevada (13104), Utah (8192686-1205) MILITARY: United States Public Health Service 1972 – 1975 BOARDS: American Board of Internal Medicine, Certified 6/76, no. 53664 Medical Oncology, Certified 10/77 GRANT SUPPORT: Prior Funding: NIH: NCI Outcomes of Triaged Family Care in Advanced Cancer 5R01CA107383-04 $9,758 (annual direct) 09/28/04 - 05/31/09 (PI:Northouse) NIH: NCI Cancer Center Support Grant 5P30CA022453-26 $1,607,780 (annual direct) 09/08/97 – 11/30/90 (PI:Ruckdeschel NIH: NCI Cancer Center Support Grant – Supplement: Cryo-immunotherapy for Lung Tumors 2P30CA022453-24 $2,500,000 (annual direct) 12/01/04 – 11/30/09 (PI:Ruckdeschel) NIH: NCI Cancer Center Support Grant – Supplement : caBIG Technology Assessment and Implementation EPA National Center for Vermiculite and Asbestos Related Cancers 83299701-0 $967,000 (total award) 09/01/06 –08/31/08 (PI: Ruckdeschel) DOD National Oncogenomic and Molecular Imaging Center (NOMIC) ERMS 07078003 $1,571,186 04/01/08 – 03/31/13 (PI Ruckdeschel) Threshold Pharmaceuticals, Inc An Open-Label, Phase II Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients with Recurrent Sensitive Small Cell Lung Carcinoma THCR- 304 $108,693 (total)11/01/06 – 11/08/07 (PI:Ruckdeschel) NCI: Parental role in Pediatric Cancer Pain and Survivorship. 5R01CA10027-01 - $866,105 09/19/03 – 08/31/07(PI Albrecht) NCI: Effects of Physician Communication on Patient Accrual. 7R01CA75003-01A3 $268,204 (annual direct),04/01/01 - 03/31/06. Dr. Teri Albrecht, PI NCI: Biopsychosocial Processes and Treatment Decision Making. 1R21CA113220-01 $75,000 (annual direct),09/30/04 – 09/29/06. Dr. Teri Albrecht, PI. CDC Cancer Prevention and Control Earmarks (National Center for Vermiculite and Asbestos Related Cancers) ACS: Institutional Research Grant. ACS 93-032-07-02 - $120,000 (annual direct). 07/01/00 - 06/30/03. PI. NCI: Moffitt Cancer Center PRCC Partnership. $125,000 (annual direct). P20CA91353-01, 5/18/01- 4/30/04. PI. NCI: Cancer Center Support Grant. P30 CA 76292-05 - $1,647,244 (annual direct). 03/06/01-01/31/05. PI. NCI: Project Link: Leaders in New Knowledge. Supplement to P30 CA76292 - $72,424 (annual direct). 05/18/01-01/31/06. PI. NIH: Mouse Barrier Facility. C06 RR017510-01 - $2,000,000 (annual direct). 9/01/02-8/31/04. PI.
  • 4.
    John C. Ruckdeschel,M.D. EDITORIAL/REVIEWACTIVITIES: Editorial: Editor in Chief: Evidence-Based Oncology (1999 - 2002) Co-Editor: Textbook of Thoracic Oncology, I and II Editions Editorial Board: Chest Current Treatment Options in Oncology Medical Oncology Social Marketing Quarterly Journal of Cancer Education Cancer Control: Journal of the Moffitt Cancer Center Section Editor for Lung and Mediastinum – Current Opinion in Oncology Reviewer: Annals of Internal Medicine Cancer Chemotherapy and Pharmacology Cancer Research Chest Journal of Clinical Oncology Journal of the National Cancer Institute Journal of Neuro-Oncology Journal of Thoracic Oncology Investigational New Drugs Preventive Medicine Proceedings, National Academy of Sciences (U.S.A.) Social Science and Medicine NATIONAL CANCER INSTITUTE - SITE VISITOR - AD HOC REVIEWER: NIH-Support Centers for Population Health and Health Disparities (P50) Co-chair 2009 NIH Loan Repayment Program Awards 2008, 2009 MD Anderson Cancer Center Support Grant 2003 Biological Mechanisms of PsychosocialEffects on Disease (BiMPED) 2002 Lung Progress Review Group (PRG) Co-Chair 2000 NCI/ACS Conference on Lung Screening, Co-Chair 2000 University of Rochester Core Grant (R. Abraham) 1999 Rapid Access to Intervention Development (RAID) Reviewer 1998 Program Project Review Committee (Subcommittee C) 1994 Cornell University Program Project (F. Barany) - Chairman 1994 Yale Cancer Center Support Grant (V. DeVita) 1994 Behavioral Medicine Study Section (Ad Hoc Reviewer) 1991, 1993 Non-Small Cell Lung Cancer Strategy Meeting (Ad Hoc Reviewer) 1990, 1992 University of Tennessee Program Project (H. Schuller) - Chairman 1992 Specialized Program of Research Emphasis - Prostate Cancer 1992 Specialized Program of Research Emphasis - Lung Cancer 1992 Special Review Committee - Community Clinical Oncology Program 1990 Dana Farber Cancer Center Program Project (E. Frei) 1990 Memorial Sloan-Kettering Cancer Center Program Project (J. Bertino) 1989 Middle Atlantic Oncology Program 1985 Piedmont Oncology Group (R. Capizzi) 1985 Catholic Medical Center Program Project (D. Martin) 1979 Lung Cancer Study Group (E. Holmes) 1978 External Advisor/Reviewer: Samuel Ochsin Cancer Center, Cedars Sinai 2010-
  • 5.
    John C. Ruckdeschel,M.D. Universityof Hawaii 2007-2008 UT San Antonio/CTRC, Chair 2007-2010 University of Oklahoma Cancer Center 2005 -2006 Penn State Cancer Center (Chair) 2003 -2010 Behavioral Review Panel for the Nebraska Cancer & Smoking Disease Research Program 2001 - USC/Norris Comprehensive Cancer Center External Advisory Committee 1999 -2002 Rensselaer Polytechnic Institute College of Science External Advisory Board 1999 -2010 American Institute of Biological Sciences (Army, DOD reviews) 1997 - 2009 Wake Forest Cancer Center External Advisory Board, (Chair 1999 -) 1997 - 2009 U.S. Army Medical R&D Command Breast Cancer Research Program (Reviewer) 1994 - Illinois Cancer Council External Advisory Board 1989 - 1992 Tobacco Related Disease Research Program Study Section (California) 1990 - VA Merit Review Program 1989 - 1993 ACS Psychosocialand Behavioral Review Committee, (Chair 1989 -) 1986 – 1989 COMMUNITY: Health Advisory Board, University Medical Center of Southern Nevada 2010- Clark County Committee on Priorities 2009-2010 Greater Detroit Area Health Council 2007-2009 Board of Directors, University Liggett School 2006-2009 Wayne County Health Authority; Provider Advisory Committee (co-chair) 2005 -2007 Community Advisory Board, Junior League of Tampa 2002 Committee of 100 Steering Committee of Tampa Chamber of Commerce 2001 - 2002 Sun Trust Bank Board of Directors and Trust Committee of the Board 2000 - 2002 Jesuit High School Board of Trustees 2000 - 2002 Chair, Health/Bio-Medical Committee of the Tampa Chamber of Commerce 1999 Sacred Heart Church, General Chair of Capital Campaign 1998 Jesuit High School Foundation Board of Directors 1998 - 2000 Leukemia Society of America, Suncoast Chapter Board of Trustees 1995 - 1998 West Sand Lake Volunteer Fire Department, West Sand Lake, NY President 1981 - 1983, Line Officer 1982 - 1983, 1985 - 1986 1979 - 1991 Sand Lake Ambulance, West Sand Lake, NY 1984 - 1991 Board of Directors 1984 - 1985, Line Officer 1985 - 1987, Board President 1989 - 1991 President, Board of Directors, United Urban Ministry of Troy, NY 1976 - 1980 Staff Physician, People’s Free Medical Clinic, Baltimore, MD 1972 - 1975 PUBLICATIONS - PEER REVIEWED 1. Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med. 1972;287:1013-7. 2. Ruckdeschel JC, Peters T, Lee KT. Fibrinogen catabolism in rats fed thrombogenic diets. Atherosclerosis.1972;16:277-85. 3. Graziano KD, Ruckdeschel JC, Mardiney Jr MR. Cell associated immunity to measles (rubeola): the demonstration of in vitro lymphocyte tritiated thymidine incorporation in response to measles complement fixation antigen. Cellular Immunol. 1975;15:247-359. 4. Ruckdeschel JC, Graziano, KD, Mardiney Jr MR. Additional evidence that the cell associated immune systemis the primary host defense against measles (rubeola). Cell Immunol. 1975;17:11-18. 5. Ruckdeschel JC, Chang P, Martin RG, Byhardt RW, O’Connell MJ, Sutherland JC, Wiernik PH. Radiation-related pericardial effusions in patients with Hodgkin’s disease.Medicine (Baltimore). 1975;54:245-59. 6. Byhardt RW, Brace K, Ruckdeschel JC, Chang P, Martin RW, Wiernik PH. Dose and treatment factors in radiation related pericardial effusion associated with the mantle technique for hodgkin’s disease.Cancer. 1975;35:795-802. 7. Martin RW, Ruckdeschel JC, Chang P, Byhardt RW, Bouchard P, Wiernik PH. Radiation-related
  • 6.
    John C. Ruckdeschel,M.D. pericarditis.Am J Cardiol. 1975;35:216-20. 8. Dummire C, Ruckdeschel JC, Mardiney Jr MR. Suppression of in vitro lymphocyte responsiveness to PPD by measles virus: a re-exploration of the phenomenon. Cell Immunol. 1975;20:205-17. 9. Drake WP, Porkorney DR, Ruckdeschel JC, Levy CC, Mardiney Jr MR. A white blood cell ribonuclease assay forthe monitoring of malignancy. J Natl Cancer Inst. 1975;54:1475-78. 10. Ruckdeschel JC, Kramarsky B, Mardiney Jr MR. Mycoplasma contamination of membrane associated measles antigens.Inability to demonstrate in vitro lymphocyte responsiveness to measles. Cell Immunol. 1975;20:110-16. 11. Ruckdeschel JC, Schimpff SC, Smyth AC, Mardiney Jr MR. Correlation of susceptibility to herpes zoster with impaired cell associated immunity to the varicella-zoster virus in patients with hodgkin’s disease.Am J Med. 1977;62:77-85. 12. Ruckdeschel JC, Mardiney Jr MR. The demonstration of cell associated immunity to viruses.In vitro lymphocyte responsiveness to varicella-zoster antigen. J Immunol Methods.1976;13:131-43. 13. Ruckdeschel JC, Doukas J, Drake WP, Mardiney Jr MR. Application of laser cytometry to the analysis of immunologically induced in vitro lymphocyte blastogenesis.Transplantation.1977;23:396-403. 14. Doukas J, Ruckdeschel JC, Mardiney Jr MR. Quantitative and qualitative analysis of human peripheral lymphocyte proliferation to specific antigen in vitro by use of the helium neon laser. J Immunol Methods. 1977;15:229-38. 15. Mardiney Jr MR, Ruckdeschel JC. Inhibition of in vitro lymphocyte response by measles virus antigen: a reply [letter]. Cell Immunol. 1977;28:229. 16. Hahn DM, Schimpff SC, Ruckdeschel JC, Wiernik PH. Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thiotepa, or bleomycin. Cancer Treat Rep. 1977;61(8):1585-7. 17. Lempert N, MacDowell RT, Karmody A, Knight E, Cunningham TJ, Sponzo R, Horton J, Ruckdeschel JC. Vascular access for cancer chemotherapy. Cancer. 1979;43:1934-6. 18. Caradonna R, Paladine W, Ruckdeschel JC, Goldstein JC, Olsen JE, Jaski JW, Silvers SA, Hillinger S, Horton J. Methotrexate, bleomycin and high dose cis-platinum for advanced epidermoid carcinoma of the head and neck. Cancer Treat Rep. 1979;63:489-91. 19. Ruckdeschel JC, Baxter DH, McKneally MR, Killan DA, Lunia SL, Horton J. Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity. Int J Radiat Oncol Biol Phys. 1979;5:1323-8. 20. Ruckdeschel JC, Lininger L, Brzyski H, Miani M, Becker J. Serial quantitation of in vitro lymphocyte responsivenessto Concanavalin-A. Transplantation. 1979;28(3):203-6. 201 Ruckdeschel JC, Caradonna R, Paladine WJ, Hillinger SM, Horton J. Small cell anaplastic carcinoma of the lung: changing concepts and emerging problems. CA Cancer J Clin. 1979;29:84-95. 22. Blanchard C, Ruckdeschel JC, Cohen RE, Horton J, McSharry J, Shaw E. Attitudes towards cancer. I: the impact of a comprehensive oncology course on second year medical students. Cancer. 1981;47:2756-62. 23. Lunia SL, Ruckdeschel JC, McKneally MF, Killam E, Baxter D, Kellar S, Ray P, McIlduff J, Lininger L, Chodos R, Horton J. Non-Invasive evaluation of mediastinal metastases in bronchogenic carcinoma: a prospective comparison of chest radiography and gallium-67 scanning.Cancer. 1981;47:672-9. 24. Rodichok LD, Harper GR, Ruckdeschel JC, Price A, Roberson G, Barron KD, Horton J. Early diagnosis of spinal epidural metastases.Am J Med. 1981;70:1181-7. 25. Ruckdeschel JC, Mehta CR, Salazar OM, Cohen M, Vogl S, Koons LS, Lerner H. Chemotherapy of inoperable non-small cell bronchogenic carcinoma. Cancer Treat Rep. 1981;65:965-72. 26. Ruckdeschel JC, Mehta CR, Salazar OM, Cunningham TJ, Creech RH, Sponzo RW. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575 generation III, HAM vs CAMP. Cancer Treat Rep. 1981;65:959-63. 27. Brandman J, Ruckdeschel JC, O’Donnell M, Horton J. Rapid tumor necrosis leading to serious pulmonary infections in patients treated intensively for small cell cancer of the lung. N Y State J Med. 1981;81:1332-4. 28. Ruckdeschel JC, McKneally MF, Baxter DH, Devore C, Kellar S, Killam D, Caradonna R, Sedransk N, McIlduff J, Horton J. Regional immunotherapy has a detrimental effect on the response to combined irradiation and chemotherapy in locally advanced non-small cell bronchogenic carcinoma. Cancer Immunol Immunother. 1981;11:277-82. 29. Ferraro JA, Horton J, Weissman C, Ruckdeschel JC, O’Donnell M, Ludlum D. Treatment of advanced colorectal carcinoma with AMSA. Cancer Treat Rep. 1981;65:345-7. 30. Cohen RE, Ruckdeschel JC, Blanchard CG, Rohrbaugh M, Horton J. Attitudes towards cancer. II: a
  • 7.
    John C. Ruckdeschel,M.D. comparativeanalysis of cancer patients,medical students,medical residents,physicians and cancer educators.Cancer. 1982;50:1218-23. 31. Ruckdeschel JC, Lea JW, Brown S, Horton J. Content-bias in the neoplastic-related items of the national board of medical examiners part II examination. Med Pediatr Oncol. 1982;10:269-74. 32. Ettinger SD, Day R, Ferraro JA, Ruckdeschel JC, Woll JE, Vogl SE. A phase II study ofAMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma: an Eastern Cooperative Oncology Group study.Am J Clin Oncol. 1983;6:167-70. 33. Ahles TA, Blanchard EB, Ruckdeschel JC. The multidimensional nature of cancer-related pain. Pain. 1983;17:277-88. 34. Blanchard CB, Ruckdeschel JC, Blanchard EB, Arena JG, Saunders NL, Malloy ED. Interactions between oncologists and patients during rounds.Ann Intern Med. 1983;99:694-9. 35. Ahles T, Ruckdeschel JC, Blanchard EB. Cancer-related pain. I: prevalence in an outpatient setting as a function of stage of disease and type of cancer. J PsychosomRes. 1984;28:115-9. 36. Zimmerman MS, Ruckdeschel JC, Hussain M. Chemotherapy-induced interstitial pneumonitis during treatment of small cell anaplastic lung cancer. J Clin Oncol. 1984;2:396-405. 37. Ahles T, Ruckdeschel JC, Blanchard EB. Cancer-related pain. II: assessment with visual analogue scales. J PsychosomRes. 1984;28:121-4. 38. Arsenau JC, Wolter JM, Juperminc M, Ruckdeschel JC. A phase II study of bruceantin (NSC-165, 563) in advanced malignant melanoma. Invest New Drugs. 1983;1:239-42. 39. Creech RH, Tritchler D, Ettinger DS, Ferraro JA, Ruckdeschel JC, Vogl SE, Woll J. Phase II study of PALA amsacrine, teniposide and zinostatin in small cell lung carcinoma (EST-2579). Cancer Treat Rep. 1984;68:1183-4. 40. Spiers ASD, Ruckdeschel JC, Horton J. Effectiveness of pentostatin (2’-deoxyoformycin) in refractory lymphoid neoplasms. Scand J Haematol. 1984;32:130-4. 41. Ruckdeschel JC, Day R, Weissman CH, Stolbach LL, Creech RH. Chemotherapy for metastatic non- small cell bronchogenic carcinoma: cyclophosphamide, doxorubicin and etoposide versus mitomycin- vinblastine (EST 2575, generation IV). Cancer Treat Rep. 1984;68:1325-9. 42. Ruckdeschel JC, Finkelstein D, Creech RH, Mason BA. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, general V: a randomized comparison of four cisplatin-containing regimens. J Clin Oncol. 1985;3:72-9. 43. Vogl SE, Camacho F, Berenzweig M, Ruckdeschel JC. Chemotherapy for esophagealcancerwith mitoguanazone, methotrexate, bleomycin and cisplatin. Cancer Treat Rep. 1985;69:21-3. 44. O’Donnell MR, Ruckdeschel JC, Baxter D, McKneally MF, Caradonna R, Horton J. Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung. Cancer Treat Rep. 1985;69:571-5. 45. Bonomi P, O’Reilly W, Vogl SE, Ruckdeschel JC, Stolbach L, Bunting N, Creech RH. Intensive induction treatment of small cell bronchogenic carcinoma with cyclophosphamide,methotrexate and etoposide.Cancer Treat Rep.1985;69:1007-9. 46. Ettinger DS, Finkelstein DM, Harper GR, Ruckdeschel JC, Chang AY, Camacho FJ, Marsh JC, Silber R, Wolter JM. Phase II study of mitoxantrone, aclarubicin and diaziquinone in the treatment of non-small cell lung carcinoma: an Eastern Cooperative Oncology Group study.Cancer Treat Rep. 1985;69:1033-4. 47. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RA, Mason RC, Joss BA, Vogl S. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol. 1986;4:14-22. 48. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: anEastern Cooperative Oncology Group study.J Clin Oncol. 1986;4:702-9. 49. Blanchard CG, Ruckdeschel JC, Fletcher BA, Blanchard EB. The impact of oncologists behavioron patient satisfaction with morning rounds.Cancer. 1986;58:387-93. 50. Cohen RE, Blanchard EB, Ruckdeschel JC, Smolen RC. Prevalence and correlates of post-treatment and anticipatory nausea and vomiting in cancer chemotherapy. J PsychosomRes. 1986;30:643-54. 51. Funa K, Dawson N, Jewett PB, Agren H, Ruckdeschel JC, Bunn Jr PA, Gazdar AF. Automated fluorescent analysis for drug-induced cytotoxicity assays.Cancer Treat Rep. 1986;70:1147-51. 52. Rodichok LD, Ruckdeschel JC, Harper GR, Cooper G, Prevosti L, Fernando L, Baxter DH. Early detection and treatment of spinal epidural metastases:the role of myelography. Ann Neurol. 1986;20:696- 702. 53. Mulshine J, Glatstein E, Ruckdeschel JC. Treatment of non-small cell lung cancer [invited review]. J
  • 8.
    John C. Ruckdeschel,M.D. ClinOncol.1986;11:1704-15. 54. Blanchard CG, Ruckdeschel JC. Psychosocialaspects ofcancer in adults: implications for teaching medicalstudents. J Cancer Educ. 1986;1:237-48. 55. Ruckdeschel JC, Carney DN, Oie H, Russell EF, Gazdar AF. In vitro chemosensitivity of human lung cancer cell lines. Cancer Treat Rep. 1987;71:697-704. 56. Trump DL, Elson P, Borden EC, Harris J, Tuttle R, Whisnant JK, Oken M, Carignan JR, Ruckdeschel JC, Davis TE.High dose lymphoblastoid interferon in advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study.Cancer Treat Rep. 1987;71:165-69. 57. Baker RR, Ettinger DS, Ruckdeschel JC, Eggleston JC, McKneally MF, Abeloff MD, Woll JE, Adelstein DJ. The role of surgery in the management of selected patients with small cell carcinoma of the lung. J Clin Oncol.1987;5:697-702. 58. Blanchard CG, Ruckdeschel JC, Labrecque MS, Frisch S, Blanchard EB. The impact of a designated cancer unit on house staffbehaviors toward patients.Cancer. 1987;60:2348-54. 59. Finkelstein DM, Cassileth BR, Bonomi PD, Ruckdeschel JC, Ezdinli EZ, Wolter JM. A pilot study of the functional living index-cancer (FLIC) scale for the assessment ofquality of life for metastatic lung cancer patients: an Eastern Cooperative Oncology Group study.Am J Clin Oncol. 1988;11:630-33. 60. Ruckdeschel JC. Whither screening for lung cancer [editorial]. J Natl Cancer Inst.1988;80:78-9. 61. Blanchard CG, Labrecque MS, Ruckdeschel JC, Blanchard EB. Information and decision-making preferences of hospitalized adult cancer patients.Soc Sci Med. 1988;27:1139-45. 62. Ruckdeschel JC. Attempts to enhance locoregional control of cancer by radiotherapy, phototherapy and combined modality therapy [invited review]. Curr Opin Oncol. 1989;1:231-5. 63. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Glick J. Combination chemotherapy versus single agents followed by combination chemotherapy in stageIVnon-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group study.J Clin Oncol. 1989;7:1602-13. 64. Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol.1990;8:230-40. 65. Aisner SC, Finkelstein DM, Ettinger DS, Abeloff MD, Ruckdeschel JC, Eggleston JC. The clinical significance of variant-morphology small cell carcinoma of the lung. J Clin Oncol. 1990;8:402-8. 66. Blanchard CG, Labrecque MS, Ruckdeschel JC, Blanchard EB. Physician behaviors, patient perceptions and patient characteristics as predictors of satisfaction of hospitalized adult cancer patients.Cancer. 1990;65:186-92. 67. Ettinger DS, Finkelstein DM, Donehower RC, Chang AYC, Greene M, Blum R, Hahn RG, Ruckdeschel JC. A phase II study of n-methylformamide, spirogermanium and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583). An ECOG Study.Med Ped Oncol. 1989;17:197- 201. 68. Braun MA, Killam DA, Remick SC, Ruckdeschel JC. Lung cancer in patients seropositive for human immunodeficiency virus. Radiology. 1990;175:341-3. 69. Remick SC, Diamond C, Migliozzi JA, Solis O, Wagner H, Haase RF, Ruckdeschel JC. Primary central nervous systemlymphoma (PCL) in patients with and without AIDS. A retrospective analysis and review of the literature. Medicine. 1990;69(6):345-60. 70. Ruckdeschel JC. Is chemotherapy for metastatic non-small cell lung cancer “worth it?” [editorial]. J Clin Oncol. 1990;8:1293-6. 71. Nelles WB, Blanchard CG, McCaffrey RJ, Ruckdeschel JC. Social supports and breast cancer: a review. J Psychosoc Oncol. 1991;9(2):21-34. 72. Kobassa SCO, Spinetta JJ, Cohen J, Crano WD, Hatchett S, Kaplan BH, Lansky SB, Prout MN, Ruckdeschel JC, Siegel K, Wellisch DK. Social environment and social support.Cancer. 1991;67 (suppl 1):788-93. 73. Johnson DH, Ruckdeschel JC, Keller JH, Lyman GH, Kallas GJ, MacDonald J, DeConti RC, Lee J. A randomized trial to compare intravenous and orally administered etoposide in combination with cisplatin for the treatment of small cell lung cancer. Cancer. 1991;67(suppl):245. 74. Ettinger DS, Finkelstein DM, Abeloff MD, Chang YC, Smith TJ, Oken MM, Ruckdeschel JC. Phase II study of nmethylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of
  • 9.
    John C. Ruckdeschel,M.D. advancedsmall cell lung cancer. Invest New Drugs. 1990;9(2):183-85. 75. Remick SC, Harper GR, Abdullah MA, McSharry JJ, Ross JS, Ruckdeschel JC. Metastatic breast cancer in a young patient seropositive for human immunodeficiency virus. J Natl Cancer Inst. 1991;83:447. 76. Labrecque MS, Blanchard CG, Ruckdeschel JC, Blanchard EB. The impact of family presence on the physician cancer patient interaction. Soc Sci Med. 1991;33:1253-61. 77. Remick SC, Ruckdeschel JC. Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy and outcome. Med Pediatr Oncol. 1992;20:89-99. 78. Ruckdeschel JC, Piantadosi S, and the LCSG. Quality-of-life assessment in lung surgery for bronchogenic carcinoma. Theor Surg. 1991;6:201-5. 79. Ruckdeschel JC, Moores D, Lee JY, Einhorn LH, Mandelbaum I, Koeller J, Weiss GR, Losada M, Keller J. Intrapleural therapy for malignant pleural effusions: a randomized comparison of bleomycin and tetracycline. Chest. 1991;100:1528-35. 80. Henry DH, Beall GN, Benson CA, Carey J, Cone L, Eron LJ, Fiala M, Fischl M, Gabin S, Galpin J, Gottlieb M, Groopman JE, Hooton T, Jemsek J, Levine R, Miles S, Rinehart JJ, Rios A, Robbins W, Ruckdeschel JC, Smith J, Spruance S, Starrett B, Toney J, Zalusky R, Abels R, Bryant E, Larholt R, Sampson A, Rudnick S. Recombinant human erythropoietin in the treatment of the anemia associated with human immunodeficiency virus infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med. 1991;117:739-48. 81. Ruckdeschel JC. Chemotherapy of metastatic non-small cell carcinoma of the lung. Hematol Oncol. 1992;10:25-30. 82. Ruckdeschel JC. Special problems in the older cancer patient: spinal cord compression and pleural effusions. Oncology. 1992;6(2):119-23. 83. Sklarin NT, Wiernik PH, Grove WR, Benson L, Mittelman A, Maroun JA, Steward JA, Robert F, Doroshow JH, Rosen PJ, Jolivet J, Ruckdeschel JC, Robert NJ, Velez-Garcia E, Bergsagel DE, Panasci LC, van der Merwe AM, Longueville JJ, Leiby J. A phase II trial of CI-921 in advanced malignancies. Invest New Drugs. 1992;10:309-12. 84. Ruckdeschel JC, Modi SP, el-Hamouly W, Portuese E, Archer S. N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines. J Med Chem. 1992;35(26):4854-7. 85. Grossman SA, Ruckdeschel JC, Moynihan T, Finkelstein D, Ettinger DS, Mahoney E, Trump DL. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol. 1993;11:561-9. 86. Ruckdeschel JC. Therapeutic options for the treatment of small cell and non-small cell cancer of the lung. Curr Opin Oncol. 1993;5(2):323-34. 87. Ruckdeschel JC. Cellular characterization of lung cancer - a caveat [editorial]. Chest. 1993;104(2):331. 88. Scott F, Cuttitta F, Treston A, Avis I, Gupta P, Ruckdeschel JC, Kelly K, Piantadosi S, Tockman M, Mulshine J. Prospective trial evaluating immune-cytochemical-based sputumtechniques for early lung cancer detection: assays for promotion factors in the bronchial lavage. J Cell Biochem Suppl. 1993;17F:175-83. 89. Maroun J, Ruckdeschel JC, Natale R, Morgan R, Dallaire B, Sisk R, Gyves J. Multicenter phase II study of brequinar sodium in patients with advanced lung cancer. Cancer Chemother Pharmacol. 1993;21(1):64-6. 90. Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagner H, Portuese E, Wighton T, Powell D, Pearce T, Horton J, Ruckdeschel JC. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-hodgkin’s lymphoma. J Clin Oncol. 1993;11(9):1691- 702. 91. el-Hamouly WS, Ruckdeschel JC, Archer S. Preparation and antitumor activity of an n- methylcarbamate derivative of amsacrine. Eur J Med Chem. 1993;28:913-6. 92. Tockman MS, Erozan YS, Gupta P, PiantadosiS, Mulshine JL, Ruckdeschel JC, and the LCEDWG Investigators. The early detection of second primary lung cancers by sputum immune-staining. Chest. 1994;106(6):385s-90s. 93. Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel JC, Giaccone G, the LCSG, the Eastern Cooperative Oncology Group and the European Organization for Research and Treatment of Cancer. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response ofsmall cell lung cancer to combination chemotherapy. Chest. 1994;106(6):320s-3s. 94. Ruckdeschel JC, Piantadosi S, for the Lung Cancer Study Group. Quality of life in lung cancer
  • 10.
    John C. Ruckdeschel,M.D. surgicaladjuvant trials. Chest. 1994;106(6):324s-8s. 95. Wagner H, Lad T, Piantadosi S, Ruckdeschel JC, for the Lung Cancer Study Group. Randomized phase II evaluation of pre-operative radiation therapy and pre-operative chemotherapy with mitomycin-c, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung: LCSG 881. Chest. 1994;106(6):348s-54s. 96. Linnoila RI, PiantadosiS, Ruckdeschel JC, for the Lung Cancer Study Group. Impact of neuroendocrine differentiation in non-small cell lung cancer: the LCSG experience. Chest. 1994;106(6):367s-71s 97. Shaw GL, Falk RT, DesLauriers J, Nesbitt JC, McKneally MF, Frame JN, Feld R, Issaq HJ, Ruckdeschel JC, Hoover RN. Lung tumor resection does not affect debrisoquine metabolism. Cancer Epidemiol Biomarkers Prev. 1994;3:141-4. 98. Ruckdeschel JC. Chemical pleurodesis for malignant pleural effusions: a reply [letter]. Ann Intern Med. 1994;121(2):150. 99. Remick SC, Reddy M, Herman D, Grace C, Harper G, Willis K, Candon B, Horton J, Ruckdeschel JC. Continuous infusion bleomycin in AIDS-related kaposi sarcoma. J Clin Oncol. 1994;12(6):1130-6. 100. Ruckdeschel JC. Special report: Lung Cancer Study Group - final analysis. Cancer Control. 1994;1:283-5. 101. Ruckdeschel JC. Lung cancer: time for an end to nihilism. Cancer Control. 1994;2(5):430-1. 102. Ruckdeschel JC, Blanchard C, Albrecht T. Psychosocialoncology research: where we have been, where we are going and why we won’t get there. Cancer. 1994;74(4):1458-63. 103. Holmes EC, Ruckdeschel JC. Preoperative chemotherapy for locally advanced non-small cell lung cancer. Semin Oncol. 1994;21:3(6):97-100. 104. McCaffrey RJ, Orsillo SM, Ortega A, Pendry, D., Haase RF, Ruckdeschel JC, WagnerH. Neuropsychological sequelae of prophylactic cranial irradiation therapy: a prospective study.Assessment in Rehabilitation and Exceptionality. 1995;2(1):25-33. 105. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.J Clin Oncol. 1995;13(7):1615-22. 106. Blanchard CG, Albrecht TL, Ruckdeschel JC, Grant III CH, Hemmick RM. The role of social support in adaptation to cancer and to survival. J Psychosoc Oncol. 1995;13(1/2):75-95. 107. Remick SC, Chmura M, Bromberg C, Sporn J, Healey B, Hilstro J, DeConti RC, Horton J, Ruckdeschel JC, Harper GR. Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Cancer Clin Trials. 1996;19(2):125-31. 108. Stock HS, Rosellini RA, Abrahamsen GC, McCaffrey RJ, Ruckdeschel JC. Methotrexate does not interfere with an appetitive pavlovian conditioning task in sprague-dawley rats. Physiol Behav. 1995;58(5):969-73. 109. Ruckdeschel JC. Rapid, cost-effective diagnosis of spinal cord compression due to cancer. Cancer Control. 1995;2(4):320-3. 110. Antonia S, Wagner H, Williams C, Alberts WM, Hubbell, D., Robinson L, Hilstro J, Ruckdeschel JC. Concurrent paclitaxel/cisplatin with thoracic radiation in patients with non-small cell carcinoma of the lung. Semin Oncol. 1995;22(4):34-7. 111. Ruckdeschel JC. Management of malignant pleural effusions. Semin Oncol. 1995;22(2):58-63. 112. Ruckdeschel JC, Albrecht T, Blanchard C, Hemmick R. Communication, accrual to clinical trials and the physician patient relationship: implications for training program. J Cancer Educ. 1996;11(2):73-9. 113. Ruckdeschel JC. Preoperative paclitaxel plus carboplatin for patients with intermediate-risk non- small cell lung cancer. Semin Oncol. 1996;23(6):62-7. 114. Pisters KMW, Kris MG, Bunn Jr PA, Johnson DH, Ruckdeschel JC, Crowley JJ, Ginsberg RJ. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Semin Oncol. 1997;24(4)(suppl 4):41-4. 115. Antonia S, Ruckdeschel JC. Improving our management of NSCLC and mesothelioma [editorial]. Cancer Control. 1997;4(4):293. 116. Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK, Ruckdeschel JC, Taylor PR, Zhurkov T, Zhou W, Qiao Y, Yas SX. Prospective detection of preclinical lung cancer: preliminary results from two studies ofhnRNP A2/B1 overexpression. Clin Cancer Res. 1997;3:2237-46. 117. Spiers ASD, Esseltine DLW, Ruckdeschel JC, Davies NP, Horton J. Metastatic adenoid cystic carcinoma of salivary glands.Case reports and review of the literature. Cancer Control. 1996;3(4):336-42.
  • 11.
    John C. Ruckdeschel,M.D. 118.Blanchard CG, Albrecht TL, Ruckdeschel JC. The crisis of cancer: psychologicalimpact on family caregivers. Oncology. 1997;11(2):189-94. 119. Larson GP, Zhang G, Ding S, Foldenauer K, Vdar N, Gatti RA, Neuberg D, Lunetta KL, Ruckdeschel JC, Longmate J, Flanagan S, Krontiris TG. An allelic variant in the ATM locus implicated in breast cancer susceptibility. Genet Test. 1998;1(3):165-70. 120. Ruckdeschel JC. Slow but real progress in the treatment of thoracic malignancy [editorial review]. Curr Opin Oncol. 1998;10(2):119-21. 121. Ruckdeschel JC, Gridelli C, Perrone F, Monfardini S, Giaccone G. Current controversies in cancer: are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer? Pro. Eur J Cancer. 1998;34(13):1993-9. 122. Remick SC, Sedransk N, Haase R, Craffey M, Subramanian N, Dowlati A, Nazeer T, Ramnes C, Blanchard C, Mastrianni D, Balducci L, Horton J, Ruckdeschel JC. Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies. Drugs. 1999;58(3):99-107. 123. Albrecht TL, Blanchard C, Ruckdeschel JC, Coovert M, Strongbow RM. Strategic physician communication and oncology clinical trials. J Clin Oncol. 1999;17(10):3324-32. 124. Ruckdeschel JC. Update in oncology. Ann Intern Med. 1999;16:131(10):760-7. 125. Yuen AR, Fuks JZ, Ettinger DS, Chang AY, Ruckdeschel JC, Phan SC, Blum RH. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group study (PA586). Cancer J Sci Am. 2000;6(1):34-9. 126. Simendinger E, Ruckdeschel JC, Vizzi D. Does e-commerce belong in a cancer & research institution? J Healthcare Manag. 2000;45:3. 127. Chirikos TN, Ruckdeschel JC, Krischer JP. Impact of clinical trials on the cost of cancer care. Med Care. 2001;39(4):373-83. 128. Bennett CL, Stinson TJ, Votel V, Robertson L, Leedy D, O’Brien P, Hobbs J, Sutton T, Ruckdeschel JC, Chirikos TN, Weiner RS, Ramsey MM, Wicha MS. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project. J Clin Oncol. 2000;18(15):2805-10. 129. Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease Jr RF, Weeks JC: Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2B for high- risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002;20(5):1311-8. 130. Chirikos TN, Ruckdeschel JC, Krischer JP. Economic analysis of cancer treatment costs:anothertool for oncology managers. J Oncol Mgmt. 2001;10(3):11-17. 131. Jacobsen PB, Meade CD, Stein KD, Chirikos TN, Small BJ, Ruckdeschel JC. Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy. J Clin Oncol. 2002;20:2851-62. 132. Riddle DL, Albrecht TL, Coovert MD, Penner LA, Ruckdeschel JC, Blanchard CG, Quinn G, Urbizu D. Differences in audiotaped versus videotaped physician – patient interactions. J Nonverbal Behavior. 2002;26:219-39. 133. Albrecht TL, Ruckdeschel JC, Ray III FL, Pethe BJ, Riddle DL, Strohm J, Penner LA, Coovert MD, Quinn G, Blanchard CG. A portable, unobtrusive device for videorecording clinical interactions. Behav Res Methods.2005;37(1):165-9. 134. Albrecht TL, Ruckdeschel JC, Riddle DL, Blanchard CG, Penner LA, Coovert MD, Quinn G. Communication and consumer decision making about cancer clinical trials. Patient Educ Couns. 2003;50:39-42. 135. Albrecht TL, Penner LA, Ruckdeschel JC. Understanding patient decisions about clinical trials: a proposed theoretical model and associated methodologies to examine the process.J Cancer Educ. 2003;18:210-4. 136. Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, WagnerH, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (Iressa, ZD1839) in previously treated advanced non-small cell lung cancer. Experience from a single institution. Cancer Control. 2003;10:388-95. 137. Larson GP, Ding Y, Cheng LSC, Lundberg C, Gagalang V, Rivas G, Geller L, Weitzel J, MacDonald D, Archambeau J, Slater J, Neuberg D, Daly MB, Angel I, Benson III AB, Smith K, Kirkwood JM,
  • 12.
    John C. Ruckdeschel,M.D. O'DwyerPJ, Raskay B, Sutphen R, Drew R, Stewart JA, Werndli J, Johnson D, Ruckdeschel JC, Elston RC, Krontiris TG. Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. Cancer Research. 2004;65: 805-814. 138. Quinn GP, Jacobsen PB, Albrecht TL, Ellison BAB, Newman NW, Bell M, Ruckdeschel JC. Real- time patient satisfaction survey and improvement process.Hosp Top. 2004;82(3):26-32 139. Ruckdeschel JC. Fatigue is becoming an exhausting problem [editorial]. Cancer. 2005;103(2):213-5. 140. Albrecht TL, Ruckdeschel JC, Ray FL 3rd,Pethe BJ, Riddle DL, Strohm J, Penner LA, CoovertMD, Quinn G, Blanchard CG. A portable, unobtrusive device for video recording clinical interactions. Behav Res Methods 2005, 37(1):165-9. 141. Ruckdeschel JC. The problem of lung cancer as a paradigm-keynote address.Ethnicity Dis. 2005; 15(suppl 1):S1-2. 142. Ruckdeschel JC. Early detection and treatment of spinal cord compression. Oncology. 2005; 19(1):81-92. 143. Albrecht TL, Franks MM, Ruckdeschel JC. Communication and informed consent.Curr Opin Oncol. 2005;17:336-9. 144. Cote ML, Kardia SL, Wenzlaff AS, Ruckdeschel JC, Schwartz AG. Risk of lung cancer among white and black relatives of individuals with early lung cancer. JAMA; 2005;293(24): 3036-42. 145. Eggly S, Penner L, Albrecht TL, Cline RJW, FosterT, Naughton M, Peterson A, Ruckdeschel, JC. Discussing 'bad news' in the outpatient oncology clinic: rethinking current communication guidelines. J Clin Oncol. 2006, 24(4):716-719. 146. Schwartz AG and Ruckdeschel JC. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2006; 173(1): 16-22. 147. Ruckdeschel JC. Second line chemotherapy for non-small cell lung cancer. Chest 2006; 129(4):840-2 148. Albrecht TL, Kuerer H, Ruckdeschel JC, Mendez J, Harper F, American College of Surgeons Oncology Group. Transdisciplinary studies of surgical oncology trial accrual: A National Institute of Health/ National Cancer Institute Roadmap-affiliated project update. Cancer. 2006; 107(1): 171-4. 149. Eggly S, Penner LA, Greene M, Harper FW, Ruckdeschel JC, Albrecht TL. Information seeking during “bad news” oncology interactions: Question asking by patients and their companions. Soc Sci Med. 2006; 63(11): 2974-85. 150. Robinson LA, Ruckdeschel JC, WagnerH Jr, Stevens CW. Treatment of non-small cell lung cancer- stage IIIA; ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007, 132(3Suppl): 243S-265S. 151. Paterson A., Cline R., FosterT, Jones E, Penner L, Parrott R,. Keller C, Naughton M, Taub J, Ruckdeschel JC, Albrecht T. Parent’s interpersonal distance and touch behavior and child pain and distress:Journal of Nonverbal Behavior 2007;31: 79-97. 152. Penner L, Orom H, Franks M, Albrecht T, FosterT, Ruckdeschel JC. Camera-related behaviors during video recorded medical interactions: Journal of Nonverbal Behavior 2007;31: 99-117. 153. Cline RJW, Penner LA, Harper FWK, FosterTS, Ruckdeschel JC, Albrecht T. Patients’ Internet use for cancer information and socioeconomic status as co-advantages in oncologist-patient communication. Journal of Oncology Practice. 2007; 3: 167-171. 154. Gadgeel SM, Ruckdeschel JC, Heath EL, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and celecoxib a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007;2(4): 299-305. 155. Eggly, S., Albrecht, T.L., Harper, F.W.K., Foster, T.,., Franks, M.M., Ruckdeschel, JC. Oncologists’ recommendation of clinical trial participation to patients.Patient Education and Counseling. 2008; 70(1):143-8. 156. Albrecht, T.L., Eggly S.S., Gleason M.E., Harper F.W., Foster T.S., Petereson A.M., Orom H, Penner L.A., Ruckdeschel JC. Influence of clinical communication on patients’decision making on participation in clinical trials. J Clin Oncol. 2008; 26(16): 2666-73. 157. Gadgeel SM, Wozniak A, Ruckdeschel JC, Heilbrun LK, Venkatramanamoorthy R, Chaplen RA, Kraut MJ and Kalemkerian GP. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer. J Thor Oncol. 2008; 3:1293-300. 158. Whitehouse AC, Black CB, Heppe MS, Ruckdeschel JC, Levin SM. Environmental exposure to
  • 13.
    John C. Ruckdeschel,M.D. LibbyAsbestos and mesotheliomas. Am J Ind Med. 2008; 51:877-80. 159. Schwartz AG, Cote ML, Wenzlaff AS, Van Dyke A, Chen W, Ruckdeschel JC, Gadgeel S, Soubani A. Chronic obstructive lung diseases and risk of non-small cell lung cancer. J Thorac Oncol 2009; 4: 291-9. 160. Albrecht TL, Eggly SS, Penner LA, Cline RJW, Ruckdeschel JC. Studying the Process of Clinical Communication: Issues ofContext, Concepts and Research Directions. J Health Commun. 2009; 14 Suppl1: 47-56. 161. Pena T, LoRusso PM, Ruckdeschel JC, Goncalves P, Soubani AO. Pulmonary metastasis of basal cell carcinoma: a rare manifestation of a common disease with variable clinical course. J Thorac Oncol. 2009; 4:1026-7. 162. Gleason ME, Harper FW, Eggly S, Ruckdeschel JC, Albrecht TL. The influence of patient expectations regarding cure on treatment decisions.Patient Educ Couns.2009;75:263-9. Epub 2009 Jan 14. 163. Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, Tarca A, Dou QP, Lonardo F, Ruckdeschel JC, Pass HI, Wali A. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol. 2010:66:455-66. 164. Schneider BJ, Kalemkerian GP, Ramnath N, Kraut MJ, Wozniak AJ, Worden FP, Ruckdeschel JC, Zhang X, Chen W, Gadgeel SM. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kitpositive, extensive-stage small-cell lung cancer. Clin Lung Cancer. 2010; 11:223-7. 165. Cline RJ, Orom H, Berry-Bobovski L, Hernandez T, Black CB, Schwartz AG, Ruckdeschel JC. Community-level social support responses in a slow-motion technological disaster: the case of Libby, Montana.AM J Community Psychol. 2010; 46: 1-18. 166. Turner JT, Khoury JD, Ruckdeschel JC. Granulomatous Solitary Pulmonary Nodule. J Bronchol Intervent Pulmonol. 2011; 18:111. 167. Soubani AO, Ruckdeschel JC, The outcome of medical intensive care for lung cancer patients: the case for optimism. J Thorac Oncol, 2011; 6:633-8. 168. Gadgeel SW, Ruckdeschel JC, Patel, BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Marquette L, Turrisi A. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients.J Thorac Oncol 2011: 6; 927-33. 169. Northouse LL, Mood DW, Schafenacker A, Kalemkerian G, Zalupski M, LoRusso P, Hayes DF, Hussain M, Ruckdeschel JC, Fendrick MA, Trask PC, Ronis DL, Kershaw T. Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancerpatients and their family caregivers. Psycho- Oncology 2013;22: 555-63. 170. Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston M,Goodman G, Clamon G,Okawara G, Marks R, Frechette E, McCaskill-Stevens W, Lippman SM, Ruckdeschel JC, and Khuri FR. A Randomized, Double Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non Small Cell Lung Cancer (ECOG 5597) J. Clin Oncol2013, 31:4179-85. 171. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez C, Ros HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC , Fein L, He X, Hall HR, Kawabe T, Sharma S. Randomized Phase II Trial of Pemetrexed/Cisplatin with or without CBP501 in Patients with Advanced Malignant Pleural Mesothelioma Lung Cancer. 2014 Sep; 85(3):429-34. 172. Hahn EE, Tang T, Lee JS, Munoz-Plaza C, Adesina O, Shen E, Rowley B, Maeda JL, Mosen DM, Ruckdeschel JC, Gould M.Use of advanced imaging for staging of early breast cancer in two integrated health care systems:Adherence with a Choosing Wisely Recommendation. Submitted J Oncol Practice 2014 BOOK CHAPTERS, LETTERS, MONOGRAPHS, SYMPOSIA REPORTS 1. Ruckdeschel JC. Tumor registries [letter]. JAMA. 1973;266-72. 2. Ruckdeschel JC. Case records of the Massachusetts General Hospital [invited discussion].N Engl J Med.1974;291:1297-1303. 3. Ruckdeschel JC, Wiernik PH. Reactions to radiation therapy [letter]. N Engl J Med. 1975;293:668-9. 4. Ruckdeschel JC. Amantadine and pulmonary peripheral airways [letter]. Ann Int Med. 1977;86:369-70. 5. Ruckdeschel JC, Lininger L, Brzyski H, Miani M, Becker J. Re-analysis of in vitro lymphocyte blastogenesis using the laser cytometry assay.In: Baum S, editor. Experimental hematology today.
  • 14.
    John C. Ruckdeschel,M.D. Farmington,CT: Karger; 1979.p.123-8. 6. Ruckdeschel JC. Diagnosis and management of small cell anaplastic (oat cell) cancer of the lung. Current concepts in oncology.1979;1:18-24. 7. Ruckdeschel JC. Lung cancer - mediguide to oncology. 1981;1(6). 8. Ruckdeschel JC. Early diagnosis of lung cancer [editorial]. Clinical Cancer Briefs. 1981;2:2. 9. Ruckdeschel JC. Immunotherapy of Human Cancer: An Overview. In: Schimpff S, Moossa AR, Robson MC, eds.Comprehensive Textbook of Oncology. Baltimore: Willliams and Wilkins Publishers; 1984. 10. Ruckdeschel JC, Balint J, Gross P, Laufer F. Instructionalcosts for full-time faculty in an academic department of internal medicine. In: Hurst W, editor. Teaching internal medicine. 1984. 11. Ruckdeschel JC, Blanchard CG, Blanchard EB. Direct measurement of physician behavior as a potential method of evaluating medical education. In: Hurst W, editor. Teaching internal medicine. 1984. 12. Muggia FM, Goldin A, Ruckdeschel JC. New drugs in lung cancer. Proceedings of the 4th Mediterranean Congress of Chemotherapy; 1984 Oct 19-25; Rhodes, Greece. Chemioterapia. 1984;4(2 Suppl):1138-9. 13. Ruckdeschel JC, Oie HK, Gazdar AF. In vitro characterization of non-small cell lung cancer. In: Hansen HH,Nijhoff M, editors. Lung cancer: basic and clinical aspects.Boston:Kluwer; 1986. p. 49-59. 14. Ruckdeschel JC. Chemotherapy in metastatic lung cancer: Reply [letter]. J Clin Oncol. 1986;4:1151-2. 15. Ruckdeschel JC. Chemotherapy of non-small cell lung cancer. In: Kimura K, Ota K, Heberman RB, Takita H, editors. Cancer chemotherapy: challenges for the future, vo. 2. pp 202-209, Eds. K. Kimura, K. Ota, R.B. Heberman, H. Takita. Tokyo: Excerpta Medica; 1987. p 202-209. 16. Ruckdeschel JC. Management of malignant pleural effusions.Semin Oncol. 1988;15(3 suppl3):24-8. 17. Ruckdeschel JC, Moores D. Malignant pleural effusions: diagnosis and management [monograph, video]. NewYork, NY: LP Communications; 1988. 18. Ruckdeschel JC. Chemotherapy of disseminated non-small cell lung cancer. In Bitram J, Golomb H, editors. Lung cancer: a comprehensive treatise. New York, NY: Grune & Stratton; 1988. p 233-41. 19. Ruckdeschel JC. Clinical advances in management of malignant pleural effusions.J Crit Illn. 1988. 20. Ruckdeschel JC, Moores D. Non-small cell lung cancer: a multimodality approach to treatment [monograph, video]. New York, NY: LP Communications, 1989. 21. Ruckdeschel JC. Lung cancer: an introduction. In: Roth J, Ruckdeschel J, WeisenburgerT, editors. Textbook of Thoracic Oncology. Philadelphia, PA: WB Saunders; 1989. p 2-5. 22. Mulshine J, Ruckdeschel JC. The role of chemotherapy in the management of disseminated non-small cell lung cancer. In: Roth J, Ruckdeschel J, WeisenburgerT, editors. Textbook of thoracic oncology. Philadelphia, PA: WB Saunders; 1989. p 220-8. 23. Blanchard CG, Ruckdeschel JC. Quality of life. In: Roth J, Ruckdeschel J, Weisenburger T, editors. Textbook of Thoracic Oncology. Philadelphia, PA: WB Saunders; 1989. p. 681-6. 24. Ruckdeschel JC. Book review: Arriagada R, LeChevalier T, editors. Treatment modalities in lung cancer. J Natl Cancer Inst. 1989; 8:633-4. 25. Ruckdeschel JC, Moores D. MPE II: recent findings in the clinical management of malignant pleural effusions [monograph, video]. New York: LP Communications; 1990. 26. Ruckdeschel JC. Etoposide in the management of non-small cell lung cancer. Cancer. 1991;67(suppl):250. 27. Ruckdeschel JC, editor. Malignant pleural effusions:recent advances in diagnosis and management. Bristol-Myers Squibb; 1992. 28. Ruckdeschel JC, Holmes EC. Preoperative chemotherapy for locally advanced non-small cell lung cancer. In: Pass H, editor. Chest Clinics of North America. 1991;1:1-12. 29. Holmes EC, Ruckdeschel JC. Postoperative chemotherapy for non-small cell lung cancer. In: Pass H, editor. Chest Clinics of North America. 1991;1(1):89-97. 30. Ruckdeschel JC. “Current surgical approach to non-small cell lung cancer” by McCormack P [invited commentary]. Oncology. 1991;5(11):44-6. 31. Ruckdeschel JC. Comprehensive textbook of oncology [review]. J Natl Cancer Inst. 1992;84:1596-7. 32. Moffett MJ, Ruckdeschel JC. Bleomycin and tetracycline in malignant pleural effusions.Semin Oncol. 1992;19(suppl):59-62. 33. Ruckdeschel JC. A comparative overview of non-small cell lung cancer: 1980 v 1991. Lung cancer. 1993;9(suppl):15-24.
  • 15.
    John C. Ruckdeschel,M.D. 34.Remick SC, WagnerH, Ruckdeschel JC. Management of the patient with HIV-associated lymphomas and hodgkins disease.AIDS reader. 1991;1:204-13. 35. Ruckdeschel JC. Lung cancer - 1993. Mediguide to oncology.1994;14(1):1-8. 36. Ruckdeschel JC. The role of standard dose etoposide in the management of non-small cell lung cancer. Semin Oncol. 1992;19(6):39-44. 37. Wagner H, Ruckdeschel JC. Treatment of locally advanced and metastatic non-small cell lung cancer. Advances in Oncology. 1993;9(5):22-9. 38. Ruckdeschel JC. Preoperative and postoperative adjunctive therapy for resectable non-small cell lung cancer. In: Roth J, Cox J, Hong WK, editors. Lung cancer. Boston: Blackwell Scientific Publications; 1993. p. 239-51. 39. Ruckdeschel JC. The future role of carboplatin. Semin Oncol. 1994;21(5):114-8. 40. Ruckdeschel JC. Spinal cord compression due to cancer: early diagnosis and treatment. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, editors. Clinical oncology.New York: Churchill Livingstone; 1995. p. 619-28. 41. Ruckdeschel JC. Carcinoma of the lung current therapy. In: Rakel R, editor. Conn’s current therapy. Philadelphia: WB Saunders; 1994. p.156-63. 42. Ruckdeschel JC, Robinson LA. Non-small cell lung cancer: surgery and postoperative adjuvant chemotherapy. In: Pass H, Mitchell D, Johnson A,Turrisi J, editors. Lung cancer: principles & practice. Philadelphia: JB Lippincott; 1996. P.839-49. 43. Ruckdeschel JC. Current status and future role of carboplatin [monograph]. Bristol-Myers Squibb, 1994. 44. Ruckdeschel JC. Future directions in non-small cell lung cancer-a personalview. Lung cancer. 1995;12(2):s147- 52. 45. Ruckdeschel JC. Lung cancer: an overview. In: Roth J, Ruckdeschel J, Weisenburger T, editors. Thoracic Oncology II. Philadelphia: WB Saunders; 1995. p.3-4. 46. Williams C, Ruckdeschel JC. Management of disseminated non-small cell lung cancer. In: Roth J, Ruckdeschel J, Weisenburger T, editors. Thoracic Oncology II. Philadelphia: WB Saunders; 1995. p.181-7. 47. Moores D, Ruckdeschel JC. Pleural effusions in patients with malignancy. In: Roth J, Ruckdeschel J, WeisenburgerT, editors. Thoracic Oncology II. Philadelphia: WB Saunders; 1995. p.556-66. 48. Wagner H, Ruckdeschel JC. Screening, early detection and early intervention strategies for cancer of the respiratory system(lung and bronchus).In: Reintgen D, Clark RA, editors. Cancer screening. St. Louis: Mosby Year Book; 1995. p.118-49. 49. Ruckdeschel JC. The cost of success in the treatment of thoracic malignancies [commentary]. Curr Opin Oncol. 1995;7:131-3. 50. Blanchard C, Ruckdeschel JC, Albrecht T. Patient-family communication with physicians.In: Bader, Cooper, DeNour, editors. Cancer and the family. West Sussex : John Wiley & Sons; 1996. p.369-87. 51. Ruckdeschel JC. Introduction: LCSG - the final analysis.Chest. 1994;106(6):279s. 52. Ruckdeschel JC, Aisner J, Ettinger DS, Johnson DH, Wagner H. Small cell lung cancer [monograph]. Bristol Myers Squibb, 1995. 53. Ruckdeschel JC. Malignant effusions in the chest.In: Kirkwood JM, Lotze MT, Yasko JM, editors. Current cancer therapeutics.2nd ed. Philadelphia: Churchill-Livingstone; 1996. p.304-8. 54. Ruckdeschel JC. We have met the enemy . . . and they is us![commentary]. Curr Opin Oncol. 1996;8:103-5. 55. Ruckdeschel JC. Malignant pleural effusion: a cost-effectiveness analysis ofpleurodesis [monograph]. Bristol Myers Squibb, 1996. 56. Ruckdeschel JC, Wagner H, Robinson L. Locally advanced lung cancer - controversies in management. ASCO Educational Book, 1996. 57. Ruckdeschel JC, Wagner H, Robinson L. Locally advanced lung cancer: controversies in management. Advances in Oncology. 1996;12(3):22-8. 58. Ruckdeschel JC, Wagner H, Robinson L. Cáncer de Pulmón Localmente Avanzado [Locally Advanced Lung Cancer] (Spanish). Revista argentina cancerología.1996;24(2):90-2. 59. Ruckdeschel JC. Breaking clinical and administrative barriers. In: Semendinger, editor. The challenge of health care leadership. Chicago: AHA Publishing; 1997. p.51-68. 60. Ruckdeschel JC, Robinson L. Malignant pleural effusions: questions and controversies [monograph]. Bristol Myers Squibb, 1997. 61. Ruckdeschel JC. Combined modality therapy of non-small cell lung cancer. Semin Oncol.
  • 16.
    John C. Ruckdeschel,M.D. 1997;24(4):429-39. 62.Robinson L, Ruckdeschel JC. Management of pleural and pericardial effusions. In: Berger, Portenoy, Weissman, editors. Lung cancer: principles and practice of supportive oncology.Philadelphia: JB Lippincott; 1998. p.327-52. 63. Ruckdeschel JC. Treating lung cancer. Coping. 1997;38-9. 64. Antonia S, Robinson LA, Ruckdeschel JC, WagnerH. Lung cancer. In: Balducci, Lyman, Ersher, editors. Comprehensive geriatric oncology.2nd ed. London: Harwood Academic Publishers; 1997. p.613- 30. 65. Ruckdeschel JC. Editorial overview: lung and mediastinum. Curr Opin Oncol. 1997;9(2):147-8. 66. Bonomi P, Ruckdeschel JC. New approaches in the treatment of stage IV non-small cell lung cancer [monograph]. Bristol Myers Squibb, 1997. 67. Ruckdeschel JC. IASLC proceedings - future directions in non-small cell lung cancer: a continuing perspective [review]. Oncology. 1998;12(2):90-6. 68. Ruckdeschel JC. Preoperative and postoperative adjunctive therapy for resectable non-small cell lung cancer. In: Roth JA, Cox JD, Hong WK, editors. Lung Cancer. 2nd ed. Boston: Blackwell Scientific; 1997. p.207-16. 69. Garland LL, Ruckdeschel JC, Wagner Jr H, Williams Jr C, Shaw G, Antonia S, Heise M, Hilstro J, Cantor A. Single agent paclitaxel as second-line chemotherapy for resistant,metastatic non-small cell lung cancer. In: Johnson, Klastersky, editors. Taxanes in lung cancer therapy. New York: Marcel Dekker, Inc.; 1998. p.117-26. 70. Ruckdeschel JC, Aisner J, Ettinger D, Jett J, Wagner H. Current approaches to managing patients with small cell lung cancer [monograph]. Smith Kline Beecham, 1997. 71. Ruckdeschel JC. A prospective randomized trial of bleomycin vs doxycycline vs talc for the intrapleural treatment of malignant pleural effusions. In: Jett J, editor. Current clinical trials in thoracic oncology - what the chest physician needs to know. 1997;1(3). 72. Ruckdeschel JC. Malignant effusions in the chest.In: Kirkwood JM, Lotze MT, Yasko JM, editors. Current Cancer Therapeutics,3rd ed. New York: Churchill Livingstone; 1998. p.324-8. 73. Ruckdeschel JC, Aisner J, Evans W, Gandara D, Green M, Holmes EC, Ihde DC, Johnson DH, Sause WT, Wagner Jr H. Commentary and review of presentations on lung cancer [monograph]. Bristol Myers Squibb, 1998. 74. Mackey CS, Ruckdeschel JC. Lung cancer. In: Sullivan P, Guilford AM, editors. Swallowing Intervention in Oncology. San Diego: Singular Publishing; 1999. p.117-33. 75. Ruckdeschel JC. Chemotherapy for lung cancer: new agents with significant benefit. Primary Care & Cancer. 1998;18(5):26-32. 76. Ruckdeschel JC. Spinal cord compression. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, editors. Clinical Oncology. 2nd ed. New York: Churchill Livingstone; 1999. p.811-9. 77. Tockman M, Ruckdeschel JC, Mulshine J. The early detection of second primary lung cancers by sputum immunostaining. In: Jett J, editor. Current clinical trials in thoracic oncology - what the chest physician needs to know. 1998;2(1):3,8-9. 78. Yanes B, Bonomi PD, Curran Jr WJ, Ginsberg RJ, Khuri FR, Ruckdeschel JC, Weiland JE. Advances in lung cancer management: 1997 Miami Valley hospitallung conference [monograph]. Bristol Myers Squibb, 1998. 79. Ruckdeschel JC. Myths and facts about lung cancer: What You Need to Know. Melville (NY): PRR Publishers; 1999. 80. Blanchard C, Albrecht T, Ruckdeschel JC. Patient family communication with physicians.In: Bader, Cooper, DeNour, editors. Cancer and the family. 2nd ed. West Sussex(England): John Wiley & Sons,Ltd; 2000. p.477-95. 81. Ruckdeschel JC. Intrapleural therapy.In: Ratain MJ, Tempero M, Skosey C, editors. Oncology therapeutics:a quick reference guide. Philadelphia: WB Saunders; 2000. 82. Simon G, Ginsberg R, Ruckdeschel JC. Small cell lung cancer. Chest Surg Clin N Am. 2001;11(1):165-8. 83. Ruckdeschel JC, Robinson L. Management of pleural and pericardial effusions. In: Berger, Portenoy, Weissman, editors. Lung cancer ; principles and practice of palliative care and supportive oncology. Philadelphia: Lippincott,Williams & Wilkins. In press 2001. 84. Ruckdeschel JC, Jablons D. Malignant effusions of the chest.In: Kirkwood JM, Lotze MT, Yasko JM,
  • 17.
    John C. Ruckdeschel,M.D. editors.CurrentCancer Therapeutics.4th ed. Philadelphia: Current Medicine; 2001. 85. Ruckdeschel JC. Myths and facts about lung cancer: What You Need to Know. Melville (NY): PRR Publishers; 2002. 86. Robinson LA, WagnerH, Ruckdeschel JC. Lung cancer guidelines, treatment of stage IIIA non-small cell lung cancer. Chest. 2003;123(suppl 1): 3325-75. 87. Albrecht TA, Blanchard CG, Ruckdeschel JC, Coovert MA. The mediating role of communication in cancer treatment decision making. In: Brashers D, Goldsmith D, and Lammers L, editors. Communication in the management of health and illness. Manwah (NJ): Lawrence Erlbaum & Associates.In press. 88. Ruckdeschel JC, Greene J, Sommers KE, Fields KK. Respiratory complications of cancer and its treatment. In: Kufe DW, Holland JF, Frei E, editors. Cancer Medicine 6. Hamilton (ON); Lewiston (NY) [distributor]: BC Decker. 2003. 89. Alberts WM, Bepler G, Hazelton T, Ruckdeschel JC, Williams Jr JH. Lung cancer. Practice organization. Chest. 2003;123(suppl 1):2202-5. 90. Ninane V, LePechoux C, Curran W, Furuse K, Liptay M, Meert AP, Paesmans M, Rami-Porta R, Roelandts R, Ruckdeschel JC, Sculier JP, Senan S, Smit EF. Critical factors for patient management. Lung Cancer. 2003;42(suppl):57-8. 91. Ruckdeschel JC, guest editor. Update in the management of lung cancer. New York (NY): RogersMIS. 2004;3(2). 92. Ruckdeschel JC. Spinal cord compression [book chapter]. In: Abeloff M, Armitage J, and Niederhuber J, editors. Clinical Oncology. Philadelphia: Churchill-Livingstone; 2004. p.1063-71. 93. Ruckdeschel JC. Lung cancer [book chapter]. In: Abeloff M, Armitage J, and Niederhuber J, editors. Clinical Oncology. Philadelphia: Churchill-Livingstone; 2004. p.1649-743. 94. Ruckdeschel JC. Myths and facts about lung cancer. What You Need to Know. Melville (NY): PRR Publishers; 2004. 95. Helft PR, Albrecht TL, Back A, Ruckdeschel JC. Challenges to physician communication about treatment options to patients.ASCO Educational Book Alexandria: American Society of Clinical Oncology; 2006 96. Ruckdeschel JC. At the Core of Oncology (book chapter) In: The Art and Science of Oncology. Boston (MA): Aspatore Books; 2007. pp33-44. ABSTRACTS 1. Ruckdeschel JC, Wiernik PH. Carcinoembryonic antigen in patients with hematologic malignancies [abstract].USAEC Report Conf. 1974;73:1141. 2. Ruckdeschel JC, Graziano KD, Mardiney Jr MR. Parameters of in vitro lymphocyte responsiveness to measles antigen [abstract]. Fed Proc. 1974;33:619. 3. Ruckdeschel JC, Doukas J, Mardiney Jr MR. Direct, quantitative analysis of in vitro lymphocyte responsivenessto antigen,mitogen and allogeneic cells using a new laser based cell sizing apparatus [abstract]. Fed Proc. 1975;34:995. 4. Ruckdeschel JC, Schimpff SC, Dunmire C, Smyth AC, Wiernik PH, Mardiney Jr MR. Correlation of susceptibility to herpes zoster with impaired cell associated immunity to the varicella zoster virus in patients with hodgkin’s disease [abstract]. Clin Res. 1975;23:311A. 5. Ruckdeschel JC, Martin RG, Byhardt RW. Nonradiotherapeutic factors in the development of radiation related pericardial effusions in patients treated for hodgkin’s disease [abstract]. Proc ASCO. 1975;16:238. 6. Ruckdeschel JC, Dunmire C, Mardiney Jr MR. Cell associated immunity to measles in SSPE. Evidence for impaired lymphocyte transformation in response to measles antigen [abstract]. Arch Neurol. 1975;32:497. 7. Ruckdeschel JC, Doukas J, Mardiney Jr MR. Application of laser cytometry to the analysis of immunologically induced in vitro lymphocyte responsiveness [abstract].Clin Res. 1975;23:585A. 8. Jones III PP, Ruckdeschel JC, Eckert C, Horton J. Management of rectal villous adenomas with particular reference to the high incidence of associated colonic malignancies [abstract]. Clin Res. 1977;25:408A. 9. Ruckdeschel JC, Lininger L, Brzyski H, Miani M, Becker J. Re-analysis of in vitro lymphocyte blastogenesis using the laser cytometry assay [abstract]. Exp Hematol. 1978;6:70.
  • 18.
    John C. Ruckdeschel,M.D. 10.Caradonna R, Paladine W, Goldstein J, Ruckdeschel JC, Hillinger S, Horton J. Combination chemotherapy with high dose cis-diamine dichloroplatinum, methotrexate and bleomycin for epidermoid carcinoma of the head and neck [abstract]. Proc Am Assoc Cancer Res. 1978;19:401. 11. Ruckdeschel JC, Horton J, McKneally MF. Cytoxan, adriamycin, methotrexate and procarbazine (CAMP) in the management of bronchogenic carcinoma [abstract]. Proc ASCO. 1978;19:378. 12. Ruckdeschel JC, Becker JR, Miani MA, Lininger L, Brzyski H. Sequential analysis of cell-associated immunity (CAI) by laser cytometry [abstract]. Fed Proc. 1978;37(6):1843. 13. Ruckdeschel JC, McSharry J, Caliguiri L, Horton J. Cellular basis of cancer medicine: an integrated approach to the clinical and biological aspects of oncology [abstract]. Fed Proc. 1978;37(6):1548. 14. Ferraro J, Lansing L, Ruckdeschel JC. Giant cell cancer of the lung: a rapidly fatal histologic variant [abstract]. Proc ASCO. 1979;20:405. 15. Lunia SL, Ruckdeschel JC, McKneally MF, Killam D, Baxter D, McIlduff JB, Ray P, Chodos R, Horton J. Mediastinal involvement by bronchogenic carcinoma: correlation of chest radiography, gallium scanning and surgical biopsy [abstract]. Proc ASCO. 1979;20:405. 16. Brzyski H, Konchanin L, Baustin A, Ruckdeschel JC. Abnormal mitogen induced lymphocyte proliferation in patients with lung cancer: possible role of the surface modulating assembly [abstract]. Proc AACR. 1979;20:148. 17. Ruckdeschel JC, Brzyski H. Dissociation of blast transformation and radionucleotide incorporation by agentsinterfering with surface modulating assembly activity [abstract]. Clin Res. 1979;27:335A. 18. Ruckdeschel JC, McKneally MF, Devore C, Baxter D, Sedransk N, Caradonna R, Horton J. Regional immunotherapy fails to improve response to combined radiation and chemotherapy in patients with stage III non-oat cell bronchogenic carcinoma confined to the thorax: a controlled comparison [abstract]. Proc ASCO/AACR. 1980;21:374. 19. Harper GR, Rodichok LD, Ruckdeschel JC, Price A, Sedransk N, Horton J. Early Detection of Spinal Epidural Metastases [abstract].Proc ASCO/AACR. 1980;21:189. 20. Cohen RE, Blanchard C, Rohrbaugh M, Horton J, Ruckdeschel JC. Physician attitudes towards cancer: variations based on experience and specialty [abstract]. Proc ASCO/AACR. 1980;21:383. 21. Brandman J, Ruckdeschel JC, O’Donnell M, Horton J, Harrington G. Unexpected pulmonary complications of intensive therapy for small cell cancer of the lung (SCCL) [abstract]. Proc ASCO/AACR. 1980;21:459. 22. Ferraro J, Hillinger S, O’Donnell M, McNamee R, Ruckdeschel JC, Horton J. Treatment of advanced large bowel cancer with m-AMSA. A GITSG pilot study [abstract].Proc ASCO/AACR. 1980;21:420. 23. Weissman CH, Ruckdeschel JC, Ferraro J, Reilly C, Horton J. Cyclophosphamide, adriamycin and VP-16-213 (CAVP-16) chemotherapy in the management of advanced non-oat cell bronchogenic carcinoma (NOBC) [abstract]. Proc ASCO/AACR. 1980;21:459. 24. Ruckdeschel JC, Creech R, Mehta C. Chemotherapy of advanced non-oat cell bronchogenic carcinoma: the Eastern Cooperative Oncology Group experience [abstract]. In: Hansen H, Dombernowsky, editors. Abstracts II world conference on lung cancer. Princeton (NJ): Excerpta Medica; 1980. p.237. 25. McKneally MF, Maver C, Bennett J, Ruckdeschel JC. Evaluation of regional BCG in lung cancer [abstract]. In: Hansen H, Dombernowsky, editors. Abstracts II world conference on lung cancer. Princeton (NJ): Excerpta Medica; 1980. p.108. 26. Ruckdeschel JC, Harper GR, Rodichok LD. Early diagnosis of spinal epidural metastases [abstract]. Clin Res. 1980;28:652A. 27. Cohen R, Ruckdeschel JC, Blanchard C, Last C, Horton J. Adaptation to mastectomy: variation based on time from surgery and use of adjuvant chemotherapy [abstract]. Abstract Medical and Pediatric Oncology 8:424, 1980. 28. O'Donnell M, Ruckdeschel JC, Sedransk N, Baxter D, Spiers A, Horton J. Does intensive induction chemotherapy improve survival in small cell cancer of the lung (SCCL)?: a randomized comparison [abstract]. Proc ASCO/AACR. 1981;22:168. 29. Ruckdeschel JC, Filardi HG, Konchanin L, Wiener G, Sedransk N. S/G2 arrest: an alternate mechanism for diminished lymphocyte proliferation in patients with cancer [abstract]. Proc ASCO/AACR. 1981;22:319. 30. Cohen RE, Sheehan AP, Ruckdeschel JC, Blanchard EB, Hall VI, Poleto MA, Cassidy MH, Horton J. Patient and treatment factors in the development of chemotherapy-related nausea and vomiting [abstract]. Proc ASCO/AACR. 1981;22:418.
  • 19.
    John C. Ruckdeschel,M.D. 31.Horton J, Eyerson W, Baxter D, Ruckdeschel JC. Post operative radiation (RT) for rectal cancer is not always innocuous [abstract]. Proc ASCO/AACR. 1981;22:414. 32. Blanchard CG, Ruckdeschel JC, Saunders NL, Malloy D, Horton J. The measurement of physician behavior on inpatient rounds [abstract].Med Ped Oncol. 1981;9:567. 33. Ruckdeschel JC, Blanchard CG, Cohen RE. Assessment ofattitudes toward cancer [abstract]. Med Ped Oncol. 1981;9:452-3. 34. Ruckdeschel JC, Blanchard CG, Saunders N, Malloy ED, Blanchard E, Horton J. Patient-physician interactions: the measurement of physician behavior on inpatient oncology rounds [abstract]. Proc ASCO. 1982;1:49. 35. Ahles T, Blanchard EB, Ruckdeschel JC, Sheehan AP. Assessing the multidimensional aspects of cancer-related pain: toward a practical assessment package [abstract]. Proc ASCO. 1982;1:49. 36. Harper GR, Rodichok LD, Prevosti L, Lininger L, Ruckdeschel JC. Early diagnosis of spinal epidural metastases leads to improved treatment outcome [abstract]. Proc ASCO. 1982;1:6. 37. Ruckdeschel JC, Mason B, Ettinger D, Creech R, Mehta C, Stanley K. Failure to define a "standard" chemotherapy for metastatic non-small cell bronchogenic carcinoma [abstract]. Proc AACR. 1982;23:39. 38. Ruckdeschel JC, Mason B, Ettinger D, Creech R, Mehta C, Stanley K. Chemotherapy of metastatic non-oat cell bronchogenic carcinoma: the Eastern Cooperative Oncology Group experience [abstract]. In Secretariat, editor. Abstracts III World Conference on Lung Cancer. Proceedings of the 3rd World Conference on Lung Cancer; 1982 May 17-20; Tokyo, Japan. p.185. 39. Blanchard CG, Ruckdeschel JC, Blanchard EB, Arena J, Saunders N, Malloy D. Do attitudes predict behavior? Correlation of oncologists'attitudes with their observed behavior toward cancer patients [abstract]. Med Pediatr Oncol. 1982;10:49A. 40. Spiers ASD, Ruckdeschel JC, Horton J, Rauch AE, O'Donnell MR, Burkart PT. Effectiveness of pentostatin (2' deoxycoformycin, DCF) in refractory lymphoid neoplasms [abstract]. Blood. 1982;60(1):163a. 41. Ruckdeschel JC, Zimmerman MS, Hussain M. Chemotherapy-induced interstitial pneumonitis during treatment of small cell anaplastic lung cancer [abstract]. Proc ASCO. 1983;2:199. 42. Bonomi P, O'Reilly W, Vogl S, Ruckdeschel JC, Creech R, Stolbach L. A phase II trial of cyclophosphomide,VP16 and methotrexate in small cell bronchogenic carcinoma (SCBC): an Eastern Cooperative Oncology Group pilot study [abstract].Proc ASCO. 1983;2:199. 43. Berenzweig M, Vogl S, Camacho F, Ruckdeschel JC. Esophageal squamous cancerchemotherapy (CT) with methylglyoxal bis-guanylhydrazone (MGBG), methotrexate (M), bleomycin (B) and diamminedichloroplatinum (D) - "MGBG-MBD" [abstract]. Proc ASCO. 1983;2:125. 44. Blanchard CG, Ruckdeschel JC, Blanchard EB, Murray S, Pallmeyer TP, Fried K. The relationship between physician behavior on inpatient oncology rounds and patient satisfaction [abstract]. Med Pediatr Oncol. 1983;11:43A-44A. 45. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Mason BA, Vogl SE, Joss RA. Chemotherapy of metastatic nonsmall cell bronchogenic carcinoma (NSCBC): a randomized comparison of the four most active regimens [abstract]. Proc AACR. 1984;25:171. 46. Armstrong M, Harper G, Line B, Ruckdeschel JC. Dual isotope technique for in vitro quantitative assessment ofintra-arterial (IA) drug delivery to hepatic metastases [abstract].Proc AACR. 1984;25:169. 47. Harper G, Cooper L, Baxter D, Fernando L, Ruckdeschel JC. Value of myelography (MG) for planning treatment (RT) of spinal epidural metastases (SEM) [abstract]. Proc ASCO. 1984;3:72. 48. Blanchard CG, Ruckdeschel JC, Blanchard EB, Fletcher BA. Patient satisfaction with specific behaviors of medical oncologists during inpatient rounds [abstract]. Proc ASCO. 1984;3:72. 49. Bunting N, Bonomi P, O'Reilly W, Vogl S, Creech R, Ruckdeschel JC, Stolbach L, Ettinger D. Prognostic factors in patients with small cell bronchogenic carcinoma treated on an eastern cooperative oncology group phase II trial [abstract]. Proc ASCO. 1984;3:228. 50. Ruckdeschel JC, Finkelstein DM, Creech RH, Ettinger DS. Chemotherapy of metastatic non-small cell bronchogenic carcinoma [abstract]. Clin Res. Apr 1984. 51. Blanchard CG, Ruckdeschel JC, Fletcher BA, Blanchard EB. Predictors of high and low patient satisfaction on inpatient oncology rounds [abstract].Med Pediatr Oncol. 1984;12:24A. 52. Line BR, Harper GR, Armstrong M, Ruckdeschel JC. Dual isotope technique for in vivo quantitative assessment ofintra-arterial (IA) drug delivery to hepatic metastases [abstract].J Nucl Med. 1984;25:41. 53. Ettinger DS, Baker RR, Eggleston JC, Abeloff MD, Ruckdeschel JC, McKneally MF, Woll J, Adelstein D. Prospective evaluation of the role of surgery in limited disease (LD) small cell lung cancer.
  • 20.
    John C. Ruckdeschel,M.D. AnEastern Cooperative Oncology Group pilot study [abstract].Proc ASCO. 1985;4:180. 54. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Mason BA, Vogl SE, Joss RA. Predictors of improved response and survival in metastatic non-small cell bronchogenic carcinoma (NSCBC) [abstract]. Proc ASCO. 1985;4:187. 55. Ruckdeschel JC, Gazdar AF, Carney DN, Russell EF, Oie H. The use of human lung cancer cell lines for in vitro chemosensitivity testing [abstract]. Proc AACR. 1985;26:367. 56. Gazdar AF, Oie H, Russell E, Carney DN, Linnoila J, Ruckdeschel JC, et al. Establishment and characterization of a large comprehensive panel of cell lines demonstrates the diversity of human lung cancer [abstract]. Proc AACR. 1985;26;27. 57. Ruckdeschel JC, Finkelstein DM, Ettinger DS. Chemosensitivity of metastatic non-small cell lung cancer (NSCLC) [abstract]. Proc. IV World Conference on Lung Cancer; 1985 Aug 25-30; Toronto, Canada. 58. Ruckdeschel JC, Gazdar AF, Carney DN, Russell EF, Oie H. In Vitro chemosensitivity testing for human non-small cell lung cancer: the role of cell lines [abstract]. Proc. IV World Conference on Lung Cancer; 1985 Aug 25-30; Toronto, Canada. 59. Blanchard CG, Fletcher BA, Ruckdeschel JC, Frisch S, Blanchard EB, Brady AC. The measurement of house staff interactions with cancer and non-cancer patients [abstract]. Med Pediatr Oncol. 1985;13:14A. 60. Wagner H, Ruckdeschel JC, Bonomi P, Danjux C, Richter M, Ettinger D. Treatment of locally advanced non-small cell lung cancer (NSCLC) with mitomycin C, vinblastine and cis-DDP (MVP) followed by radiation therapy (RT): an Eastern Cooperative Oncology Group pilot study [abstract]. Proc ASCO. 1985;4:183. 61. Ettinger DS, Mehta CR, Abeloff MD, Ruckdeschel JC, Aisner S. A randomized comparison of conventionalchemotherapy with immediate alternation of non-cross resistant chemotherapy in extensive disease (ED) small cell lung cancer (SLCLC) [abstract]. Proc ASCO. 1986;5:170. 62. Bennett JA, Ruckdeschel JC, Riley K, Kaye-Wenzel M. Differential chemosensitivity of lewis lung carcinoma (LLC) to cyclophosphamide (CYT) and doxorubicin (DOX): accurate prediction by the subrenal capsule (SRC) and novel dye exclusion (NDE) assays [abstract].Proc AACR. 1986;27:413. 63. Ruckdeschel JC, Riley K. In vitro chemosensitivity of human cancer cell lines to 4-hydroperoxy- cyclophosphamide (4HC), melphalan (M), phosphoramide mustard (PM) and nitrogen mustard (NM) [abstract]. Proc AACR. 1986;27:411. 64. Labrecque MS, Blanchard CG, Ruckdeschel JC, Blanchard EB. The impact of cancer patient decision- making preferences on patient satisfaction [abstract]. J Cancer Educ. 1986;1(3):213. 65. Ruckdeschel JC, Riley K. Dose-dependent cytotoxicity of etoposide in human lung cancer cell lines: role of thesolvent carrier [abstract]. Proc AACR. 1987;28:425. 66. Ettinger DS, Mehta CR, Abeloff MD, Ruckdeschel JC, Aisner S. Maintenance chemotherapy versus no maintenance chemotherapy in complete responders following induction chemotherapy in extensive disease (ED) small cell lung cancer (SCLC) [abstract]. Proc ASCO. 1987;6:175. 67. Bonomi P, Mehta C, Ruckdeschel JC, Blum R, Mason B, Greene M. Phase II-III trial of mitomycin- vinblastinecisplatin (MVP); vinblastin-cisplatin (VP); MVP alternating with cyclophosphamide- adriamycin-methotrexateprocarbazine (MVP/CAMP); CBDCA followed by MVP; and CHIP followed by MVP in patients with metastatic non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group study [abstract]. Proc ASCO. 1987;7:177. 68. Aisner SC, Ettinger D, Finkelstein D, Ruckdeschel JC, Mehta C, Abeloff M, Eggleston J. The clinical significance of variant morphology (small cell/large cell) small cell carcinoma of the lung (SCCL) [abstract]. Proc ASCO. 1988;7:A752. 69. Fudin J, DeConti R, Ruckdeschel JC. Chemical phlebitis due to CI-921: The role of formulation/ dissolution characteristics [abstract]. Proc AACR. 1989;30:A968. 70. Ruckdeschel JC, Piantadosi S. Assessment ofquality of life (QL) by the functional living index-cancer (FLIC) is superior to performance status for prediction of survival in patients with lung cancer [abstract]. Proc ASCO. 1989;8:A1209. 71. Ruckdeschel JC, Archer S. Rational design of a novel ellipticine derivative with significant activity against human lung cancer cell lines [abstract]. Proc AACR. 1989;30:A2420. 72. Ruckdeschel JC, Moores D, Lee J, Einhorn L, Mandelbaum J, Koeller J, Weiss G, Losada M, Keller J. Management of malignant pleural effusions (MPE): a randomized comparison of tetracycline and bleomycin [abstract]. Proc ASCO. 1990;9:323. 73. Moores D, Ruckdeschel JC, Lee J, Einhorn L, Mandelbaum I, Koeller J, Weiss G, Losada M, Keller J.
  • 21.
    John C. Ruckdeschel,M.D. Malignantpleural effusion: a randomized comparison of tetracycline and bleomycin [abstract]. Chest. 1990;98(2):44. 74. Wagner Jr H, Lad T, Ruckdeschel JC. Randomized phase I comparison of preoperative radiation therapy (XRT) and chemotherapy with mitomycin-C, vinblastine and cisplatin for patients with pathologic stage IIIA and IIIB non-small cell lung cancer (NSCLC) [abstract]. Proc ASTRO. 1990 Oct. 75. Diamond C, Remick S, Migliozzi J, Solis O, WagnerH, Haase R, Ruckdeschel JC. Primary central nervous systemlymphoma (PCL) in patients with and without acquired immunodeficiency syndrome (AIDS) [abstract]. Proc ASCO. 1990;9:A367. 76. Ross JS, Samaan S, Ruckdeschel JC, Wagner H. DNA ploidy in atypical carcinoid tumors of the lung [abstract]. Lab Invest.1991;64(1):118A. 77. Ruckdeschel JC, Archer S, Cioli D, Portuese E. Antitumor properties of some n-methylcarbamates derived from ellipticine and olivacine [abstract]. Proc AACR. 1991;32:2412. 78. Remick S, McSharry J, Wolf B, Blanchard C, Gorman P, Slaga J, Wagner H, Harper G, Horton J, Ruckdeschel JC. Novel oral combination chemotherapy (CT) in the management of AIDS-related non- hodgkin's lymphoma (NHL) [abstract]. Proc ASCO. 1991;10:32. 79. Bromberg C, Remick S, Harper G, Sporn J, Healey B, Hilstro J, von Roemeling R, Horton J, Ruckdeschel JC. Concurrent 72-hour continuous infusion (CI) of etoposide (VP-16) and cisplatin (DDP) in metastatic breast cancer [abstract]. Proc ASCO. 1991;10:49. 80. Grossman SA, Ruckdeschel JC, Moynihan T, Finkelstein D, Ettinger D, Mahoney E, Trump D. Randomized prospective comparison of intraventricular (IT) methotrexate (MTX) and thiotepa (TT) for neoplastic meningitis (NM) [abstract]. Proc ASCO. 1991;10:127. 81. Moore M, Robert F, Cripps F, Ruckdeschel JC, Neidhart J, Natale R, Dallaire B, Gyves J. A phase II study of brequinar sodium (DuP 785, NSC 368390) in gastrointestinal(GI) cancers (ca) [abstract]. Proc ASCO. 1991;10:152. 82. von Roemeling R, Fisher H, DeConti R, Horton J, Wilbur H, Hrushesky W, Ruckdeschel JC. Continuous FUDR infusion for hormone refractory prostate cancer: A phase I/II study [abstract].Proc ASCO. 1991;10:171. 83. Ruckdeschel JC, Linnoila RI, Mulshine JL, Kim K, Aisner S, Gazdar AF, Jensen SM, Bonomi P. The impact of neuroendocrine (NE) and epithelial (EPI) differentiation on response and survival in lung cancer: the ECOG experience [abstract]. Proc ASCO. 1991;10:248(A849). 84. Linnoila RI, Ruckdeschel JC, Piantadosi S, Jensen SM, Mulshine JL. The impact of neuroendocrine (NE) and epithelial (EPI) differentiation on recurrence and survival in patients (pts) with resected non- small cell lung cancer (NSCLC): the LCSG experience [abstract]. Proc ASCO. 1991;10:248(A850). 85. Maroun J, Ruckdeschel JC, Natale R, Morgan R, Robert F, Berkowitz I, Dallaire B, Wilgosz G. A phase II study of brequinar sodium (DuP 785, NSC 368390) in lung cancers [abstract]. Proc ASCO. 1991;10:A850. 86. Bonomi P, Finkelstein D, Chang A, Ruckdeschel JC. Decreasing response rates in eastern cooperative oncology group (ECOG) stage IV non-small cell lung cancer (NSCLC) trials: comparison of sequential studies [abstract].Proc ASCO. 1991;10:261. 87. Hisington S, Remick S, MacDowell R, Hilstro J, Ramnes C, Izqierdo R, Harper G, Ruckdeschel JC. Venous access via a peripherally implanted device: a preliminary trial [abstract]. Proc ASCO. 1991;10:327. 88. Ruckdeschel JC, Linnoila RI, Mulshine JL, Kim K, Piantadosi S, Aisner S, Jensen SM, Gazdar AF for the Eastern Cooperative Oncology Group and Lung Cancer Study Groups. The impact of neuroendocrine and epithelial differentiation on recurrence and survival in patients with lung cancer [abstract]. Sixth World Conference on Lung Cancer; 1991 Nov 10-14; Melbourne, Australia. Lung Cancer. 1991;7 (suppl):56. 89. Doroshow J, Ruckdeschel JC, Freytes C, Robert F, Havlin K, Adams D, Sisk R, Dallaire B, Gyves J. A phase II study of DUP 937 in head and neck cancer [abstract]. Proc ASCO. 1992;11:247. 90. von Roemeling R, DeConti R, Horton J, Remick S, Harper G, Hrushesky W, Ruckdeschel JC. Toxicity of circadian FUDR infusion: a randomized phase I pilot study [abstract].Chronobiology: Mechanisms and Therapeutic Applications; 1991; Paris, France. 91. Wagner Jr H, Ruckdeschel JC, Williams C, Heise M, Hilstro J. Single agent taxol (Tax) as second-line chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC) [abstract]. Lung Cancer. 1994;11(suppl 1):120. 92. Ruckdeschel JC, Wagner Jr H, Williams C, Heise M, Hilstro J. Second-line chemotherapy for resistant,
  • 22.
    John C. Ruckdeschel,M.D. metastatic,non-small cell lung cancer (NSCLC): the role of taxol (Tax) [abstract]. Proc ASCO. 1994;13:A1200. 93. Farrell P, Horton J, Ruckdeschel J, Simon J, Cohen G. A national education program in oncology for physicians - role of a new medical journal [abstract]. J Cancer Educ. 1994;9(3):A17. 94. Ruckdeschel JC, Albrecht TL, Blanchard C, Hemmick RM. Communication strategies for accruing patients to clinical trial: implications for training programs [abstract]. Proceedings of the AACE 30th Annual Meeting; 1995. p.A70. 95. Wolff AC, Ettinger DS, Neuberg D, Comis R, Ruckdeschel JC, Bonomi PD, Johnson DH. A phase II study ofifosfamide, carboplatin and oral etoposide (ICE) chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Group study [abstract].Proc ASCO. 1994;3:A1198. 96. Ruckdeschel JC, Pattern SG, Cutherbertson DD, Murtagh FR, Arrington JA. Spinal cord compression in lung cancer. MRI as the first diagnostic test is more cost effective [abstract]. Lung Cancer. 1997;18(1):A826. 97. Wagner H, Antonia SJ, Williams C, Alberts M, Hubble D, Robinson L, Hilstro J, Ruckdeschel JC, Shaw G. Concurrent paclitaxel/cisplatin (PC) with thoracic radiation (TR) in patients with stage IIIA/B non-small cell lung cancer (NSCLC) [abstract]. Proc ASCO. 1997;16:A1610. 98. Robinson LA, Ruckdeschel JC. Induction chemotherapy in pleural mesothelioma precludes the technical performance of an extrapleural pneumonectomy [abstract]. 4th International Mesothelioma Conference; 1997 May 13- 15; p.47. 99. Krontiris TG, Larson GP, Weitzel JN, Benson AB, Daly MB, DeVore RF, Kirkwood JM, Lunetta KL, Neuberg DS, O’Dwyer PJ, Ruckdeschel JC, Wagner H, Stewart JA. Mapping interactive cancer susceptibility loci (eastern cooperative oncology group) [abstract]. Proc ASCO. 1998;17:A2147. 100. Jiroutek M, Johnson D, Blum R, Bonomi P, Chang A, Ettinger D, Ruckdeschel J, Schiller J, Sandler A. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of eastern cooperative oncology group (ECOG) trials from 1981-1982 [abstract]. Proc ASCO. 1998;17:A1774. 101. Garland LL, WagnerH, Shaw GS, Williams CC, Anatonia SA, Khoor A, Meulemans LM, Nimmons KA, Ruckdeschel JC. Phase I dose-escalation study of constant rate infusion gemcitabine in combination with taxotere in advanced non-small cell lung cancer [abstract]. Proc ASCO. 1998;17:A1864. 102. Chirikos T, Ruckdeschel JC. Some predictors of the cumulative costs of lung cancer care [abstract]. Proc ASCO. 1999;A1946. 103. Garland LL, WagnerJr HJ, Shaw GS, Williams CC, Antonia SA, Muelemans LM, Nimmons KA, Ruckdeschel JC. Phase I study of constant dose rate infusion gemcitabine with taxotere in advanced non- small cell lung cancer [abstract]. Proc ASCO. 1999;A1632. 104. Garland L, Khoor A, Grendys E, Fiorica J, Walsh F, Alberts W, Role M, Anderson W, Ruckdeschel J. Utility of thyroid transcription factor-1 (TTF-1) in differentiating pulmonary adenocarcinoma from ovarian or primaryperitoneal adenocarcinoma in women with malignant pleural effusion (MPE) [abstract]. Proc ASCO. 2000;19:548a. 105. Wright D, Garland L, Wagner H, Clark R, Hazelton T, Shaw G, Antonia S, Williams C, Alberts WM, Ruckdeschel JC. MRI imaging of the spine is superior to bone scintigraphy in diagnosis of spine metastases in patients with nonsmall cell lung cancer (NSCLC) [abstract]. Proc ASCO. 2000;19:503a. 106. Stinson TJ, Bennett CL, Vogel V, Lewedy D, Jobbs J, Ruckdeschel JC, Chirikos TN, Weiner RS, Wicha MS. A multi-center study ofthe costs ofenrolling cancer patients on phase II clinical trials [abstract]. Proc ASCO. 2000;19:A1695. 107. Sullivan DM, Rago R, Ruckdeschel JC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Bulanhagui C, Gupta E, Tarby C, Sonnichsen D, Gustafson N, Gallant G. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, given every three weeks in patients with advanced malignancies [abstract]. ERSOTC. 2000. 108. Ruckdeschel JC. Malignant pleural effusions [abstract]. Lung Cancer. 2000;29(2):123. 109. Sullivan DM, Mahany JJ, Tetteh LF, Ruckdeschel JC, Williams CC, Antonia SJ, Lush RM, Sun S-L. A phase I study of combination therapy with oral 9-nitrocamptothecin and oral etoposide [abstract]. Submitted 2001. 110. Ruckdeschel JC, Spitz M, Saxman S. Summary report of the national cancer institute progress review group for lung cancer [abstract]. Lung Cancer 2001;34(suppl 1):S7-S8. 111. Ruckdeschel JC, Simon G, Antonia S, Haura E, Williams C, Wagner H, Rocha Lima C, Ettienne K, Vaughn J, Bepler G. ZD1839 (‘Iressa’) as a single agent for the treatment of metastatic non-small-cell lung
  • 23.
    John C. Ruckdeschel,M.D. cancer[abstract]. Proc ASCO. 2002. 112. Nordquist L, Simon GR, Alberts WM, Ruckdeschel JC. Improved survival in never smokers versus current smokers with primary adenocarcinoma of the lung [abstract]. Proc ASCO. 2002.9 113. Riddle DL, Albrecht TL, Coovert MD, Penner LA, Quinn G, Ruckdeschel JC, Blanchard CE. Observer video probased coding: emperical evidence of value added [abstract]. Measuring Behavior. 2002. 114. Eggly S, Albrecht T, Penner L, Cline R, Ruckdeschel JC, Berkely S, FosterT, Naughton M, Peterson A. “I know it’s bad, but how bad is it?” Challenges to current guidelines for communication bad news in the outpatient oncology clinic [abstract]. Medical Encounter. 2004;18. 115. Quinn GP, Jacobsen PB, Wells NL, Peredo C, Albrecht TL, Ruckdeschel JC, Bell M. Real-time patient satisfaction survey and improvement process [abstract].Psychooncology.2004;13(suppl 1):S29. 116. Franks M, Eggly S, Figueroa M, Hendriks M, Foster T, Ruckdeschel JC, Albrecht T. Physician communication and patient intention to accrue to cancer clinical trials [abstract]. Cancer Epidemiology, Biomarkers & Prevention. 2005;14;S2738. 117. Penner L, Franks M, Albrecht T, Foster T, Ruckdeschel JC. Using Noldus Observer® to Assess the Reactivity of Video Recordings of Medical Interactions [abstract]. Measuring Behavior. 2005. 118. Cline R, Harper F, Penner L, Albrecht T, Ruckdesche JC, Peterson A, Jones E, Taub J, Simon L. Who’s in the room? Relationships between parents’ communication and children’s stress during painful cancer treatment procedures [abstract]. Annals of Behavioral Medicine. 2005;29;S38. 119. Greene M, Eggly S, Penner L, FosterT, Albrecht T, Rehan S, Ruckdeschel JC. Patient and companion questions during discussions ofbad news in oncology interactions [poster]. APOS. 2005. 120. Penner L, Cline R, Jones E, Taub J, Ruckdeschel JC, Albrecht T. Dispositional and affective correlates of treatment related pain among pedicatric cancer patients [abstract]. Annals of Behavioral Medicine. 2006;30 121. Penner L, Cline R, FosterT, Jones E, Penner Taub J, Ruckdeschel JC, Albrecht T. Indirect support: Effects of multiple caregivers on nonverbal immediacy experienced by children during painful pediatric oncology procedures[abstract].Annals of Behavioral Medicine. 2006;30. 122. Cline R, Jones E, Peterson A, Penner L, Taub J, Ruckdeschel JC, Albrecht T,. Verbal combat: Risks of invalidating children’s experiences during painful oncology procedures [abstract]. Annals of Behavioral Medicine. 2006;30. 123. Eggly S, Franks M, Hendriks M, Figueroa M, Foster T, Ruckdeschel JC, Albrecht T. Frequency and context of oncologist’recommendations regarding clinical trials [abstract]. Annals of Behavioral Medicine. 2006;30. 124. Eggly S, Harper F, Penner L, FosterT, Rana J, Osborn D, Ruckdeschel JC, Albrecht T. Patient/companion information seeking during offers of clinical trials [abstract]. Annals of Behavioral Medicine. 2007; 33;S098. 125. Harper F, Gleason M, Eggly S, Ruckdeschel JC, Albrecht T. Expectations about cure, physician- patient communication, and treatment decision-making in cancer patients [abstract]. Annals of Behavioral Medicine. 2007;33;S097. 126. Rizvi N, Kris, M, Miller V, Azzoli C,Krug L, Bekele S,Chaplen R, Ruckdeschel J, Gadgeel S. A pahse II study of XL647 in non small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations. J Thor Oncol. 2007; 2(8) S737. 127. Karp DD, Lee S, Shae G, Johnson D, Kucuk O, Clamon G, Marks R, Johnston M,Okawara G, Ruckdeschel J. Progress Report: Eastern Cooperative Oncology Group (ECOG) E5597, an intergroup phase III randomized trial of selenium supplementation in resected stage I non small cell lung cancer. J Thor Oncol. 2007; 2(8) S811. 128. Gadgeel SM, Ruckdeschel JC, Wozniak A, Patel B, Heilbrun LK, Chen W, Venkat R, Chaplen R, Turrisi A. Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by Docetaxel in stage III nonsmall cell lung cancer (NSCLC) patients.J Clin Oncol; 2008:26(15S): 414s. 129. Gleason ME, Harper FW, Eggly S, Ruckdeschel JC, Albrecht TL. The influence of patient and companion cure expectations on treatment decisions. J Clin Oncol 2008; 26(15S): 518s. 130. Eggly S, Harper F, Penner L, FosterT, Austin T, Ruckdeschel J, Albrecht T. Information seeking by patients and companions during cancer clinical interactions. Psycho-Oncology.2008; 17: S1163. 131. Gadgeel SM, Ruckdeschel JC, Wozniak AJ, Chen W, Hackstock D, Galasso C, Burger A, Ivy SP, LoRusso P, Edelman MJ. Cebiranib, a VEGF receptor 1,2 and 3 inhibitor, and pemetrexed in patiens (pts) with recurrent nonsmall cell lung cancer (NSCLC). ASCO Annual Meeting. 2011; Abstract #77915. 132. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ,
  • 24.
    John C. Ruckdeschel,M.D. BaumanJE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, Fernandez C, Hall R, Kawabe T, and Sharma S. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM). ASCO AnnualMeeting 2012 Abstract 96454 133. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, Fernandez C, Hall R, Kawabe T, and Sharma S. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM). International Mesothelioma Research Group 2012 Abstract 223. 134. Ruckdeschel JC, Sause WT, Belnap T, Jones C, Rowley, B. Oncology quality improvement as a cornerstone of the transition to accountable care J Clin Oncol 30, 2012 (suppl 34 abst 141). 135. Sause WT, Ruckdeschel JC, Belnap TW, Jones C, Rowley BD. Building success in quality improvement: An analysis of what barriers hinder and what catalysts promote the widespread adoption of quality improvement initiatives. J Clin Oncol 30, 2012 (suppl 34, abst 122). 136. Belnap TW, Sause WT, Rowley,BD, Jones C, Ruckdeschel JC. The role, use, and nuances of clinical data systems in oncology quality improvement. J Clin Oncol 30, 2012 (suppl34, abst 135). 137. Sause WT, Rees WV, Ruckdeschel JC, Jones CW, Rowley BD, Pena K. Evolution of quality to value added care in a large healthcare organization. J Clin Oncol 31, 2013 In Press. 138. Ruckdeschel JC, Rees WV, Parkinson BT, Belnap T, Rowley BD, Pena K. The impact of screening mammography in women 40-49 years of age as a function of tumor biology. J Clin Oncol 31, 2013 In Press. 139. Pillai NR, Lee SJ, Karp DD, AisnerS, Ruckdeschel JC, Ramalingam S, and Khuri FR. Second Primary Lung Cancers:Analysis of E5597 Selenium Chemoprevention Study. J Clin Oncol: 2014 140. Hahn EE, Tang T, Lee JS, Munoz-Plaza C, Adesina O, Shen E, Rowley B, Maeda JL, Mosen DM, Ruckdeschel JC, Gould M. Use of advanced imaging for staging of early breast cancer in two integrated health care systems:Adherence with a Choosing Wisely Recommendation. J Clin Oncol 2015.